#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Methamphetamine dependence with and without psychotic symptoms: A multi-modal brain imaging study
#Text=Objective
#Text=Methamphetamine dependence can lead to psychotic symptoms which may be mediated by frontal, striatal, limbic, and thalamic regions.
1-1	0-15	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[1]
1-2	16-26	dependence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[1]
1-3	27-31	with	_
1-4	32-35	and	_
1-5	36-43	without	_
1-6	44-53	psychotic	_
1-7	54-62	symptoms	_
1-8	62-63	:	_
1-9	64-65	A	_
1-10	66-77	multi-modal	_
1-11	78-83	brain	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[2]
1-12	84-91	imaging	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol[2]
1-13	92-97	study	_
1-14	98-107	Objective	_
1-15	108-123	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[3]
1-16	124-134	dependence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[3]
1-17	135-138	can	_
1-18	139-143	lead	_
1-19	144-146	to	_
1-20	147-156	psychotic	_
1-21	157-165	symptoms	_
1-22	166-171	which	_
1-23	172-175	may	_
1-24	176-178	be	_
1-25	179-187	mediated	_
1-26	188-190	by	_
1-27	191-198	frontal	_
1-28	198-199	,	_
1-29	200-208	striatal	_
1-30	208-209	,	_
1-31	210-216	limbic	_
1-32	216-217	,	_
1-33	218-221	and	_
1-34	222-230	thalamic	_
1-35	231-238	regions	_
1-36	238-239	.	_

#Text=There are few neuroimaging data that allow comparison of individuals with methamphetamine dependence who do, and do not, have psychosis.
2-1	240-245	There	_
2-2	246-249	are	_
2-3	250-253	few	_
2-4	254-266	neuroimaging	_
2-5	267-271	data	_
2-6	272-276	that	_
2-7	277-282	allow	_
2-8	283-293	comparison	_
2-9	294-296	of	_
2-10	297-308	individuals	_
2-11	309-313	with	_
2-12	314-329	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[4]
2-13	330-340	dependence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[4]
2-14	341-344	who	_
2-15	345-347	do	_
2-16	347-348	,	_
2-17	349-352	and	_
2-18	353-355	do	_
2-19	356-359	not	_
2-20	359-360	,	_
2-21	361-365	have	_
2-22	366-375	psychosis	_
2-23	375-376	.	_

#Text=Two complementary imaging techniques were employed to investigate neurocircuitry associated with methamphetamine dependence with and without psychotic symptoms.
3-1	377-380	Two	_
3-2	381-394	complementary	_
3-3	395-402	imaging	_
3-4	403-413	techniques	_
3-5	414-418	were	_
3-6	419-427	employed	_
3-7	428-430	to	_
3-8	431-442	investigate	_
3-9	443-457	neurocircuitry	_
3-10	458-468	associated	_
3-11	469-473	with	_
3-12	474-489	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[5]
3-13	490-500	dependence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[5]
3-14	501-505	with	_
3-15	506-509	and	_
3-16	510-517	without	_
3-17	518-527	psychotic	_
3-18	528-536	symptoms	_
3-19	536-537	.	_

#Text=Methods
#Text=Three groups of participants were recruited: methamphetamine dependent (MAA) (N = 11), methamphetamine dependent with psychotic symptoms (MAP) (N = 14), and controls (N = 14).
4-1	538-545	Methods	_
4-2	546-551	Three	_
4-3	552-558	groups	_
4-4	559-561	of	_
4-5	562-574	participants	_
4-6	575-579	were	_
4-7	580-589	recruited	_
4-8	589-590	:	_
4-9	591-606	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[6]
4-10	607-616	dependent	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[6]
4-11	617-618	(	_
4-12	618-621	MAA	_
4-13	621-622	)	_
4-14	623-624	(	_
4-15	624-625	N	_
4-16	625-626	 	_
4-17	626-627	=	_
4-18	627-628	 	_
4-19	628-630	11	_
4-20	630-631	)	_
4-21	631-632	,	_
4-22	633-648	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[7]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[8]
4-23	649-658	dependent	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[7]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[8]
4-24	659-663	with	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[7]
4-25	664-673	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[7]
4-26	674-682	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[7]
4-27	683-684	(	_
4-28	684-687	MAP	_
4-29	687-688	)	_
4-30	689-690	(	_
4-31	690-691	N	_
4-32	691-692	 	_
4-33	692-693	=	_
4-34	693-694	 	_
4-35	694-696	14	_
4-36	696-697	)	_
4-37	697-698	,	_
4-38	699-702	and	_
4-39	703-711	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-40	712-713	(	_
4-41	713-714	N	_
4-42	714-715	 	_
4-43	715-716	=	_
4-44	716-717	 	_
4-45	717-719	14	_
4-46	719-720	)	_
4-47	720-721	.	_

#Text=Resting brain glucose metabolism was measured using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) and cerebral perfusion was assessed using arterial spin labelling (ASL) magnetic resonance imaging.
5-1	722-729	Resting	_
5-2	730-735	brain	_
5-3	736-743	glucose	_
5-4	744-754	metabolism	_
5-5	755-758	was	_
5-6	759-767	measured	_
5-7	768-773	using	_
5-8	774-775	[	_
5-9	775-778	18F	_
5-10	778-779	]	_
5-11	779-797	fluorodeoxyglucose	_
5-12	798-799	(	_
5-13	799-802	FDG	_
5-14	802-803	)	_
5-15	804-812	positron	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]
5-16	813-821	emission	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]
5-17	822-832	tomography	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]
5-18	833-834	(	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]
5-19	834-837	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]
5-20	837-838	)	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[9]
5-21	839-842	and	_
5-22	843-851	cerebral	_
5-23	852-861	perfusion	_
5-24	862-865	was	_
5-25	866-874	assessed	_
5-26	875-880	using	_
5-27	881-889	arterial	_
5-28	890-894	spin	_
5-29	895-904	labelling	_
5-30	905-906	(	_
5-31	906-909	ASL	_
5-32	909-910	)	_
5-33	911-919	magnetic	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[10]
5-34	920-929	resonance	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[10]
5-35	930-937	imaging	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[10]
5-36	937-938	.	_

#Text=Results
#Text=Methamphetamine abusers (MAA and MAP groups) had decreased glucose metabolism compared to healthy controls in the left insula, left precentral gyrus, and the anterior cingulate cortex.
6-1	939-946	Results	_
6-2	947-962	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[11]
6-3	963-970	abusers	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[11]
6-4	971-972	(	_
6-5	972-975	MAA	_
6-6	976-979	and	_
6-7	980-983	MAP	_
6-8	984-990	groups	_
6-9	990-991	)	_
6-10	992-995	had	_
6-11	996-1005	decreased	_
6-12	1006-1013	glucose	_
6-13	1014-1024	metabolism	_
6-14	1025-1033	compared	_
6-15	1034-1036	to	_
6-16	1037-1044	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
6-17	1045-1053	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]
6-18	1054-1056	in	_
6-19	1057-1060	the	_
6-20	1061-1065	left	_
6-21	1066-1072	insula	_
6-22	1072-1073	,	_
6-23	1074-1078	left	_
6-24	1079-1089	precentral	_
6-25	1090-1095	gyrus	_
6-26	1095-1096	,	_
6-27	1097-1100	and	_
6-28	1101-1104	the	_
6-29	1105-1113	anterior	_
6-30	1114-1123	cingulate	_
6-31	1124-1130	cortex	_
6-32	1130-1131	.	_

#Text=Compared to MAA participants, MAP participants had 1) decreased glucose metabolism in the left precentral gyrus and the left inferior frontal gyrus and 2) increased glucose metabolism in the putamen and pallidum.
7-1	1132-1140	Compared	_
7-2	1141-1143	to	_
7-3	1144-1147	MAA	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
7-4	1148-1160	participants	_
7-5	1160-1161	,	_
7-6	1162-1165	MAP	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[13]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[14]
7-7	1166-1178	participants	_
7-8	1179-1182	had	_
7-9	1183-1184	1	_
7-10	1184-1185	)	_
7-11	1186-1195	decreased	_
7-12	1196-1203	glucose	_
7-13	1204-1214	metabolism	_
7-14	1215-1217	in	_
7-15	1218-1221	the	_
7-16	1222-1226	left	_
7-17	1227-1237	precentral	_
7-18	1238-1243	gyrus	_
7-19	1244-1247	and	_
7-20	1248-1251	the	_
7-21	1252-1256	left	_
7-22	1257-1265	inferior	_
7-23	1266-1273	frontal	_
7-24	1274-1279	gyrus	_
7-25	1280-1283	and	_
7-26	1284-1285	2	_
7-27	1285-1286	)	_
7-28	1287-1296	increased	_
7-29	1297-1304	glucose	_
7-30	1305-1315	metabolism	_
7-31	1316-1318	in	_
7-32	1319-1322	the	_
7-33	1323-1330	putamen	_
7-34	1331-1334	and	_
7-35	1335-1343	pallidum	_
7-36	1343-1344	.	_

#Text=MAP participants also had increased cerebral perfusion in the right putamen and right pallidum compared to MAA.
8-1	1345-1348	MAP	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[15]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[16]
8-2	1349-1361	participants	_
8-3	1362-1366	also	_
8-4	1367-1370	had	_
8-5	1371-1380	increased	_
8-6	1381-1389	cerebral	_
8-7	1390-1399	perfusion	_
8-8	1400-1402	in	_
8-9	1403-1406	the	_
8-10	1407-1412	right	_
8-11	1413-1420	putamen	_
8-12	1421-1424	and	_
8-13	1425-1430	right	_
8-14	1431-1439	pallidum	_
8-15	1440-1448	compared	_
8-16	1449-1451	to	_
8-17	1452-1455	MAA	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
8-18	1455-1456	.	_

#Text=Conclusion
#Text=Findings support the involvement of frontal, striatal, and limbic regions in methamphetamine dependence.
9-1	1457-1467	Conclusion	_
9-2	1468-1476	Findings	_
9-3	1477-1484	support	_
9-4	1485-1488	the	_
9-5	1489-1500	involvement	_
9-6	1501-1503	of	_
9-7	1504-1511	frontal	_
9-8	1511-1512	,	_
9-9	1513-1521	striatal	_
9-10	1521-1522	,	_
9-11	1523-1526	and	_
9-12	1527-1533	limbic	_
9-13	1534-1541	regions	_
9-14	1542-1544	in	_
9-15	1545-1560	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[17]
9-16	1561-1571	dependence	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[17]
9-17	1571-1572	.	_

#Text=Furthermore, they indicate that glucose metabolism and cerebral perfusion in these regions are disrupted in methamphetamine dependent individuals with psychotic symptoms.
10-1	1573-1584	Furthermore	_
10-2	1584-1585	,	_
10-3	1586-1590	they	_
10-4	1591-1599	indicate	_
10-5	1600-1604	that	_
10-6	1605-1612	glucose	_
10-7	1613-1623	metabolism	_
10-8	1624-1627	and	_
10-9	1628-1636	cerebral	_
10-10	1637-1646	perfusion	_
10-11	1647-1649	in	_
10-12	1650-1655	these	_
10-13	1656-1663	regions	_
10-14	1664-1667	are	_
10-15	1668-1677	disrupted	_
10-16	1678-1680	in	_
10-17	1681-1696	methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[18]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]
10-18	1697-1706	dependent	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[18]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[19]
10-19	1707-1718	individuals	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[18]
10-20	1719-1723	with	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[18]
10-21	1724-1733	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[18]
10-22	1734-1742	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[18]
10-23	1742-1743	.	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[18]

#Text=Highlights
#Text=Methamphetamine abusers (MA) had decreased metabolism in insula and frontal cortex.
11-1	1744-1754	Highlights	_
11-2	1755-1770	Methamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[20]
11-3	1771-1778	abusers	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[20]
11-4	1779-1780	(	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[20]
11-5	1780-1782	MA	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[20]
11-6	1782-1783	)	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[20]
11-7	1784-1787	had	_
11-8	1788-1797	decreased	_
11-9	1798-1808	metabolism	_
11-10	1809-1811	in	_
11-11	1812-1818	insula	_
11-12	1819-1822	and	_
11-13	1823-1830	frontal	_
11-14	1831-1837	cortex	_
11-15	1837-1838	.	_

#Text=Metabolism in MA with psychosis with respect to MA without psychosis was decreased in frontal areas and increased in basal ganglia.
12-1	1839-1849	Metabolism	_
12-2	1850-1852	in	_
12-3	1853-1855	MA	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[21]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[22]
12-4	1856-1860	with	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[21]
12-5	1861-1870	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[21]
12-6	1871-1875	with	_
12-7	1876-1883	respect	_
12-8	1884-1886	to	_
12-9	1887-1889	MA	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
12-10	1890-1897	without	_
12-11	1898-1907	psychosis	_
12-12	1908-1911	was	_
12-13	1912-1921	decreased	_
12-14	1922-1924	in	_
12-15	1925-1932	frontal	_
12-16	1933-1938	areas	_
12-17	1939-1942	and	_
12-18	1943-1952	increased	_
12-19	1953-1955	in	_
12-20	1956-1961	basal	_
12-21	1962-1969	ganglia	_
12-22	1969-1970	.	_

#Text=Brain perfusion was also increased in basal ganglia of MAP.
13-1	1971-1976	Brain	_
13-2	1977-1986	perfusion	_
13-3	1987-1990	was	_
13-4	1991-1995	also	_
13-5	1996-2005	increased	_
13-6	2006-2008	in	_
13-7	2009-2014	basal	_
13-8	2015-2022	ganglia	_
13-9	2023-2025	of	_
13-10	2026-2029	MAP	_
13-11	2029-2030	.	_

#Text=Results show partial correspondence between ASL and FDG-PET.
14-1	2031-2038	Results	_
14-2	2039-2043	show	_
14-3	2044-2051	partial	_
14-4	2052-2066	correspondence	_
14-5	2067-2074	between	_
14-6	2075-2078	ASL	_
14-7	2079-2082	and	_
14-8	2083-2090	FDG-PET	_
14-9	2090-2091	.	_

#Text=Introduction
#Text=Methamphetamine (MA) abuse has been of particular concern for a number of reasons including its association with the psychotic disorder methamphetamine-associated psychosis (MAP), which may be mediated by frontal, striatal, limbic, and thalamic regions.
15-1	2092-2104	Introduction	_
15-2	2105-2120	Methamphetamine	_
15-3	2121-2122	(	_
15-4	2122-2124	MA	_
15-5	2124-2125	)	_
15-6	2126-2131	abuse	_
15-7	2132-2135	has	_
15-8	2136-2140	been	_
15-9	2141-2143	of	_
15-10	2144-2154	particular	_
15-11	2155-2162	concern	_
15-12	2163-2166	for	_
15-13	2167-2168	a	_
15-14	2169-2175	number	_
15-15	2176-2178	of	_
15-16	2179-2186	reasons	_
15-17	2187-2196	including	_
15-18	2197-2200	its	_
15-19	2201-2212	association	_
15-20	2213-2217	with	_
15-21	2218-2221	the	_
15-22	2222-2231	psychotic	_
15-23	2232-2240	disorder	_
15-24	2241-2267	methamphetamine-associated	_
15-25	2268-2277	psychosis	_
15-26	2278-2279	(	_
15-27	2279-2282	MAP	_
15-28	2282-2283	)	_
15-29	2283-2284	,	_
15-30	2285-2290	which	_
15-31	2291-2294	may	_
15-32	2295-2297	be	_
15-33	2298-2306	mediated	_
15-34	2307-2309	by	_
15-35	2310-2317	frontal	_
15-36	2317-2318	,	_
15-37	2319-2327	striatal	_
15-38	2327-2328	,	_
15-39	2329-2335	limbic	_
15-40	2335-2336	,	_
15-41	2337-2340	and	_
15-42	2341-2349	thalamic	_
15-43	2350-2357	regions	_
15-44	2357-2358	.	_

#Text=Fortunately, brain imaging research has advanced our understanding of the neurocircuitry and neurochemistry of methamphetamine dependence and MAP.
16-1	2359-2370	Fortunately	_
16-2	2370-2371	,	_
16-3	2372-2377	brain	_
16-4	2378-2385	imaging	_
16-5	2386-2394	research	_
16-6	2395-2398	has	_
16-7	2399-2407	advanced	_
16-8	2408-2411	our	_
16-9	2412-2425	understanding	_
16-10	2426-2428	of	_
16-11	2429-2432	the	_
16-12	2433-2447	neurocircuitry	_
16-13	2448-2451	and	_
16-14	2452-2466	neurochemistry	_
16-15	2467-2469	of	_
16-16	2470-2485	methamphetamine	_
16-17	2486-2496	dependence	_
16-18	2497-2500	and	_
16-19	2501-2504	MAP	_
16-20	2504-2505	.	_

#Text=In vivo human studies using positron emission tomography (PET) and magnetic resonance imaging (MRI) to investigate MA-associated neurotoxicity have shown reduced density of dopaminergic markers such as D2 receptors, dopamine transporters (DAT) and vesicular monoamine transporter-2, as well as reduced density of serotonin transporters.
17-1	2506-2508	In	_
17-2	2509-2513	vivo	_
17-3	2514-2519	human	_
17-4	2520-2527	studies	_
17-5	2528-2533	using	_
17-6	2534-2542	positron	_
17-7	2543-2551	emission	_
17-8	2552-2562	tomography	_
17-9	2563-2564	(	_
17-10	2564-2567	PET	_
17-11	2567-2568	)	_
17-12	2569-2572	and	_
17-13	2573-2581	magnetic	_
17-14	2582-2591	resonance	_
17-15	2592-2599	imaging	_
17-16	2600-2601	(	_
17-17	2601-2604	MRI	_
17-18	2604-2605	)	_
17-19	2606-2608	to	_
17-20	2609-2620	investigate	_
17-21	2621-2634	MA-associated	_
17-22	2635-2648	neurotoxicity	_
17-23	2649-2653	have	_
17-24	2654-2659	shown	_
17-25	2660-2667	reduced	_
17-26	2668-2675	density	_
17-27	2676-2678	of	_
17-28	2679-2691	dopaminergic	_
17-29	2692-2699	markers	_
17-30	2700-2704	such	_
17-31	2705-2707	as	_
17-32	2708-2710	D2	_
17-33	2711-2720	receptors	_
17-34	2720-2721	,	_
17-35	2722-2730	dopamine	_
17-36	2731-2743	transporters	_
17-37	2744-2745	(	_
17-38	2745-2748	DAT	_
17-39	2748-2749	)	_
17-40	2750-2753	and	_
17-41	2754-2763	vesicular	_
17-42	2764-2773	monoamine	_
17-43	2774-2785	transporter	_
17-44	2785-2786	-	_
17-45	2786-2787	2	_
17-46	2787-2788	,	_
17-47	2789-2791	as	_
17-48	2792-2796	well	_
17-49	2797-2799	as	_
17-50	2800-2807	reduced	_
17-51	2808-2815	density	_
17-52	2816-2818	of	_
17-53	2819-2828	serotonin	_
17-54	2829-2841	transporters	_
17-55	2841-2842	.	_

#Text=Human studies using [18F]fluorodeoxyglucose (FDG) PET have investigated global and regional cerebral glucose metabolism in MA abuse.
18-1	2843-2848	Human	_
18-2	2849-2856	studies	_
18-3	2857-2862	using	_
18-4	2863-2864	[	_
18-5	2864-2867	18F	_
18-6	2867-2868	]	_
18-7	2868-2886	fluorodeoxyglucose	_
18-8	2887-2888	(	_
18-9	2888-2891	FDG	_
18-10	2891-2892	)	_
18-11	2893-2896	PET	_
18-12	2897-2901	have	_
18-13	2902-2914	investigated	_
18-14	2915-2921	global	_
18-15	2922-2925	and	_
18-16	2926-2934	regional	_
18-17	2935-2943	cerebral	_
18-18	2944-2951	glucose	_
18-19	2952-2962	metabolism	_
18-20	2963-2965	in	_
18-21	2966-2968	MA	_
18-22	2969-2974	abuse	_
18-23	2974-2975	.	_

#Text=Cerebral glucose metabolism serves as a marker of neuronal activity and is altered in drug addiction (reviewed in).
19-1	2976-2984	Cerebral	_
19-2	2985-2992	glucose	_
19-3	2993-3003	metabolism	_
19-4	3004-3010	serves	_
19-5	3011-3013	as	_
19-6	3014-3015	a	_
19-7	3016-3022	marker	_
19-8	3023-3025	of	_
19-9	3026-3034	neuronal	_
19-10	3035-3043	activity	_
19-11	3044-3047	and	_
19-12	3048-3050	is	_
19-13	3051-3058	altered	_
19-14	3059-3061	in	_
19-15	3062-3066	drug	_
19-16	3067-3076	addiction	_
19-17	3077-3078	(	_
19-18	3078-3086	reviewed	_
19-19	3087-3089	in	_
19-20	3089-3090	)	_
19-21	3090-3091	.	_

#Text=Studies by both as well as show decreases in both striatal and thalamic glucose metabolism in MA abusers compared to healthy controls.
20-1	3092-3099	Studies	_
20-2	3100-3102	by	_
20-3	3103-3107	both	_
20-4	3108-3110	as	_
20-5	3111-3115	well	_
20-6	3116-3118	as	_
20-7	3119-3123	show	_
20-8	3124-3133	decreases	_
20-9	3134-3136	in	_
20-10	3137-3141	both	_
20-11	3142-3150	striatal	_
20-12	3151-3154	and	_
20-13	3155-3163	thalamic	_
20-14	3164-3171	glucose	_
20-15	3172-3182	metabolism	_
20-16	3183-3185	in	_
20-17	3186-3188	MA	_
20-18	3189-3196	abusers	_
20-19	3197-3205	compared	_
20-20	3206-3208	to	_
20-21	3209-3216	healthy	_
20-22	3217-3225	controls	_
20-23	3225-3226	.	_

#Text=Other studies have reported decreased cerebral glucose metabolism in the anterior cingulate cortex (ACC) of individuals with MA abuse when compared to controls.
21-1	3227-3232	Other	_
21-2	3233-3240	studies	_
21-3	3241-3245	have	_
21-4	3246-3254	reported	_
21-5	3255-3264	decreased	_
21-6	3265-3273	cerebral	_
21-7	3274-3281	glucose	_
21-8	3282-3292	metabolism	_
21-9	3293-3295	in	_
21-10	3296-3299	the	_
21-11	3300-3308	anterior	_
21-12	3309-3318	cingulate	_
21-13	3319-3325	cortex	_
21-14	3326-3327	(	_
21-15	3327-3330	ACC	_
21-16	3330-3331	)	_
21-17	3332-3334	of	_
21-18	3335-3346	individuals	_
21-19	3347-3351	with	_
21-20	3352-3354	MA	_
21-21	3355-3360	abuse	_
21-22	3361-3365	when	_
21-23	3366-3374	compared	_
21-24	3375-3377	to	_
21-25	3378-3386	controls	_
21-26	3386-3387	.	_

#Text=There are, however, no FDG PET data that allow comparison of methamphetamine dependence with and without psychosis.
22-1	3388-3393	There	_
22-2	3394-3397	are	_
22-3	3397-3398	,	_
22-4	3399-3406	however	_
22-5	3406-3407	,	_
22-6	3408-3410	no	_
22-7	3411-3414	FDG	_
22-8	3415-3418	PET	_
22-9	3419-3423	data	_
22-10	3424-3428	that	_
22-11	3429-3434	allow	_
22-12	3435-3445	comparison	_
22-13	3446-3448	of	_
22-14	3449-3464	methamphetamine	_
22-15	3465-3475	dependence	_
22-16	3476-3480	with	_
22-17	3481-3484	and	_
22-18	3485-3492	without	_
22-19	3493-3502	psychosis	_
22-20	3502-3503	.	_

#Text=Studies show that although a large majority of the symptoms of MA-induced psychosis resolve within 1 month, some may persist for 6 months, and others for even >6 months.
23-1	3504-3511	Studies	_
23-2	3512-3516	show	_
23-3	3517-3521	that	_
23-4	3522-3530	although	_
23-5	3531-3532	a	_
23-6	3533-3538	large	_
23-7	3539-3547	majority	_
23-8	3548-3550	of	_
23-9	3551-3554	the	_
23-10	3555-3563	symptoms	_
23-11	3564-3566	of	_
23-12	3567-3577	MA-induced	_
23-13	3578-3587	psychosis	_
23-14	3588-3595	resolve	_
23-15	3596-3602	within	_
23-16	3603-3604	1	_
23-17	3604-3605	 	_
23-18	3605-3610	month	_
23-19	3610-3611	,	_
23-20	3612-3616	some	_
23-21	3617-3620	may	_
23-22	3621-3628	persist	_
23-23	3629-3632	for	_
23-24	3633-3634	6	_
23-25	3634-3635	 	_
23-26	3635-3641	months	_
23-27	3641-3642	,	_
23-28	3643-3646	and	_
23-29	3647-3653	others	_
23-30	3654-3657	for	_
23-31	3658-3662	even	_
23-32	3663-3664	>	_
23-33	3664-3665	6	_
23-34	3665-3666	 	_
23-35	3666-3672	months	_
23-36	3672-3673	.	_

#Text=There are also reports of symptoms reoccurring after long periods of abstinence.
24-1	3674-3679	There	_
24-2	3680-3683	are	_
24-3	3684-3688	also	_
24-4	3689-3696	reports	_
24-5	3697-3699	of	_
24-6	3700-3708	symptoms	_
24-7	3709-3720	reoccurring	_
24-8	3721-3726	after	_
24-9	3727-3731	long	_
24-10	3732-3739	periods	_
24-11	3740-3742	of	_
24-12	3743-3753	abstinence	_
24-13	3753-3754	.	_

#Text=MA-induced psychosis presents clinically similarly to acute paranoid schizophrena.
25-1	3755-3765	MA-induced	_
25-2	3766-3775	psychosis	_
25-3	3776-3784	presents	_
25-4	3785-3795	clinically	_
25-5	3796-3805	similarly	_
25-6	3806-3808	to	_
25-7	3809-3814	acute	_
25-8	3815-3823	paranoid	_
25-9	3824-3836	schizophrena	_
25-10	3836-3837	.	_

#Text=Some of the most thoroughly investigated regions with alterations in schizophrenia include the cerebral cortex, hippocampus and basal ganglia (structures include the putamen and pallidum).
26-1	3838-3842	Some	_
26-2	3843-3845	of	_
26-3	3846-3849	the	_
26-4	3850-3854	most	_
26-5	3855-3865	thoroughly	_
26-6	3866-3878	investigated	_
26-7	3879-3886	regions	_
26-8	3887-3891	with	_
26-9	3892-3903	alterations	_
26-10	3904-3906	in	_
26-11	3907-3920	schizophrenia	_
26-12	3921-3928	include	_
26-13	3929-3932	the	_
26-14	3933-3941	cerebral	_
26-15	3942-3948	cortex	_
26-16	3948-3949	,	_
26-17	3950-3961	hippocampus	_
26-18	3962-3965	and	_
26-19	3966-3971	basal	_
26-20	3972-3979	ganglia	_
26-21	3980-3981	(	_
26-22	3981-3991	structures	_
26-23	3992-3999	include	_
26-24	4000-4003	the	_
26-25	4004-4011	putamen	_
26-26	4012-4015	and	_
26-27	4016-4024	pallidum	_
26-28	4024-4025	)	_
26-29	4025-4026	.	_

#Text=Due to the considerable diversity of symptoms in schizophrenia, it is widely accepted that impairments are not localized to specific regions, but rather involve the disruption of several regions.
27-1	4027-4030	Due	_
27-2	4031-4033	to	_
27-3	4034-4037	the	_
27-4	4038-4050	considerable	_
27-5	4051-4060	diversity	_
27-6	4061-4063	of	_
27-7	4064-4072	symptoms	_
27-8	4073-4075	in	_
27-9	4076-4089	schizophrenia	_
27-10	4089-4090	,	_
27-11	4091-4093	it	_
27-12	4094-4096	is	_
27-13	4097-4103	widely	_
27-14	4104-4112	accepted	_
27-15	4113-4117	that	_
27-16	4118-4129	impairments	_
27-17	4130-4133	are	_
27-18	4134-4137	not	_
27-19	4138-4147	localized	_
27-20	4148-4150	to	_
27-21	4151-4159	specific	_
27-22	4160-4167	regions	_
27-23	4167-4168	,	_
27-24	4169-4172	but	_
27-25	4173-4179	rather	_
27-26	4180-4187	involve	_
27-27	4188-4191	the	_
27-28	4192-4202	disruption	_
27-29	4203-4205	of	_
27-30	4206-4213	several	_
27-31	4214-4221	regions	_
27-32	4221-4222	.	_

#Text=Studies looking at active psychosis in Alzheimer's disease and schizophrenia showed decreased cerebral glucose metabolism in the orbitofrontal cortex (OFC), and increases in medial temporal regions, basal ganglia, and left thalamic regions, with decreases in the cerebellum.
28-1	4223-4230	Studies	_
28-2	4231-4238	looking	_
28-3	4239-4241	at	_
28-4	4242-4248	active	_
28-5	4249-4258	psychosis	_
28-6	4259-4261	in	_
28-7	4262-4273	Alzheimer's	_
28-8	4274-4281	disease	_
28-9	4282-4285	and	_
28-10	4286-4299	schizophrenia	_
28-11	4300-4306	showed	_
28-12	4307-4316	decreased	_
28-13	4317-4325	cerebral	_
28-14	4326-4333	glucose	_
28-15	4334-4344	metabolism	_
28-16	4345-4347	in	_
28-17	4348-4351	the	_
28-18	4352-4365	orbitofrontal	_
28-19	4366-4372	cortex	_
28-20	4373-4374	(	_
28-21	4374-4377	OFC	_
28-22	4377-4378	)	_
28-23	4378-4379	,	_
28-24	4380-4383	and	_
28-25	4384-4393	increases	_
28-26	4394-4396	in	_
28-27	4397-4403	medial	_
28-28	4404-4412	temporal	_
28-29	4413-4420	regions	_
28-30	4420-4421	,	_
28-31	4422-4427	basal	_
28-32	4428-4435	ganglia	_
28-33	4435-4436	,	_
28-34	4437-4440	and	_
28-35	4441-4445	left	_
28-36	4446-4454	thalamic	_
28-37	4455-4462	regions	_
28-38	4462-4463	,	_
28-39	4464-4468	with	_
28-40	4469-4478	decreases	_
28-41	4479-4481	in	_
28-42	4482-4485	the	_
28-43	4486-4496	cerebellum	_
28-44	4496-4497	.	_

#Text=Arterial spin labeling (ASL) is a MRI technique which uses magnetically tagged blood as a tracer, and is also used to measure regional cerebral blood flow (rCBF).
29-1	4498-4506	Arterial	_
29-2	4507-4511	spin	_
29-3	4512-4520	labeling	_
29-4	4521-4522	(	_
29-5	4522-4525	ASL	_
29-6	4525-4526	)	_
29-7	4527-4529	is	_
29-8	4530-4531	a	_
29-9	4532-4535	MRI	_
29-10	4536-4545	technique	_
29-11	4546-4551	which	_
29-12	4552-4556	uses	_
29-13	4557-4569	magnetically	_
29-14	4570-4576	tagged	_
29-15	4577-4582	blood	_
29-16	4583-4585	as	_
29-17	4586-4587	a	_
29-18	4588-4594	tracer	_
29-19	4594-4595	,	_
29-20	4596-4599	and	_
29-21	4600-4602	is	_
29-22	4603-4607	also	_
29-23	4608-4612	used	_
29-24	4613-4615	to	_
29-25	4616-4623	measure	_
29-26	4624-4632	regional	_
29-27	4633-4641	cerebral	_
29-28	4642-4647	blood	_
29-29	4648-4652	flow	_
29-30	4653-4654	(	_
29-31	4654-4658	rCBF	_
29-32	4658-4659	)	_
29-33	4659-4660	.	_

#Text=As with FDG PET studies, ASL studies, in humans, include those examining schizophrenia.
30-1	4661-4663	As	_
30-2	4664-4668	with	_
30-3	4669-4672	FDG	_
30-4	4673-4676	PET	_
30-5	4677-4684	studies	_
30-6	4684-4685	,	_
30-7	4686-4689	ASL	_
30-8	4690-4697	studies	_
30-9	4697-4698	,	_
30-10	4699-4701	in	_
30-11	4702-4708	humans	_
30-12	4708-4709	,	_
30-13	4710-4717	include	_
30-14	4718-4723	those	_
30-15	4724-4733	examining	_
30-16	4734-4747	schizophrenia	_
30-17	4747-4748	.	_

#Text=Under normal, standard conditions, glucose metabolism and blood flow are tightly coupled.
31-1	4749-4754	Under	_
31-2	4755-4761	normal	_
31-3	4761-4762	,	_
31-4	4763-4771	standard	_
31-5	4772-4782	conditions	_
31-6	4782-4783	,	_
31-7	4784-4791	glucose	_
31-8	4792-4802	metabolism	_
31-9	4803-4806	and	_
31-10	4807-4812	blood	_
31-11	4813-4817	flow	_
31-12	4818-4821	are	_
31-13	4822-4829	tightly	_
31-14	4830-4837	coupled	_
31-15	4837-4838	.	_

#Text=We would therefore expect perfusion findings to reflect the findings from PET.
32-1	4839-4841	We	_
32-2	4842-4847	would	_
32-3	4848-4857	therefore	_
32-4	4858-4864	expect	_
32-5	4865-4874	perfusion	_
32-6	4875-4883	findings	_
32-7	4884-4886	to	_
32-8	4887-4894	reflect	_
32-9	4895-4898	the	_
32-10	4899-4907	findings	_
32-11	4908-4912	from	_
32-12	4913-4916	PET	_
32-13	4916-4917	.	_

#Text=The only study – to our knowledge – looking at cerebral perfusion in MA dependence is that by who used a contrast agent.
33-1	4918-4921	The	_
33-2	4922-4926	only	_
33-3	4927-4932	study	_
33-4	4933-4934	–	_
33-5	4935-4937	to	_
33-6	4938-4941	our	_
33-7	4942-4951	knowledge	_
33-8	4952-4953	–	_
33-9	4954-4961	looking	_
33-10	4962-4964	at	_
33-11	4965-4973	cerebral	_
33-12	4974-4983	perfusion	_
33-13	4984-4986	in	_
33-14	4987-4989	MA	_
33-15	4990-5000	dependence	_
33-16	5001-5003	is	_
33-17	5004-5008	that	_
33-18	5009-5011	by	_
33-19	5012-5015	who	_
33-20	5016-5020	used	_
33-21	5021-5022	a	_
33-22	5023-5031	contrast	_
33-23	5032-5037	agent	_
33-24	5037-5038	.	_

#Text=They found MA to have a decreased rCBF bilaterally in the putamen/insular cortex and in a right lateral parietal brain region, and increased rCBF bilaterally in left temporoparietal white matter (WM), and in left occipital, and right posterior parietal regions.
34-1	5039-5043	They	_
34-2	5044-5049	found	_
34-3	5050-5052	MA	_
34-4	5053-5055	to	_
34-5	5056-5060	have	_
34-6	5061-5062	a	_
34-7	5063-5072	decreased	_
34-8	5073-5077	rCBF	_
34-9	5078-5089	bilaterally	_
34-10	5090-5092	in	_
34-11	5093-5096	the	_
34-12	5097-5104	putamen	_
34-13	5104-5105	/	_
34-14	5105-5112	insular	_
34-15	5113-5119	cortex	_
34-16	5120-5123	and	_
34-17	5124-5126	in	_
34-18	5127-5128	a	_
34-19	5129-5134	right	_
34-20	5135-5142	lateral	_
34-21	5143-5151	parietal	_
34-22	5152-5157	brain	_
34-23	5158-5164	region	_
34-24	5164-5165	,	_
34-25	5166-5169	and	_
34-26	5170-5179	increased	_
34-27	5180-5184	rCBF	_
34-28	5185-5196	bilaterally	_
34-29	5197-5199	in	_
34-30	5200-5204	left	_
34-31	5205-5220	temporoparietal	_
34-32	5221-5226	white	_
34-33	5227-5233	matter	_
34-34	5234-5235	(	_
34-35	5235-5237	WM	_
34-36	5237-5238	)	_
34-37	5238-5239	,	_
34-38	5240-5243	and	_
34-39	5244-5246	in	_
34-40	5247-5251	left	_
34-41	5252-5261	occipital	_
34-42	5261-5262	,	_
34-43	5263-5266	and	_
34-44	5267-5272	right	_
34-45	5273-5282	posterior	_
34-46	5283-5291	parietal	_
34-47	5292-5299	regions	_
34-48	5299-5300	.	_

#Text=FDG is a glucose analogue, and FDG uptake is related to glucose metabolism, albeit in a non-linear way.
35-1	5301-5304	FDG	_
35-2	5305-5307	is	_
35-3	5308-5309	a	_
35-4	5310-5317	glucose	_
35-5	5318-5326	analogue	_
35-6	5326-5327	,	_
35-7	5328-5331	and	_
35-8	5332-5335	FDG	_
35-9	5336-5342	uptake	_
35-10	5343-5345	is	_
35-11	5346-5353	related	_
35-12	5354-5356	to	_
35-13	5357-5364	glucose	_
35-14	5365-5375	metabolism	_
35-15	5375-5376	,	_
35-16	5377-5383	albeit	_
35-17	5384-5386	in	_
35-18	5387-5388	a	_
35-19	5389-5399	non-linear	_
35-20	5400-5403	way	_
35-21	5403-5404	.	_

#Text=ASL allows examination of regional cerebral blood flow.
36-1	5405-5408	ASL	_
36-2	5409-5415	allows	_
36-3	5416-5427	examination	_
36-4	5428-5430	of	_
36-5	5431-5439	regional	_
36-6	5440-5448	cerebral	_
36-7	5449-5454	blood	_
36-8	5455-5459	flow	_
36-9	5459-5460	.	_

#Text=Looking at two complementary imaging techniques measuring CBF and glucose metabolism may provide insights into the neural mechanisms underlying these MA-associated pathologies.
37-1	5461-5468	Looking	_
37-2	5469-5471	at	_
37-3	5472-5475	two	_
37-4	5476-5489	complementary	_
37-5	5490-5497	imaging	_
37-6	5498-5508	techniques	_
37-7	5509-5518	measuring	_
37-8	5519-5522	CBF	_
37-9	5523-5526	and	_
37-10	5527-5534	glucose	_
37-11	5535-5545	metabolism	_
37-12	5546-5549	may	_
37-13	5550-5557	provide	_
37-14	5558-5566	insights	_
37-15	5567-5571	into	_
37-16	5572-5575	the	_
37-17	5576-5582	neural	_
37-18	5583-5593	mechanisms	_
37-19	5594-5604	underlying	_
37-20	5605-5610	these	_
37-21	5611-5624	MA-associated	_
37-22	5625-5636	pathologies	_
37-23	5636-5637	.	_

#Text=Therefore, this study examined the differences in cerebral glucose metabolism (using FDG-PET) and rCBF (with ASL) between MA and healthy controls; moreover, these variables were compared between MA with and without psychosis.
38-1	5638-5647	Therefore	_
38-2	5647-5648	,	_
38-3	5649-5653	this	_
38-4	5654-5659	study	_
38-5	5660-5668	examined	_
38-6	5669-5672	the	_
38-7	5673-5684	differences	_
38-8	5685-5687	in	_
38-9	5688-5696	cerebral	_
38-10	5697-5704	glucose	_
38-11	5705-5715	metabolism	_
38-12	5716-5717	(	_
38-13	5717-5722	using	_
38-14	5723-5730	FDG-PET	_
38-15	5730-5731	)	_
38-16	5732-5735	and	_
38-17	5736-5740	rCBF	_
38-18	5741-5742	(	_
38-19	5742-5746	with	_
38-20	5747-5750	ASL	_
38-21	5750-5751	)	_
38-22	5752-5759	between	_
38-23	5760-5762	MA	_
38-24	5763-5766	and	_
38-25	5767-5774	healthy	_
38-26	5775-5783	controls	_
38-27	5783-5784	;	_
38-28	5785-5793	moreover	_
38-29	5793-5794	,	_
38-30	5795-5800	these	_
38-31	5801-5810	variables	_
38-32	5811-5815	were	_
38-33	5816-5824	compared	_
38-34	5825-5832	between	_
38-35	5833-5835	MA	_
38-36	5836-5840	with	_
38-37	5841-5844	and	_
38-38	5845-5852	without	_
38-39	5853-5862	psychosis	_
38-40	5862-5863	.	_

#Text=Methods and materials
#Text=Participants
#Text=Characteristics of participants included across both modalities.
39-1	5864-5871	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[23]
39-2	5872-5875	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[23]
39-3	5876-5885	materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[23]
39-4	5886-5898	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-5	5899-5914	Characteristics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-6	5915-5917	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-7	5918-5930	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-8	5931-5939	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-9	5940-5946	across	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-10	5947-5951	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-11	5952-5962	modalities	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
39-12	5962-5963	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]

#Text=Table 1\t \t
#Text=\tParticipant group\t\t \tVariables\tHC\tMAA\tMAP\tp value\t \tNumber (n)\t14\t11\t14\t–\t \tMales\t7\t5\t9\t0.6\t \tAge, years\t26.3 (4.7)\t29 (4.2)\t26.1 (6)\t0.2\t \tEducation, years\t11.5 (1.1)\t10.6 (2)\t10.4 (2.6)\t0.1\t \tAge of first MA-use, years\t–\t18.2 (7.6)\t18.2 (6.9)\t0.9\t \tDuration of use, years\t–\t8 (4.6)\t7.9 (4.7)\t0.1\t \tTime since last use, days\t–\t39.6 (21.2)\t37.6 (19.7)\t0.5\t \t
#Text=Abbreviations: MA, methamphetamine; HC, healthy controls; MAA, methamphetamine abusers; MAP, methamphetamine abusers with psychotic symptoms; M, male participants; Data shown as mean values (standard deviation); p value for the statistical tests: Chi-Square test for gender distribution (across 3 groups), one-way ANOVA for age and education (across 3 groups) and Student two-sample t-test (unequal variance assumed) for the drug use measures (MAA vs MAP).
40-1	5964-5969	Table	_
40-2	5970-5971	1	_
40-3	5976-5987	Participant	_
40-4	5988-5993	group	_
40-5	5997-6006	Variables	_
40-6	6007-6009	HC	_
40-7	6010-6013	MAA	_
40-8	6014-6017	MAP	_
40-9	6018-6019	p	_
40-10	6020-6025	value	_
40-11	6028-6034	Number	_
40-12	6035-6036	(	_
40-13	6036-6037	n	_
40-14	6037-6038	)	_
40-15	6039-6041	14	_
40-16	6042-6044	11	_
40-17	6045-6047	14	_
40-18	6048-6049	–	_
40-19	6052-6057	Males	_
40-20	6058-6059	7	_
40-21	6060-6061	5	_
40-22	6062-6063	9	_
40-23	6064-6067	0.6	_
40-24	6070-6073	Age	_
40-25	6073-6074	,	_
40-26	6075-6080	years	_
40-27	6081-6085	26.3	_
40-28	6086-6087	(	_
40-29	6087-6090	4.7	_
40-30	6090-6091	)	_
40-31	6092-6094	29	_
40-32	6095-6096	(	_
40-33	6096-6099	4.2	_
40-34	6099-6100	)	_
40-35	6101-6105	26.1	_
40-36	6106-6107	(	_
40-37	6107-6108	6	_
40-38	6108-6109	)	_
40-39	6110-6113	0.2	_
40-40	6116-6125	Education	_
40-41	6125-6126	,	_
40-42	6127-6132	years	_
40-43	6133-6137	11.5	_
40-44	6138-6139	(	_
40-45	6139-6142	1.1	_
40-46	6142-6143	)	_
40-47	6144-6148	10.6	_
40-48	6149-6150	(	_
40-49	6150-6151	2	_
40-50	6151-6152	)	_
40-51	6153-6157	10.4	_
40-52	6158-6159	(	_
40-53	6159-6162	2.6	_
40-54	6162-6163	)	_
40-55	6164-6167	0.1	_
40-56	6170-6173	Age	_
40-57	6174-6176	of	_
40-58	6177-6182	first	_
40-59	6183-6189	MA-use	_
40-60	6189-6190	,	_
40-61	6191-6196	years	_
40-62	6197-6198	–	_
40-63	6199-6203	18.2	_
40-64	6204-6205	(	_
40-65	6205-6208	7.6	_
40-66	6208-6209	)	_
40-67	6210-6214	18.2	_
40-68	6215-6216	(	_
40-69	6216-6219	6.9	_
40-70	6219-6220	)	_
40-71	6221-6224	0.9	_
40-72	6227-6235	Duration	_
40-73	6236-6238	of	_
40-74	6239-6242	use	_
40-75	6242-6243	,	_
40-76	6244-6249	years	_
40-77	6250-6251	–	_
40-78	6252-6253	8	_
40-79	6254-6255	(	_
40-80	6255-6258	4.6	_
40-81	6258-6259	)	_
40-82	6260-6263	7.9	_
40-83	6264-6265	(	_
40-84	6265-6268	4.7	_
40-85	6268-6269	)	_
40-86	6270-6273	0.1	_
40-87	6276-6280	Time	_
40-88	6281-6286	since	_
40-89	6287-6291	last	_
40-90	6292-6295	use	_
40-91	6295-6296	,	_
40-92	6297-6301	days	_
40-93	6302-6303	–	_
40-94	6304-6308	39.6	_
40-95	6309-6310	(	_
40-96	6310-6314	21.2	_
40-97	6314-6315	)	_
40-98	6316-6320	37.6	_
40-99	6321-6322	(	_
40-100	6322-6326	19.7	_
40-101	6326-6327	)	_
40-102	6328-6331	0.5	_
40-103	6335-6348	Abbreviations	_
40-104	6348-6349	:	_
40-105	6350-6352	MA	_
40-106	6352-6353	,	_
40-107	6354-6369	methamphetamine	_
40-108	6369-6370	;	_
40-109	6371-6373	HC	_
40-110	6373-6374	,	_
40-111	6375-6382	healthy	_
40-112	6383-6391	controls	_
40-113	6391-6392	;	_
40-114	6393-6396	MAA	_
40-115	6396-6397	,	_
40-116	6398-6413	methamphetamine	_
40-117	6414-6421	abusers	_
40-118	6421-6422	;	_
40-119	6423-6426	MAP	_
40-120	6426-6427	,	_
40-121	6428-6443	methamphetamine	_
40-122	6444-6451	abusers	_
40-123	6452-6456	with	_
40-124	6457-6466	psychotic	_
40-125	6467-6475	symptoms	_
40-126	6475-6476	;	_
40-127	6477-6478	M	_
40-128	6478-6479	,	_
40-129	6480-6484	male	_
40-130	6485-6497	participants	_
40-131	6497-6498	;	_
40-132	6499-6503	Data	_
40-133	6504-6509	shown	_
40-134	6510-6512	as	_
40-135	6513-6517	mean	_
40-136	6518-6524	values	_
40-137	6525-6526	(	_
40-138	6526-6534	standard	_
40-139	6535-6544	deviation	_
40-140	6544-6545	)	_
40-141	6545-6546	;	_
40-142	6547-6548	p	_
40-143	6549-6554	value	_
40-144	6555-6558	for	_
40-145	6559-6562	the	_
40-146	6563-6574	statistical	_
40-147	6575-6580	tests	_
40-148	6580-6581	:	_
40-149	6582-6592	Chi-Square	_
40-150	6593-6597	test	_
40-151	6598-6601	for	_
40-152	6602-6608	gender	_
40-153	6609-6621	distribution	_
40-154	6622-6623	(	_
40-155	6623-6629	across	_
40-156	6630-6631	3	_
40-157	6632-6638	groups	_
40-158	6638-6639	)	_
40-159	6639-6640	,	_
40-160	6641-6648	one-way	_
40-161	6649-6654	ANOVA	_
40-162	6655-6658	for	_
40-163	6659-6662	age	_
40-164	6663-6666	and	_
40-165	6667-6676	education	_
40-166	6677-6678	(	_
40-167	6678-6684	across	_
40-168	6685-6686	3	_
40-169	6687-6693	groups	_
40-170	6693-6694	)	_
40-171	6695-6698	and	_
40-172	6699-6706	Student	_
40-173	6707-6717	two-sample	_
40-174	6718-6724	t-test	_
40-175	6725-6726	(	_
40-176	6726-6733	unequal	_
40-177	6734-6742	variance	_
40-178	6743-6750	assumed	_
40-179	6750-6751	)	_
40-180	6752-6755	for	_
40-181	6756-6759	the	_
40-182	6760-6764	drug	_
40-183	6765-6768	use	_
40-184	6769-6777	measures	_
40-185	6778-6779	(	_
40-186	6779-6782	MAA	_
40-187	6783-6785	vs	_
40-188	6786-6789	MAP	_
40-189	6789-6790	)	_
40-190	6790-6791	.	_

#Text=Participants included in each of the modalities.
41-1	6792-6804	Participants	_
41-2	6805-6813	included	_
41-3	6814-6816	in	_
41-4	6817-6821	each	_
41-5	6822-6824	of	_
41-6	6825-6828	the	_
41-7	6829-6839	modalities	_
41-8	6839-6840	.	_

#Text=Table 2\t \t
#Text=\tModality\t \tFDG PET (n = 33)\tASL MRI (n = 31)\t \tHC\tMAA\tMAP\tHC\tMAA\tMAP\t \tNumber of participants\t11\t10\t12\t11\t9\t11\t \tGender (M/F)\t6/5\t5/5\t7/5\t7/4\t4/5\t6/5\t \t
#Text=Abbreviations: HC, healthy controls; MAA, methamphetamine abusers; MAP, methamphetamine abusers with psychotic symptoms; M, male participants; F, female participants.
42-1	6841-6846	Table	_
42-2	6847-6848	2	_
42-3	6853-6861	Modality	_
42-4	6864-6867	FDG	_
42-5	6868-6871	PET	_
42-6	6872-6873	(	_
42-7	6873-6874	n	_
42-8	6874-6875	 	_
42-9	6875-6876	=	_
42-10	6876-6877	 	_
42-11	6877-6879	33	_
42-12	6879-6880	)	_
42-13	6881-6884	ASL	_
42-14	6885-6888	MRI	_
42-15	6889-6890	(	_
42-16	6890-6891	n	_
42-17	6891-6892	 	_
42-18	6892-6893	=	_
42-19	6893-6894	 	_
42-20	6894-6896	31	_
42-21	6896-6897	)	_
42-22	6900-6902	HC	_
42-23	6903-6906	MAA	_
42-24	6907-6910	MAP	_
42-25	6911-6913	HC	_
42-26	6914-6917	MAA	_
42-27	6918-6921	MAP	_
42-28	6924-6930	Number	_
42-29	6931-6933	of	_
42-30	6934-6946	participants	_
42-31	6947-6949	11	_
42-32	6950-6952	10	_
42-33	6953-6955	12	_
42-34	6956-6958	11	_
42-35	6959-6960	9	_
42-36	6961-6963	11	_
42-37	6966-6972	Gender	_
42-38	6973-6974	(	_
42-39	6974-6975	M	_
42-40	6975-6976	/	_
42-41	6976-6977	F	_
42-42	6977-6978	)	_
42-43	6979-6980	6	_
42-44	6980-6981	/	_
42-45	6981-6982	5	_
42-46	6983-6984	5	_
42-47	6984-6985	/	_
42-48	6985-6986	5	_
42-49	6987-6988	7	_
42-50	6988-6989	/	_
42-51	6989-6990	5	_
42-52	6991-6992	7	_
42-53	6992-6993	/	_
42-54	6993-6994	4	_
42-55	6995-6996	4	_
42-56	6996-6997	/	_
42-57	6997-6998	5	_
42-58	6999-7000	6	_
42-59	7000-7001	/	_
42-60	7001-7002	5	_
42-61	7006-7019	Abbreviations	_
42-62	7019-7020	:	_
42-63	7021-7023	HC	_
42-64	7023-7024	,	_
42-65	7025-7032	healthy	_
42-66	7033-7041	controls	_
42-67	7041-7042	;	_
42-68	7043-7046	MAA	_
42-69	7046-7047	,	_
42-70	7048-7063	methamphetamine	_
42-71	7064-7071	abusers	_
42-72	7071-7072	;	_
42-73	7073-7076	MAP	_
42-74	7076-7077	,	_
42-75	7078-7093	methamphetamine	_
42-76	7094-7101	abusers	_
42-77	7102-7106	with	_
42-78	7107-7116	psychotic	_
42-79	7117-7125	symptoms	_
42-80	7125-7126	;	_
42-81	7127-7128	M	_
42-82	7128-7129	,	_
42-83	7130-7134	male	_
42-84	7135-7147	participants	_
42-85	7147-7148	;	_
42-86	7149-7150	F	_
42-87	7150-7151	,	_
42-88	7152-7158	female	_
42-89	7159-7171	participants	_
42-90	7171-7172	.	_

#Text=Three groups (MA dependent, MA dependent with psychotic symptoms, and healthy controls (HC) were recruited and underwent imaging with both PET and MRI (see Table 1, Table 2).
43-1	7173-7178	Three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-2	7179-7185	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-3	7186-7187	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-4	7187-7189	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[26]
43-5	7190-7199	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[26]
43-6	7199-7200	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-7	7201-7203	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[28]
43-8	7204-7213	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[28]
43-9	7214-7218	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[28]
43-10	7219-7228	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[28]
43-11	7229-7237	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[27]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[28]
43-12	7237-7238	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-13	7239-7242	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-14	7243-7250	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]
43-15	7251-7259	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]
43-16	7260-7261	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]
43-17	7261-7263	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]
43-18	7263-7264	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[29]
43-19	7265-7269	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-20	7270-7279	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-21	7280-7283	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-22	7284-7293	underwent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-23	7294-7301	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-24	7302-7306	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-25	7307-7311	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-26	7312-7315	PET	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[30]
43-27	7316-7319	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-28	7320-7323	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[31]
43-29	7324-7325	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-30	7325-7328	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-31	7329-7334	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-32	7335-7336	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-33	7336-7337	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-34	7338-7343	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-35	7344-7345	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-36	7345-7346	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
43-37	7346-7347	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=The MA dependent participants without psychotic symptoms (MAA) were recruited from local rehabilitation and drug counselling centers, and the participants with MA dependence with psychotic symptoms (MAP) were recruited from a local psychiatric hospital.
44-1	7348-7351	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
44-2	7352-7354	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[33]
44-3	7355-7364	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[33]
44-4	7365-7377	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[33]
44-5	7378-7385	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[33]
44-6	7386-7395	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[33]
44-7	7396-7404	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[33]
44-8	7405-7406	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[33]
44-9	7406-7409	MAA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[33]
44-10	7409-7410	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[33]
44-11	7411-7415	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
44-12	7416-7425	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
44-13	7426-7430	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
44-14	7431-7436	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
44-15	7437-7451	rehabilitation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
44-16	7452-7455	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
44-17	7456-7460	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[32]
44-18	7461-7472	counselling	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-19	7473-7480	centers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-20	7480-7481	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-21	7482-7485	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-22	7486-7489	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-23	7490-7502	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[36]
44-24	7503-7507	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[36]
44-25	7508-7510	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[36]
44-26	7511-7521	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[36]
44-27	7522-7526	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[36]
44-28	7527-7536	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[36]
44-29	7537-7545	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[36]
44-30	7546-7547	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[36]
44-31	7547-7550	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[36]
44-32	7550-7551	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[35]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[36]
44-33	7552-7556	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-34	7557-7566	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-35	7567-7571	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-36	7572-7573	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-37	7574-7579	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-38	7580-7591	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-39	7592-7600	hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]
44-40	7600-7601	.	_

#Text=Controls were recruited from the same communities as the MA dependent participants.
45-1	7602-7610	Controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[38]
45-2	7611-7615	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
45-3	7616-7625	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
45-4	7626-7630	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
45-5	7631-7634	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
45-6	7635-7639	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
45-7	7640-7651	communities	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
45-8	7652-7654	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
45-9	7655-7658	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
45-10	7659-7661	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[39]
45-11	7662-7671	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[39]
45-12	7672-7684	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]
45-13	7684-7685	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[37]

#Text=All 3 groups were matched in terms of age and education, and the MA dependent and MAP groups were matched in terms of age of first use, duration of use, and the time since last use.
46-1	7686-7689	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-2	7690-7691	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-3	7692-7698	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-4	7699-7703	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-5	7704-7711	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-6	7712-7714	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-7	7715-7720	terms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-8	7721-7723	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-9	7724-7727	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-10	7728-7731	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-11	7732-7741	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-12	7741-7742	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-13	7743-7746	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-14	7747-7750	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-15	7751-7753	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[41]
46-16	7754-7763	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[41]
46-17	7764-7767	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-18	7768-7771	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[42]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[43]
46-19	7772-7778	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[42]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[43]
46-20	7779-7783	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-21	7784-7791	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-22	7792-7794	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-23	7795-7800	terms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-24	7801-7803	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-25	7804-7807	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-26	7808-7810	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-27	7811-7816	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-28	7817-7820	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-29	7820-7821	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-30	7822-7830	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-31	7831-7833	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-32	7834-7837	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-33	7837-7838	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-34	7839-7842	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-35	7843-7846	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-36	7847-7851	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-37	7852-7857	since	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-38	7858-7862	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-39	7863-7866	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]
46-40	7866-7867	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[40]

#Text=Thirty-nine participants were enrolled in total.
47-1	7868-7879	Thirty-nine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]
47-2	7880-7892	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]
47-3	7893-7897	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]
47-4	7898-7906	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]
47-5	7907-7909	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]
47-6	7910-7915	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]
47-7	7915-7916	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[44]

#Text=After initial telephonic or face-to-face screening, potential participants underwent a Structured Clinical Interview (SCID) for the DSM-IV.
48-1	7917-7922	After	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-2	7923-7930	initial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-3	7931-7941	telephonic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-4	7942-7944	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-5	7945-7957	face-to-face	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-6	7958-7967	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-7	7967-7968	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-8	7969-7978	potential	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-9	7979-7991	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-10	7992-8001	underwent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-11	8002-8003	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
48-12	8004-8014	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[46]
48-13	8015-8023	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[46]
48-14	8024-8033	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[46]
48-15	8034-8035	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[46]
48-16	8035-8039	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[46]
48-17	8039-8040	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[46]
48-18	8041-8044	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[46]
48-19	8045-8048	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[46]
48-20	8049-8055	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[46]
48-21	8055-8056	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[46]

#Text=Written informed consent was obtained after the study procedures were explained.
49-1	8057-8064	Written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-2	8065-8073	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-3	8074-8081	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-4	8082-8085	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-5	8086-8094	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-6	8095-8100	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-7	8101-8104	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-8	8105-8110	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-9	8111-8121	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-10	8122-8126	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-11	8127-8136	explained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]
49-12	8136-8137	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[45]

#Text=Participants were included in the study if they were between 18 and 40 years old.
50-1	8138-8150	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-2	8151-8155	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-3	8156-8164	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-4	8165-8167	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-5	8168-8171	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-6	8172-8177	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-7	8178-8180	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-8	8181-8185	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-9	8186-8190	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-10	8191-8198	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-11	8199-8201	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-12	8202-8205	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-13	8206-8208	40	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-14	8208-8209	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-15	8209-8214	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-16	8215-8218	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
50-17	8218-8219	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]

#Text=Both MA dependent groups were required to have a lifetime diagnosis of MA-dependence on the SCID in accordance with the DSM-IV, be currently drug abstinent (at least 7 days), but have used MA in the previous 6 months.
51-1	8220-8224	Both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-2	8225-8227	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[48]
51-3	8228-8237	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[48]
51-4	8238-8244	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-5	8245-8249	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-6	8250-8258	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-7	8259-8261	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-8	8262-8266	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-9	8267-8268	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-10	8269-8277	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-11	8278-8287	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-12	8288-8290	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-13	8291-8304	MA-dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[49]
51-14	8305-8307	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-15	8308-8311	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-16	8312-8316	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-17	8317-8319	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-18	8320-8330	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-19	8331-8335	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-20	8336-8339	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-21	8340-8346	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-22	8346-8347	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-23	8348-8350	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-24	8351-8360	currently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-25	8361-8365	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-26	8366-8375	abstinent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-27	8376-8377	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-28	8377-8379	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-29	8380-8385	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-30	8386-8387	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-31	8387-8388	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-32	8388-8392	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-33	8392-8393	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-34	8393-8394	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-35	8395-8398	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-36	8399-8403	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-37	8404-8408	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-38	8409-8411	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[50]
51-39	8412-8414	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[50]
51-40	8415-8418	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-41	8419-8427	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-42	8428-8429	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-43	8429-8430	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-44	8430-8436	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
51-45	8436-8437	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]

#Text=The MAP group were required to have had a history of experiencing psychotic symptoms lasting for at least one week in total and associated with MA use.
52-1	8438-8441	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-2	8442-8445	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[51]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[52]
52-3	8446-8451	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[51]
52-4	8452-8456	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-5	8457-8465	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-6	8466-8468	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-7	8469-8473	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-8	8474-8477	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-9	8478-8479	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-10	8480-8487	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-11	8488-8490	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-12	8491-8503	experiencing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-13	8504-8513	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-14	8514-8522	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-15	8523-8530	lasting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-16	8531-8534	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-17	8535-8537	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-18	8538-8543	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-19	8544-8547	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-20	8548-8552	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-21	8553-8555	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-22	8556-8561	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-23	8562-8565	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-24	8566-8576	associated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-25	8577-8581	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-26	8582-8584	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[53]
52-27	8585-8588	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
52-28	8588-8589	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]

#Text=Psychotic symptoms were defined as a minimum score of 3 or more on any one of the items P1, P2, P3, and G9 of the Positive and Negative Syndrome Scale (PANSS) rating scale.
53-1	8590-8599	Psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-2	8600-8608	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-3	8609-8613	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-4	8614-8621	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-5	8622-8624	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-6	8625-8626	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-7	8627-8634	minimum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-8	8635-8640	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-9	8641-8643	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-10	8644-8645	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-11	8646-8648	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-12	8649-8653	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-13	8654-8656	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-14	8657-8660	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-15	8661-8664	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-16	8665-8667	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-17	8668-8671	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-18	8672-8677	items	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-19	8678-8680	P1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-20	8680-8681	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-21	8682-8684	P2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-22	8684-8685	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-23	8686-8688	P3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-24	8688-8689	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-25	8690-8693	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-26	8694-8696	G9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-27	8697-8699	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-28	8700-8703	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-29	8704-8712	Positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]
53-30	8713-8716	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]
53-31	8717-8725	Negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]
53-32	8726-8734	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]
53-33	8735-8740	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]
53-34	8741-8742	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]
53-35	8742-8747	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]
53-36	8747-8748	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[54]
53-37	8749-8755	rating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-38	8756-8761	scale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
53-39	8761-8762	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]

#Text=In all cases, psychotic symptoms induced by MA persisted to the extent that patients required extended hospitalization.
54-1	8763-8765	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-2	8766-8769	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-3	8770-8775	cases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-4	8775-8776	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-5	8777-8786	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-6	8787-8795	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-7	8796-8803	induced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-8	8804-8806	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-9	8807-8809	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[55]
54-10	8810-8819	persisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-11	8820-8822	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-12	8823-8826	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-13	8827-8833	extent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-14	8834-8838	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-15	8839-8847	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-16	8848-8856	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-17	8857-8865	extended	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-18	8866-8881	hospitalization	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
54-19	8881-8882	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]

#Text=However, where psychotic symptoms persisted for so long that the diagnosis was uncertain, or changed to schizophrenia, for example, they were excluded.
55-1	8883-8890	However	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-2	8890-8891	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-3	8892-8897	where	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-4	8898-8907	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-5	8908-8916	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-6	8917-8926	persisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-7	8927-8930	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-8	8931-8933	so	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-9	8934-8938	long	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-10	8939-8943	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-11	8944-8947	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-12	8948-8957	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-13	8958-8961	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-14	8962-8971	uncertain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-15	8971-8972	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-16	8973-8975	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-17	8976-8983	changed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-18	8984-8986	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-19	8987-9000	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-20	9000-9001	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-21	9002-9005	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-22	9006-9013	example	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-23	9013-9014	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-24	9015-9019	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-25	9020-9024	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-26	9025-9033	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]
55-27	9033-9034	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[47]

#Text=Exclusion criteria for all groups included substance-dependence other than MA (except nicotine and marijuana), lifetime and current diagnosis of psychiatric disorders (with the exception of psychosis for the MAP group), history of psychosis prior to MA-use, medical or neurological illness or trauma that would affect the central nervous system, a reported history of a seropositive test for HIV (assessed by self-report) – HIV infection has been associated with changes in brain morphology, severe renal, hepatic, pulmonary, or endocrine disease, head injury resulting in unconsciousness, any metal implantation that would preclude MRI, known claustrophobia or intolerance for confined spaces or previous intolerance of examination in a scanner, intoxication or withdrawal delirium, pregnancy or breastfeeding, diabetes, lack of fluency in English, and left-handedness.
56-1	9035-9044	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-2	9045-9053	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-3	9054-9057	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-4	9058-9061	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-5	9062-9068	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-6	9069-9077	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-7	9078-9098	substance-dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-8	9099-9104	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-9	9105-9109	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-10	9110-9112	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[57]
56-11	9113-9114	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-12	9114-9120	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-13	9121-9129	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-14	9130-9133	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-15	9134-9143	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-16	9143-9144	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-17	9144-9145	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-18	9146-9154	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-19	9155-9158	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[56]
56-20	9159-9166	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-21	9167-9176	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-22	9177-9179	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-23	9180-9191	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-24	9192-9201	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-25	9202-9203	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-26	9203-9207	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-27	9208-9211	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-28	9212-9221	exception	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-29	9222-9224	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-30	9225-9234	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-31	9235-9238	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-32	9239-9242	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-33	9243-9246	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-34	9247-9252	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-35	9252-9253	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-36	9253-9254	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-37	9255-9262	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-38	9263-9265	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-39	9266-9275	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-40	9276-9281	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-41	9282-9284	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-42	9285-9291	MA-use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]|http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence[59]
56-43	9291-9292	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[58]
56-44	9293-9300	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-45	9301-9303	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-46	9304-9316	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-47	9317-9324	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-48	9325-9327	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-49	9328-9334	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-50	9335-9339	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-51	9340-9345	would	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-52	9346-9352	affect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-53	9353-9356	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-54	9357-9364	central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-55	9365-9372	nervous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-56	9373-9379	system	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-57	9379-9380	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-58	9381-9382	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-59	9383-9391	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-60	9392-9399	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-61	9400-9402	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-62	9403-9404	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-63	9405-9417	seropositive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-64	9418-9422	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-65	9423-9426	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-66	9427-9430	HIV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-67	9431-9432	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-68	9432-9440	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[60]
56-69	9441-9443	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-70	9444-9455	self-report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-71	9455-9456	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-72	9457-9458	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-73	9459-9462	HIV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-74	9463-9472	infection	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-75	9473-9476	has	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-76	9477-9481	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-77	9482-9492	associated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-78	9493-9497	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-79	9498-9505	changes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-80	9506-9508	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-81	9509-9514	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-82	9515-9525	morphology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-83	9525-9526	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-84	9527-9533	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-85	9534-9539	renal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-86	9539-9540	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-87	9541-9548	hepatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-88	9548-9549	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-89	9550-9559	pulmonary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-90	9559-9560	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-91	9561-9563	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-92	9564-9573	endocrine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-93	9574-9581	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-94	9581-9582	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[61]
56-95	9583-9587	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-96	9588-9594	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-97	9595-9604	resulting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-98	9605-9607	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-99	9608-9623	unconsciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-100	9623-9624	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-101	9625-9628	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-102	9629-9634	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-103	9635-9647	implantation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-104	9648-9652	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-105	9653-9658	would	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-106	9659-9667	preclude	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-107	9668-9671	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[63]
56-108	9671-9672	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[63]
56-109	9673-9678	known	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-110	9679-9693	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-111	9694-9696	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-112	9697-9708	intolerance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-113	9709-9712	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-114	9713-9721	confined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-115	9722-9728	spaces	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-116	9729-9731	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-117	9732-9740	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-118	9741-9752	intolerance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-119	9753-9755	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-120	9756-9767	examination	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-121	9768-9770	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-122	9771-9772	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-123	9773-9780	scanner	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-124	9780-9781	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-125	9782-9794	intoxication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-126	9795-9797	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-127	9798-9808	withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-128	9809-9817	delirium	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-129	9817-9818	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-130	9819-9828	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-131	9829-9831	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-132	9832-9845	breastfeeding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-133	9845-9846	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-134	9847-9855	diabetes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-135	9855-9856	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-136	9857-9861	lack	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-137	9862-9864	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-138	9865-9872	fluency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-139	9873-9875	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-140	9876-9883	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-141	9883-9884	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-142	9885-9888	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-143	9889-9904	left-handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]
56-144	9904-9905	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[62]

#Text=Urine screens were performed on both scanning days to verify MA abstinence as well as for a pregnancy test for female participants in all 3 groups.
57-1	9906-9911	Urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-2	9912-9919	screens	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-3	9920-9924	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-4	9925-9934	performed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-5	9935-9937	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-6	9938-9942	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-7	9943-9951	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-8	9952-9956	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-9	9957-9959	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-10	9960-9966	verify	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-11	9967-9969	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-12	9970-9980	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-13	9981-9983	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-14	9984-9988	well	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-15	9989-9991	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-16	9992-9995	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-17	9996-9997	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-18	9998-10007	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-19	10008-10012	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-20	10013-10016	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-21	10017-10023	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-22	10024-10036	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-23	10037-10039	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-24	10040-10043	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-25	10044-10045	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-26	10046-10052	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
57-27	10052-10053	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]

#Text=Substance use measures in the MA groups included life-time use of all major drug types, and days of drug use in the past month by drug type.
58-1	10054-10063	Substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-2	10064-10067	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-3	10068-10076	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-4	10077-10079	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-5	10080-10083	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-6	10084-10086	MA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-7	10087-10093	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-8	10094-10102	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-9	10103-10112	life-time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-10	10113-10116	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-11	10117-10119	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-12	10120-10123	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-13	10124-10129	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-14	10130-10134	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-15	10135-10140	types	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-16	10140-10141	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-17	10142-10145	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-18	10146-10150	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-19	10151-10153	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-20	10154-10158	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-21	10159-10162	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-22	10163-10165	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-23	10166-10169	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-24	10170-10174	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-25	10175-10180	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-26	10181-10183	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-27	10184-10188	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-28	10189-10193	type	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
58-29	10193-10194	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]

#Text=Measures of MA-use included age of first MA-use, frequency and quantity of MA-use in the past year, and the number of drug-free days prior to scanning.
59-1	10195-10203	Measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-2	10204-10206	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-3	10207-10213	MA-use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-4	10214-10222	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-5	10223-10226	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-6	10227-10229	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-7	10230-10235	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-8	10236-10242	MA-use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-9	10242-10243	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-10	10244-10253	frequency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-11	10254-10257	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-12	10258-10266	quantity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-13	10267-10269	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-14	10270-10276	MA-use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-15	10277-10279	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-16	10280-10283	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-17	10284-10288	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-18	10289-10293	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-19	10293-10294	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-20	10295-10298	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-21	10299-10302	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-22	10303-10309	number	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-23	10310-10312	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-24	10313-10322	drug-free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-25	10323-10327	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-26	10328-10333	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-27	10334-10336	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-28	10337-10345	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]
59-29	10345-10346	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[64]

#Text=The duration of time on neuroleptic agents for the MAP group was recorded.
60-1	10347-10350	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-2	10351-10359	duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-3	10360-10362	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-4	10363-10367	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-5	10368-10370	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-6	10371-10382	neuroleptic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-7	10383-10389	agents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-8	10390-10393	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-9	10394-10397	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-10	10398-10401	MAP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-11	10402-10407	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-12	10408-10411	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-13	10412-10420	recorded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[65]
60-14	10420-10421	.	_

#Text=The study was approved by the Health Research Ethics Committees of both the University of Cape Town and Stellenbosch University.
61-1	10422-10425	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-2	10426-10431	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-3	10432-10435	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-4	10436-10444	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-5	10445-10447	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-6	10448-10451	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-7	10452-10458	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-8	10459-10467	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-9	10468-10474	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-10	10475-10485	Committees	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-11	10486-10488	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-12	10489-10493	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-13	10494-10497	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-14	10498-10508	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-15	10509-10511	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-16	10512-10516	Cape	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-17	10517-10521	Town	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-18	10522-10525	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-19	10526-10538	Stellenbosch	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-20	10539-10549	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]
61-21	10549-10550	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[66]

#Text=Image acquisition
#Text=The PET scanning took place at the Western Cape Academic PET/CT Centre at Tygerberg Hospital.
62-1	10551-10556	Image	_
62-2	10557-10568	acquisition	_
62-3	10569-10572	The	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[67]
62-4	10573-10576	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[67]
62-5	10577-10585	scanning	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography[67]
62-6	10586-10590	took	_
62-7	10591-10596	place	_
62-8	10597-10599	at	_
62-9	10600-10603	the	_
62-10	10604-10611	Western	_
62-11	10612-10616	Cape	_
62-12	10617-10625	Academic	_
62-13	10626-10629	PET	_
62-14	10629-10630	/	_
62-15	10630-10632	CT	_
62-16	10633-10639	Centre	_
62-17	10640-10642	at	_
62-18	10643-10652	Tygerberg	_
62-19	10653-10661	Hospital	_
62-20	10661-10662	.	_

#Text=PET scans were acquired using a Phillips Gemini TF Big Bore scanner (Phillips Medical Systems).
63-1	10663-10666	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
63-2	10667-10672	scans	_
63-3	10673-10677	were	_
63-4	10678-10686	acquired	_
63-5	10687-10692	using	_
63-6	10693-10694	a	_
63-7	10695-10703	Phillips	_
63-8	10704-10710	Gemini	_
63-9	10711-10713	TF	_
63-10	10714-10717	Big	_
63-11	10718-10722	Bore	_
63-12	10723-10730	scanner	_
63-13	10731-10732	(	_
63-14	10732-10740	Phillips	_
63-15	10741-10748	Medical	_
63-16	10749-10756	Systems	_
63-17	10756-10757	)	_
63-18	10757-10758	.	_

#Text=All PET acquisitions were conducted at a similar time of day in order to minimize variations in diurnal patterns of cortisol.
64-1	10759-10762	All	_
64-2	10763-10766	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
64-3	10767-10779	acquisitions	_
64-4	10780-10784	were	_
64-5	10785-10794	conducted	_
64-6	10795-10797	at	_
64-7	10798-10799	a	_
64-8	10800-10807	similar	_
64-9	10808-10812	time	_
64-10	10813-10815	of	_
64-11	10816-10819	day	_
64-12	10820-10822	in	_
64-13	10823-10828	order	_
64-14	10829-10831	to	_
64-15	10832-10840	minimize	_
64-16	10841-10851	variations	_
64-17	10852-10854	in	_
64-18	10855-10862	diurnal	_
64-19	10863-10871	patterns	_
64-20	10872-10874	of	_
64-21	10875-10883	cortisol	_
64-22	10883-10884	.	_

#Text=On the day of the scan, participants were required to fast for 4–6 h prior to the scan, although intake of plain water was encouraged.
65-1	10885-10887	On	_
65-2	10888-10891	the	_
65-3	10892-10895	day	_
65-4	10896-10898	of	_
65-5	10899-10902	the	_
65-6	10903-10907	scan	_
65-7	10907-10908	,	_
65-8	10909-10921	participants	_
65-9	10922-10926	were	_
65-10	10927-10935	required	_
65-11	10936-10938	to	_
65-12	10939-10943	fast	_
65-13	10944-10947	for	_
65-14	10948-10949	4	_
65-15	10949-10950	–	_
65-16	10950-10951	6	_
65-17	10951-10952	 	_
65-18	10952-10953	h	_
65-19	10954-10959	prior	_
65-20	10960-10962	to	_
65-21	10963-10966	the	_
65-22	10967-10971	scan	_
65-23	10971-10972	,	_
65-24	10973-10981	although	_
65-25	10982-10988	intake	_
65-26	10989-10991	of	_
65-27	10992-10997	plain	_
65-28	10998-11003	water	_
65-29	11004-11007	was	_
65-30	11008-11018	encouraged	_
65-31	11018-11019	.	_

#Text=PET imaging was performed 30 min after the intravenous administration of a dose of 150 MBq of FDG.
66-1	11020-11023	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
66-2	11024-11031	imaging	_
66-3	11032-11035	was	_
66-4	11036-11045	performed	_
66-5	11046-11048	30	_
66-6	11048-11049	 	_
66-7	11049-11052	min	_
66-8	11053-11058	after	_
66-9	11059-11062	the	_
66-10	11063-11074	intravenous	_
66-11	11075-11089	administration	_
66-12	11090-11092	of	_
66-13	11093-11094	a	_
66-14	11095-11099	dose	_
66-15	11100-11102	of	_
66-16	11103-11106	150	_
66-17	11106-11107	 	_
66-18	11107-11110	MBq	_
66-19	11111-11113	of	_
66-20	11114-11117	FDG	_
66-21	11117-11118	.	_

#Text=Scanning was done with the subject's head supported by a headrest and bandage.
67-1	11119-11127	Scanning	_
67-2	11128-11131	was	_
67-3	11132-11136	done	_
67-4	11137-11141	with	_
67-5	11142-11145	the	_
67-6	11146-11155	subject's	_
67-7	11156-11160	head	_
67-8	11161-11170	supported	_
67-9	11171-11173	by	_
67-10	11174-11175	a	_
67-11	11176-11184	headrest	_
67-12	11185-11188	and	_
67-13	11189-11196	bandage	_
67-14	11196-11197	.	_

#Text=To correct for attenuation, a low-dose CT was performed without contrast (120 kV tube potential, 20 mAs).
68-1	11198-11200	To	_
68-2	11201-11208	correct	_
68-3	11209-11212	for	_
68-4	11213-11224	attenuation	_
68-5	11224-11225	,	_
68-6	11226-11227	a	_
68-7	11228-11236	low-dose	_
68-8	11237-11239	CT	_
68-9	11240-11243	was	_
68-10	11244-11253	performed	_
68-11	11254-11261	without	_
68-12	11262-11270	contrast	_
68-13	11271-11272	(	_
68-14	11272-11275	120	_
68-15	11275-11276	 	_
68-16	11276-11278	kV	_
68-17	11279-11283	tube	_
68-18	11284-11293	potential	_
68-19	11293-11294	,	_
68-20	11295-11297	20	_
68-21	11298-11301	mAs	_
68-22	11301-11302	)	_
68-23	11302-11303	.	_

#Text=This was followed by a 30-min dynamic acquisition of emission data.
69-1	11304-11308	This	_
69-2	11309-11312	was	_
69-3	11313-11321	followed	_
69-4	11322-11324	by	_
69-5	11325-11326	a	_
69-6	11327-11329	30	_
69-7	11329-11330	-	_
69-8	11330-11333	min	_
69-9	11334-11341	dynamic	_
69-10	11342-11353	acquisition	_
69-11	11354-11356	of	_
69-12	11357-11365	emission	_
69-13	11366-11370	data	_
69-14	11370-11371	.	_

#Text=Data were rebinned as 15 2-min scans, after reconstructing using 3D line of response row-action maximum likelihood algorithm (LOR-RAMLA).
70-1	11372-11376	Data	_
70-2	11377-11381	were	_
70-3	11382-11390	rebinned	_
70-4	11391-11393	as	_
70-5	11394-11396	15	_
70-6	11397-11398	2	_
70-7	11398-11399	-	_
70-8	11399-11402	min	_
70-9	11403-11408	scans	_
70-10	11408-11409	,	_
70-11	11410-11415	after	_
70-12	11416-11430	reconstructing	_
70-13	11431-11436	using	_
70-14	11437-11439	3D	_
70-15	11440-11444	line	_
70-16	11445-11447	of	_
70-17	11448-11456	response	_
70-18	11457-11467	row-action	_
70-19	11468-11475	maximum	_
70-20	11476-11486	likelihood	_
70-21	11487-11496	algorithm	_
70-22	11497-11498	(	_
70-23	11498-11507	LOR-RAMLA	_
70-24	11507-11508	)	_
70-25	11508-11509	.	_

#Text=Corrections for scatter, random events and attenuation were included.
71-1	11510-11521	Corrections	_
71-2	11522-11525	for	_
71-3	11526-11533	scatter	_
71-4	11533-11534	,	_
71-5	11535-11541	random	_
71-6	11542-11548	events	_
71-7	11549-11552	and	_
71-8	11553-11564	attenuation	_
71-9	11565-11569	were	_
71-10	11570-11578	included	_
71-11	11578-11579	.	_

#Text=The reconstructed images were comprised of 90 slices covering the whole brain (voxel size = 2 × 2 × 2 mm3).
72-1	11580-11583	The	_
72-2	11584-11597	reconstructed	_
72-3	11598-11604	images	_
72-4	11605-11609	were	_
72-5	11610-11619	comprised	_
72-6	11620-11622	of	_
72-7	11623-11625	90	_
72-8	11626-11632	slices	_
72-9	11633-11641	covering	_
72-10	11642-11645	the	_
72-11	11646-11651	whole	_
72-12	11652-11657	brain	_
72-13	11658-11659	(	_
72-14	11659-11664	voxel	_
72-15	11665-11669	size	_
72-16	11669-11670	 	_
72-17	11670-11671	=	_
72-18	11671-11672	 	_
72-19	11672-11673	2	_
72-20	11673-11674	 	_
72-21	11674-11675	×	_
72-22	11675-11676	 	_
72-23	11676-11677	2	_
72-24	11677-11678	 	_
72-25	11678-11679	×	_
72-26	11679-11680	 	_
72-27	11680-11681	2	_
72-28	11682-11685	mm3	_
72-29	11685-11686	)	_
72-30	11686-11687	.	_

#Text=The MRI scanning took place within 24 h of the PET scan at approximately the same time of day.
73-1	11688-11691	The	_
73-2	11692-11695	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[68]
73-3	11696-11704	scanning	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[68]
73-4	11705-11709	took	_
73-5	11710-11715	place	_
73-6	11716-11722	within	_
73-7	11723-11725	24	_
73-8	11725-11726	 	_
73-9	11726-11727	h	_
73-10	11728-11730	of	_
73-11	11731-11734	the	_
73-12	11735-11738	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
73-13	11739-11743	scan	_
73-14	11744-11746	at	_
73-15	11747-11760	approximately	_
73-16	11761-11764	the	_
73-17	11765-11769	same	_
73-18	11770-11774	time	_
73-19	11775-11777	of	_
73-20	11778-11781	day	_
73-21	11781-11782	.	_

#Text=Scanning was conducted using a 3T Siemens Magnetom Allegra at CUBIC (Cape Universities Brain Imaging Centre) in Tygerberg.
74-1	11783-11791	Scanning	_
74-2	11792-11795	was	_
74-3	11796-11805	conducted	_
74-4	11806-11811	using	_
74-5	11812-11813	a	_
74-6	11814-11816	3T	_
74-7	11817-11824	Siemens	_
74-8	11825-11833	Magnetom	_
74-9	11834-11841	Allegra	_
74-10	11842-11844	at	_
74-11	11845-11850	CUBIC	_
74-12	11851-11852	(	_
74-13	11852-11856	Cape	_
74-14	11857-11869	Universities	_
74-15	11870-11875	Brain	_
74-16	11876-11883	Imaging	_
74-17	11884-11890	Centre	_
74-18	11890-11891	)	_
74-19	11892-11894	in	_
74-20	11895-11904	Tygerberg	_
74-21	11904-11905	.	_

#Text=The following images were acquired: 1) a high resolution T1-weighted 3D anatomical image (MPRAGE): sagittal orientation, 160 slices, TR = 2530 ms, TE = 1.53, 3.21, 4.89, 6.57 ms, 240 × 256 matrix, voxel size = 1 × 1 × 1mm3, flip angle = 7 degrees; and 2) pseudo continuous arterial spin labelling (pCASL): eyes closed: scan time = 8 min, TR = 3300 ms, TE = 16 ms, flip angle = 90 degrees, voxel size = 3.6 × 3.6 × 5mm3, 64 × 64 matrix.
75-1	11906-11909	The	_
75-2	11910-11919	following	_
75-3	11920-11926	images	_
75-4	11927-11931	were	_
75-5	11932-11940	acquired	_
75-6	11940-11941	:	_
75-7	11942-11943	1	_
75-8	11943-11944	)	_
75-9	11945-11946	a	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]
75-10	11947-11951	high	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]
75-11	11952-11962	resolution	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]
75-12	11963-11965	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]|http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[70]
75-13	11965-11966	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]|http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[70]
75-14	11966-11974	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]|http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[70]
75-15	11975-11977	3D	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]
75-16	11978-11988	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]
75-17	11989-11994	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]
75-18	11995-11996	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]
75-19	11996-12002	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]
75-20	12002-12003	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[69]
75-21	12003-12004	:	_
75-22	12005-12013	sagittal	_
75-23	12014-12025	orientation	_
75-24	12025-12026	,	_
75-25	12027-12030	160	_
75-26	12031-12037	slices	_
75-27	12037-12038	,	_
75-28	12039-12041	TR	_
75-29	12041-12042	 	_
75-30	12042-12043	=	_
75-31	12043-12044	 	_
75-32	12044-12048	2530	_
75-33	12048-12049	 	_
75-34	12049-12051	ms	_
75-35	12051-12052	,	_
75-36	12053-12055	TE	_
75-37	12055-12056	 	_
75-38	12056-12057	=	_
75-39	12057-12058	 	_
75-40	12058-12062	1.53	_
75-41	12062-12063	,	_
75-42	12064-12068	3.21	_
75-43	12068-12069	,	_
75-44	12070-12074	4.89	_
75-45	12074-12075	,	_
75-46	12076-12080	6.57	_
75-47	12080-12081	 	_
75-48	12081-12083	ms	_
75-49	12083-12084	,	_
75-50	12085-12088	240	_
75-51	12088-12089	 	_
75-52	12089-12090	×	_
75-53	12090-12091	 	_
75-54	12091-12094	256	_
75-55	12095-12101	matrix	_
75-56	12101-12102	,	_
75-57	12103-12108	voxel	_
75-58	12109-12113	size	_
75-59	12113-12114	 	_
75-60	12114-12115	=	_
75-61	12115-12116	 	_
75-62	12116-12117	1	_
75-63	12117-12118	 	_
75-64	12118-12119	×	_
75-65	12119-12120	 	_
75-66	12120-12121	1	_
75-67	12121-12122	 	_
75-68	12122-12123	×	_
75-69	12123-12124	 	_
75-70	12124-12128	1mm3	_
75-71	12128-12129	,	_
75-72	12130-12134	flip	_
75-73	12135-12140	angle	_
75-74	12140-12141	 	_
75-75	12141-12142	=	_
75-76	12142-12143	 	_
75-77	12143-12144	7	_
75-78	12145-12152	degrees	_
75-79	12152-12153	;	_
75-80	12154-12157	and	_
75-81	12158-12159	2	_
75-82	12159-12160	)	_
75-83	12161-12167	pseudo	_
75-84	12168-12178	continuous	_
75-85	12179-12187	arterial	_
75-86	12188-12192	spin	_
75-87	12193-12202	labelling	_
75-88	12203-12204	(	_
75-89	12204-12209	pCASL	_
75-90	12209-12210	)	_
75-91	12210-12211	:	_
75-92	12212-12216	eyes	_
75-93	12217-12223	closed	_
75-94	12223-12224	:	_
75-95	12225-12229	scan	_
75-96	12230-12234	time	_
75-97	12234-12235	 	_
75-98	12235-12236	=	_
75-99	12236-12237	 	_
75-100	12237-12238	8	_
75-101	12238-12239	 	_
75-102	12239-12242	min	_
75-103	12242-12243	,	_
75-104	12244-12246	TR	_
75-105	12246-12247	 	_
75-106	12247-12248	=	_
75-107	12248-12249	 	_
75-108	12249-12253	3300	_
75-109	12253-12254	 	_
75-110	12254-12256	ms	_
75-111	12256-12257	,	_
75-112	12258-12260	TE	_
75-113	12260-12261	 	_
75-114	12261-12262	=	_
75-115	12262-12263	 	_
75-116	12263-12265	16	_
75-117	12265-12266	 	_
75-118	12266-12268	ms	_
75-119	12268-12269	,	_
75-120	12270-12274	flip	_
75-121	12275-12280	angle	_
75-122	12280-12281	 	_
75-123	12281-12282	=	_
75-124	12282-12283	 	_
75-125	12283-12285	90	_
75-126	12286-12293	degrees	_
75-127	12293-12294	,	_
75-128	12295-12300	voxel	_
75-129	12301-12305	size	_
75-130	12305-12306	 	_
75-131	12306-12307	=	_
75-132	12307-12308	 	_
75-133	12308-12311	3.6	_
75-134	12311-12312	 	_
75-135	12312-12313	×	_
75-136	12313-12314	 	_
75-137	12314-12317	3.6	_
75-138	12317-12318	 	_
75-139	12318-12319	×	_
75-140	12319-12320	 	_
75-141	12320-12324	5mm3	_
75-142	12324-12325	,	_
75-143	12326-12328	64	_
75-144	12328-12329	 	_
75-145	12329-12330	×	_
75-146	12330-12331	 	_
75-147	12331-12333	64	_
75-148	12334-12340	matrix	_
75-149	12340-12341	.	_

#Text=Image and data analysis
#Text=Statistical Parametric Mapping software (SPM; version SPM8; http://www.fil.ion.ucl.ac.uk/spm) and statistical non-parametric mapping software (SnPM; version SnPM13; http://warwick.ac.uk/snpm) were used to perform all the analyses across both imaging techniques.
76-1	12342-12347	Image	_
76-2	12348-12351	and	_
76-3	12352-12356	data	_
76-4	12357-12365	analysis	_
76-5	12366-12377	Statistical	_
76-6	12378-12388	Parametric	_
76-7	12389-12396	Mapping	_
76-8	12397-12405	software	_
76-9	12406-12407	(	_
76-10	12407-12410	SPM	_
76-11	12410-12411	;	_
76-12	12412-12419	version	_
76-13	12420-12424	SPM8	_
76-14	12424-12425	;	_
76-15	12426-12430	http	_
76-16	12430-12431	:	_
76-17	12431-12432	/	_
76-18	12432-12433	/	_
76-19	12433-12454	www.fil.ion.ucl.ac.uk	_
76-20	12454-12455	/	_
76-21	12455-12458	spm	_
76-22	12458-12459	)	_
76-23	12460-12463	and	_
76-24	12464-12475	statistical	_
76-25	12476-12490	non-parametric	_
76-26	12491-12498	mapping	_
76-27	12499-12507	software	_
76-28	12508-12509	(	_
76-29	12509-12513	SnPM	_
76-30	12513-12514	;	_
76-31	12515-12522	version	_
76-32	12523-12529	SnPM13	_
76-33	12529-12530	;	_
76-34	12531-12535	http	_
76-35	12535-12536	:	_
76-36	12536-12537	/	_
76-37	12537-12538	/	_
76-38	12538-12551	warwick.ac.uk	_
76-39	12551-12552	/	_
76-40	12552-12556	snpm	_
76-41	12556-12557	)	_
76-42	12558-12562	were	_
76-43	12563-12567	used	_
76-44	12568-12570	to	_
76-45	12571-12578	perform	_
76-46	12579-12582	all	_
76-47	12583-12586	the	_
76-48	12587-12595	analyses	_
76-49	12596-12602	across	_
76-50	12603-12607	both	_
76-51	12608-12615	imaging	_
76-52	12616-12626	techniques	_
76-53	12626-12627	.	_

#Text=First, SPM8 was used to segment the MPRAGE into gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF).
77-1	12628-12633	First	_
77-2	12633-12634	,	_
77-3	12635-12639	SPM8	_
77-4	12640-12643	was	_
77-5	12644-12648	used	_
77-6	12649-12651	to	_
77-7	12652-12659	segment	_
77-8	12660-12663	the	_
77-9	12664-12670	MPRAGE	_
77-10	12671-12675	into	_
77-11	12676-12680	gray	_
77-12	12681-12687	matter	_
77-13	12688-12689	(	_
77-14	12689-12691	GM	_
77-15	12691-12692	)	_
77-16	12692-12693	,	_
77-17	12694-12699	white	_
77-18	12700-12706	matter	_
77-19	12707-12708	(	_
77-20	12708-12710	WM	_
77-21	12710-12711	)	_
77-22	12712-12715	and	_
77-23	12716-12729	cerebrospinal	_
77-24	12730-12735	fluid	_
77-25	12736-12737	(	_
77-26	12737-12740	CSF	_
77-27	12740-12741	)	_
77-28	12741-12742	.	_

#Text=The segmentation step also determined the transformation to MNI (Montreal Neurological Institute) space.
78-1	12743-12746	The	_
78-2	12747-12759	segmentation	_
78-3	12760-12764	step	_
78-4	12765-12769	also	_
78-5	12770-12780	determined	_
78-6	12781-12784	the	_
78-7	12785-12799	transformation	_
78-8	12800-12802	to	_
78-9	12803-12806	MNI	_
78-10	12807-12808	(	_
78-11	12808-12816	Montreal	_
78-12	12817-12829	Neurological	_
78-13	12830-12839	Institute	_
78-14	12839-12840	)	_
78-15	12841-12846	space	_
78-16	12846-12847	.	_

#Text=PET images were realigned to correct for small patient movements and a summed image was created.
79-1	12848-12851	PET	_
79-2	12852-12858	images	_
79-3	12859-12863	were	_
79-4	12864-12873	realigned	_
79-5	12874-12876	to	_
79-6	12877-12884	correct	_
79-7	12885-12888	for	_
79-8	12889-12894	small	_
79-9	12895-12902	patient	_
79-10	12903-12912	movements	_
79-11	12913-12916	and	_
79-12	12917-12918	a	_
79-13	12919-12925	summed	_
79-14	12926-12931	image	_
79-15	12932-12935	was	_
79-16	12936-12943	created	_
79-17	12943-12944	.	_

#Text=Head movement was considered to be excessive if scan-to-scan displacement was >2 mm, overall translation in any direction was >5 mm, or overall rotation in any direction was >3 degrees.
80-1	12945-12949	Head	_
80-2	12950-12958	movement	_
80-3	12959-12962	was	_
80-4	12963-12973	considered	_
80-5	12974-12976	to	_
80-6	12977-12979	be	_
80-7	12980-12989	excessive	_
80-8	12990-12992	if	_
80-9	12993-13005	scan-to-scan	_
80-10	13006-13018	displacement	_
80-11	13019-13022	was	_
80-12	13023-13024	>	_
80-13	13024-13025	2	_
80-14	13025-13026	 	_
80-15	13026-13028	mm	_
80-16	13028-13029	,	_
80-17	13030-13037	overall	_
80-18	13038-13049	translation	_
80-19	13050-13052	in	_
80-20	13053-13056	any	_
80-21	13057-13066	direction	_
80-22	13067-13070	was	_
80-23	13071-13072	>	_
80-24	13072-13073	5	_
80-25	13073-13074	 	_
80-26	13074-13076	mm	_
80-27	13076-13077	,	_
80-28	13078-13080	or	_
80-29	13081-13088	overall	_
80-30	13089-13097	rotation	_
80-31	13098-13100	in	_
80-32	13101-13104	any	_
80-33	13105-13114	direction	_
80-34	13115-13118	was	_
80-35	13119-13120	>	_
80-36	13120-13121	3	_
80-37	13122-13129	degrees	_
80-38	13129-13130	.	_

#Text=If patient movement was excessive, the summed image was limited to that part of the acquisition when movement was considered acceptable (a minimum of 2 consecutive volumes).
81-1	13131-13133	If	_
81-2	13134-13141	patient	_
81-3	13142-13150	movement	_
81-4	13151-13154	was	_
81-5	13155-13164	excessive	_
81-6	13164-13165	,	_
81-7	13166-13169	the	_
81-8	13170-13176	summed	_
81-9	13177-13182	image	_
81-10	13183-13186	was	_
81-11	13187-13194	limited	_
81-12	13195-13197	to	_
81-13	13198-13202	that	_
81-14	13203-13207	part	_
81-15	13208-13210	of	_
81-16	13211-13214	the	_
81-17	13215-13226	acquisition	_
81-18	13227-13231	when	_
81-19	13232-13240	movement	_
81-20	13241-13244	was	_
81-21	13245-13255	considered	_
81-22	13256-13266	acceptable	_
81-23	13267-13268	(	_
81-24	13268-13269	a	_
81-25	13270-13277	minimum	_
81-26	13278-13280	of	_
81-27	13281-13282	2	_
81-28	13283-13294	consecutive	_
81-29	13295-13302	volumes	_
81-30	13302-13303	)	_
81-31	13303-13304	.	_

#Text=The summed image was coregistered to the MPRAGE image and the transformation to MNI was applied.
82-1	13305-13308	The	_
82-2	13309-13315	summed	_
82-3	13316-13321	image	_
82-4	13322-13325	was	_
82-5	13326-13338	coregistered	_
82-6	13339-13341	to	_
82-7	13342-13345	the	_
82-8	13346-13352	MPRAGE	_
82-9	13353-13358	image	_
82-10	13359-13362	and	_
82-11	13363-13366	the	_
82-12	13367-13381	transformation	_
82-13	13382-13384	to	_
82-14	13385-13388	MNI	_
82-15	13389-13392	was	_
82-16	13393-13400	applied	_
82-17	13400-13401	.	_

#Text=PET images were smoothed with a 12 mm full width at half maximum (FWHM) isotropic 3-dimensional Gaussian kernel.
83-1	13402-13405	PET	_
83-2	13406-13412	images	_
83-3	13413-13417	were	_
83-4	13418-13426	smoothed	_
83-5	13427-13431	with	_
83-6	13432-13433	a	_
83-7	13434-13436	12	_
83-8	13436-13437	 	_
83-9	13437-13439	mm	_
83-10	13440-13444	full	_
83-11	13445-13450	width	_
83-12	13451-13453	at	_
83-13	13454-13458	half	_
83-14	13459-13466	maximum	_
83-15	13467-13468	(	_
83-16	13468-13472	FWHM	_
83-17	13472-13473	)	_
83-18	13474-13483	isotropic	_
83-19	13484-13485	3	_
83-20	13485-13486	-	_
83-21	13486-13497	dimensional	_
83-22	13498-13506	Gaussian	_
83-23	13507-13513	kernel	_
83-24	13513-13514	.	_

#Text=The ASL toolbox (https://cfn.upenn.edu/~zewang/ASLtbx.php) for SPM was used to perform the ASL analysis.
84-1	13515-13518	The	_
84-2	13519-13522	ASL	_
84-3	13523-13530	toolbox	_
84-4	13531-13532	(	_
84-5	13532-13537	https	_
84-6	13537-13538	:	_
84-7	13538-13539	/	_
84-8	13539-13540	/	_
84-9	13540-13553	cfn.upenn.edu	_
84-10	13553-13554	/	_
84-11	13554-13555	~	_
84-12	13555-13561	zewang	_
84-13	13561-13562	/	_
84-14	13562-13572	ASLtbx.php	_
84-15	13572-13573	)	_
84-16	13574-13577	for	_
84-17	13578-13581	SPM	_
84-18	13582-13585	was	_
84-19	13586-13590	used	_
84-20	13591-13593	to	_
84-21	13594-13601	perform	_
84-22	13602-13605	the	_
84-23	13606-13609	ASL	_
84-24	13610-13618	analysis	_
84-25	13618-13619	.	_

#Text=Pre-processing of the ASL data included realignment of the tag and control images to correct for small head movements, coregistration of tag/control images to the structural image (MPRAGE), followed by smoothing with an 8 mm FWHM Gaussian isotropic 3D kernel.
85-1	13620-13634	Pre-processing	_
85-2	13635-13637	of	_
85-3	13638-13641	the	_
85-4	13642-13645	ASL	_
85-5	13646-13650	data	_
85-6	13651-13659	included	_
85-7	13660-13671	realignment	_
85-8	13672-13674	of	_
85-9	13675-13678	the	_
85-10	13679-13682	tag	_
85-11	13683-13686	and	_
85-12	13687-13694	control	_
85-13	13695-13701	images	_
85-14	13702-13704	to	_
85-15	13705-13712	correct	_
85-16	13713-13716	for	_
85-17	13717-13722	small	_
85-18	13723-13727	head	_
85-19	13728-13737	movements	_
85-20	13737-13738	,	_
85-21	13739-13753	coregistration	_
85-22	13754-13756	of	_
85-23	13757-13760	tag	_
85-24	13760-13761	/	_
85-25	13761-13768	control	_
85-26	13769-13775	images	_
85-27	13776-13778	to	_
85-28	13779-13782	the	_
85-29	13783-13793	structural	_
85-30	13794-13799	image	_
85-31	13800-13801	(	_
85-32	13801-13807	MPRAGE	_
85-33	13807-13808	)	_
85-34	13808-13809	,	_
85-35	13810-13818	followed	_
85-36	13819-13821	by	_
85-37	13822-13831	smoothing	_
85-38	13832-13836	with	_
85-39	13837-13839	an	_
85-40	13840-13841	8	_
85-41	13841-13842	 	_
85-42	13842-13844	mm	_
85-43	13845-13849	FWHM	_
85-44	13850-13858	Gaussian	_
85-45	13859-13868	isotropic	_
85-46	13869-13871	3D	_
85-47	13872-13878	kernel	_
85-48	13878-13879	.	_

#Text=For each subject 60 consecutive volumes were selected, which minimized both total range of motion and scan-to-scan motion.
86-1	13880-13883	For	_
86-2	13884-13888	each	_
86-3	13889-13896	subject	_
86-4	13897-13899	60	_
86-5	13900-13911	consecutive	_
86-6	13912-13919	volumes	_
86-7	13920-13924	were	_
86-8	13925-13933	selected	_
86-9	13933-13934	,	_
86-10	13935-13940	which	_
86-11	13941-13950	minimized	_
86-12	13951-13955	both	_
86-13	13956-13961	total	_
86-14	13962-13967	range	_
86-15	13968-13970	of	_
86-16	13971-13977	motion	_
86-17	13978-13981	and	_
86-18	13982-13994	scan-to-scan	_
86-19	13995-14001	motion	_
86-20	14001-14002	.	_

#Text=The participant was eliminated if there was no segment of 60 consecutive volumes where total range of motion was <1 mm and scan-to-scan motion <0.6 mm.
87-1	14003-14006	The	_
87-2	14007-14018	participant	_
87-3	14019-14022	was	_
87-4	14023-14033	eliminated	_
87-5	14034-14036	if	_
87-6	14037-14042	there	_
87-7	14043-14046	was	_
87-8	14047-14049	no	_
87-9	14050-14057	segment	_
87-10	14058-14060	of	_
87-11	14061-14063	60	_
87-12	14064-14075	consecutive	_
87-13	14076-14083	volumes	_
87-14	14084-14089	where	_
87-15	14090-14095	total	_
87-16	14096-14101	range	_
87-17	14102-14104	of	_
87-18	14105-14111	motion	_
87-19	14112-14115	was	_
87-20	14116-14117	<	_
87-21	14117-14118	1	_
87-22	14118-14119	 	_
87-23	14119-14121	mm	_
87-24	14122-14125	and	_
87-25	14126-14138	scan-to-scan	_
87-26	14139-14145	motion	_
87-27	14146-14147	<	_
87-28	14147-14150	0.6	_
87-29	14150-14151	 	_
87-30	14151-14153	mm	_
87-31	14153-14154	.	_

#Text=CBF/perfusion images were calculated from each tag and control pair using simple subtraction and using the mean of the control images as an estimate of the equilibrium magnetization of blood.
88-1	14155-14158	CBF	_
88-2	14158-14159	/	_
88-3	14159-14168	perfusion	_
88-4	14169-14175	images	_
88-5	14176-14180	were	_
88-6	14181-14191	calculated	_
88-7	14192-14196	from	_
88-8	14197-14201	each	_
88-9	14202-14205	tag	_
88-10	14206-14209	and	_
88-11	14210-14217	control	_
88-12	14218-14222	pair	_
88-13	14223-14228	using	_
88-14	14229-14235	simple	_
88-15	14236-14247	subtraction	_
88-16	14248-14251	and	_
88-17	14252-14257	using	_
88-18	14258-14261	the	_
88-19	14262-14266	mean	_
88-20	14267-14269	of	_
88-21	14270-14273	the	_
88-22	14274-14281	control	_
88-23	14282-14288	images	_
88-24	14289-14291	as	_
88-25	14292-14294	an	_
88-26	14295-14303	estimate	_
88-27	14304-14306	of	_
88-28	14307-14310	the	_
88-29	14311-14322	equilibrium	_
88-30	14323-14336	magnetization	_
88-31	14337-14339	of	_
88-32	14340-14345	blood	_
88-33	14345-14346	.	_

#Text=The mean CBF over the whole brain was then checked, and any participants with a mean CBF that was unrealistically low (<20 mL/min per 100 g) were excluded.
89-1	14347-14350	The	_
89-2	14351-14355	mean	_
89-3	14356-14359	CBF	_
89-4	14360-14364	over	_
89-5	14365-14368	the	_
89-6	14369-14374	whole	_
89-7	14375-14380	brain	_
89-8	14381-14384	was	_
89-9	14385-14389	then	_
89-10	14390-14397	checked	_
89-11	14397-14398	,	_
89-12	14399-14402	and	_
89-13	14403-14406	any	_
89-14	14407-14419	participants	_
89-15	14420-14424	with	_
89-16	14425-14426	a	_
89-17	14427-14431	mean	_
89-18	14432-14435	CBF	_
89-19	14436-14440	that	_
89-20	14441-14444	was	_
89-21	14445-14460	unrealistically	_
89-22	14461-14464	low	_
89-23	14465-14466	(	_
89-24	14466-14467	<	_
89-25	14467-14469	20	_
89-26	14469-14470	 	_
89-27	14470-14472	mL	_
89-28	14472-14473	/	_
89-29	14473-14476	min	_
89-30	14477-14480	per	_
89-31	14481-14484	100	_
89-32	14484-14485	 	_
89-33	14485-14486	g	_
89-34	14486-14487	)	_
89-35	14488-14492	were	_
89-36	14493-14501	excluded	_
89-37	14501-14502	.	_

#Text=All CBF functional images were warped to MNI (using the transformation based on the MRPAGE).
90-1	14503-14506	All	_
90-2	14507-14510	CBF	_
90-3	14511-14521	functional	_
90-4	14522-14528	images	_
90-5	14529-14533	were	_
90-6	14534-14540	warped	_
90-7	14541-14543	to	_
90-8	14544-14547	MNI	_
90-9	14548-14549	(	_
90-10	14549-14554	using	_
90-11	14555-14558	the	_
90-12	14559-14573	transformation	_
90-13	14574-14579	based	_
90-14	14580-14582	on	_
90-15	14583-14586	the	_
90-16	14587-14593	MRPAGE	_
90-17	14593-14594	)	_
90-18	14594-14595	.	_

#Text=Statistical analysis
#Text=We performed a voxel-based whole-brain analysis using statistical non-parametric mapping (SnPM13) in which we compared regional cerebral metabolic rate of glucose (using the FDG-PET images) or regional cerebral blood flow (using the ASL images) in the healthy control group and the patient group (the MAA and MAP group combined).
91-1	14596-14607	Statistical	_
91-2	14608-14616	analysis	_
91-3	14617-14619	We	_
91-4	14620-14629	performed	_
91-5	14630-14631	a	_
91-6	14632-14643	voxel-based	_
91-7	14644-14655	whole-brain	_
91-8	14656-14664	analysis	_
91-9	14665-14670	using	_
91-10	14671-14682	statistical	_
91-11	14683-14697	non-parametric	_
91-12	14698-14705	mapping	_
91-13	14706-14707	(	_
91-14	14707-14713	SnPM13	_
91-15	14713-14714	)	_
91-16	14715-14717	in	_
91-17	14718-14723	which	_
91-18	14724-14726	we	_
91-19	14727-14735	compared	_
91-20	14736-14744	regional	_
91-21	14745-14753	cerebral	_
91-22	14754-14763	metabolic	_
91-23	14764-14768	rate	_
91-24	14769-14771	of	_
91-25	14772-14779	glucose	_
91-26	14780-14781	(	_
91-27	14781-14786	using	_
91-28	14787-14790	the	_
91-29	14791-14798	FDG-PET	_
91-30	14799-14805	images	_
91-31	14805-14806	)	_
91-32	14807-14809	or	_
91-33	14810-14818	regional	_
91-34	14819-14827	cerebral	_
91-35	14828-14833	blood	_
91-36	14834-14838	flow	_
91-37	14839-14840	(	_
91-38	14840-14845	using	_
91-39	14846-14849	the	_
91-40	14850-14853	ASL	_
91-41	14854-14860	images	_
91-42	14860-14861	)	_
91-43	14862-14864	in	_
91-44	14865-14868	the	_
91-45	14869-14876	healthy	_
91-46	14877-14884	control	_
91-47	14885-14890	group	_
91-48	14891-14894	and	_
91-49	14895-14898	the	_
91-50	14899-14906	patient	_
91-51	14907-14912	group	_
91-52	14913-14914	(	_
91-53	14914-14917	the	_
91-54	14918-14921	MAA	_
91-55	14922-14925	and	_
91-56	14926-14929	MAP	_
91-57	14930-14935	group	_
91-58	14936-14944	combined	_
91-59	14944-14945	)	_
91-60	14945-14946	.	_

#Text=We used proportional scaling to normalize the image intensities.
92-1	14947-14949	We	_
92-2	14950-14954	used	_
92-3	14955-14967	proportional	_
92-4	14968-14975	scaling	_
92-5	14976-14978	to	_
92-6	14979-14988	normalize	_
92-7	14989-14992	the	_
92-8	14993-14998	image	_
92-9	14999-15010	intensities	_
92-10	15010-15011	.	_

#Text=Next, we did a similar analysis in which we compared the methamphetamine abusers with and without psychotic symptoms.
93-1	15012-15016	Next	_
93-2	15016-15017	,	_
93-3	15018-15020	we	_
93-4	15021-15024	did	_
93-5	15025-15026	a	_
93-6	15027-15034	similar	_
93-7	15035-15043	analysis	_
93-8	15044-15046	in	_
93-9	15047-15052	which	_
93-10	15053-15055	we	_
93-11	15056-15064	compared	_
93-12	15065-15068	the	_
93-13	15069-15084	methamphetamine	_
93-14	15085-15092	abusers	_
93-15	15093-15097	with	_
93-16	15098-15101	and	_
93-17	15102-15109	without	_
93-18	15110-15119	psychotic	_
93-19	15120-15128	symptoms	_
93-20	15128-15129	.	_

#Text=In all voxel- based analyses, we considered a cluster to be significant when the cluster size was significant at FWE corrected p < 0.05 with an initial uncorrected voxel level threshold p < 0.001.
94-1	15130-15132	In	_
94-2	15133-15136	all	_
94-3	15137-15142	voxel	_
94-4	15142-15143	-	_
94-5	15144-15149	based	_
94-6	15150-15158	analyses	_
94-7	15158-15159	,	_
94-8	15160-15162	we	_
94-9	15163-15173	considered	_
94-10	15174-15175	a	_
94-11	15176-15183	cluster	_
94-12	15184-15186	to	_
94-13	15187-15189	be	_
94-14	15190-15201	significant	_
94-15	15202-15206	when	_
94-16	15207-15210	the	_
94-17	15211-15218	cluster	_
94-18	15219-15223	size	_
94-19	15224-15227	was	_
94-20	15228-15239	significant	_
94-21	15240-15242	at	_
94-22	15243-15246	FWE	_
94-23	15247-15256	corrected	_
94-24	15257-15258	p	_
94-25	15258-15259	 	_
94-26	15259-15260	<	_
94-27	15260-15261	 	_
94-28	15261-15265	0.05	_
94-29	15266-15270	with	_
94-30	15271-15273	an	_
94-31	15274-15281	initial	_
94-32	15282-15293	uncorrected	_
94-33	15294-15299	voxel	_
94-34	15300-15305	level	_
94-35	15306-15315	threshold	_
94-36	15316-15317	p	_
94-37	15317-15318	 	_
94-38	15318-15319	<	_
94-39	15319-15320	 	_
94-40	15320-15325	0.001	_
94-41	15325-15326	.	_

#Text=Results
#Text=Subjects
#Text=Thirty-nine participants underwent scanning.
95-1	15327-15334	Results	_
95-2	15335-15343	Subjects	_
95-3	15344-15355	Thirty-nine	_
95-4	15356-15368	participants	_
95-5	15369-15378	underwent	_
95-6	15379-15387	scanning	_
95-7	15387-15388	.	_

#Text=Characteristics of the participants are given in Table 1.
96-1	15389-15404	Characteristics	_
96-2	15405-15407	of	_
96-3	15408-15411	the	_
96-4	15412-15424	participants	_
96-5	15425-15428	are	_
96-6	15429-15434	given	_
96-7	15435-15437	in	_
96-8	15438-15443	Table	_
96-9	15444-15445	1	_
96-10	15445-15446	.	_

#Text=Participants were predominantly of mixed ancestry in all groups and the primary route of administration for all participants was smoking.
97-1	15447-15459	Participants	_
97-2	15460-15464	were	_
97-3	15465-15478	predominantly	_
97-4	15479-15481	of	_
97-5	15482-15487	mixed	_
97-6	15488-15496	ancestry	_
97-7	15497-15499	in	_
97-8	15500-15503	all	_
97-9	15504-15510	groups	_
97-10	15511-15514	and	_
97-11	15515-15518	the	_
97-12	15519-15526	primary	_
97-13	15527-15532	route	_
97-14	15533-15535	of	_
97-15	15536-15550	administration	_
97-16	15551-15554	for	_
97-17	15555-15558	all	_
97-18	15559-15571	participants	_
97-19	15572-15575	was	_
97-20	15576-15583	smoking	_
97-21	15583-15584	.	_

#Text=Not all imaging sessions were successful for every participant (e.g. technical reasons, movement in scanner, incomplete scanning session), however the characteristics were not different between the remaining participants of each group (all p > 0.2) (see supplementary material S1 and S2).
98-1	15585-15588	Not	_
98-2	15589-15592	all	_
98-3	15593-15600	imaging	_
98-4	15601-15609	sessions	_
98-5	15610-15614	were	_
98-6	15615-15625	successful	_
98-7	15626-15629	for	_
98-8	15630-15635	every	_
98-9	15636-15647	participant	_
98-10	15648-15649	(	_
98-11	15649-15652	e.g	_
98-12	15652-15653	.	_
98-13	15654-15663	technical	_
98-14	15664-15671	reasons	_
98-15	15671-15672	,	_
98-16	15673-15681	movement	_
98-17	15682-15684	in	_
98-18	15685-15692	scanner	_
98-19	15692-15693	,	_
98-20	15694-15704	incomplete	_
98-21	15705-15713	scanning	_
98-22	15714-15721	session	_
98-23	15721-15722	)	_
98-24	15722-15723	,	_
98-25	15724-15731	however	_
98-26	15732-15735	the	_
98-27	15736-15751	characteristics	_
98-28	15752-15756	were	_
98-29	15757-15760	not	_
98-30	15761-15770	different	_
98-31	15771-15778	between	_
98-32	15779-15782	the	_
98-33	15783-15792	remaining	_
98-34	15793-15805	participants	_
98-35	15806-15808	of	_
98-36	15809-15813	each	_
98-37	15814-15819	group	_
98-38	15820-15821	(	_
98-39	15821-15824	all	_
98-40	15825-15826	p	_
98-41	15826-15827	 	_
98-42	15827-15828	>	_
98-43	15828-15829	 	_
98-44	15829-15832	0.2	_
98-45	15832-15833	)	_
98-46	15834-15835	(	_
98-47	15835-15838	see	_
98-48	15839-15852	supplementary	_
98-49	15853-15861	material	_
98-50	15862-15864	S1	_
98-51	15865-15868	and	_
98-52	15869-15871	S2	_
98-53	15871-15872	)	_
98-54	15872-15873	.	_

#Text=Participants included in the analysis for each imaging modality are shown in Table 2.
99-1	15874-15886	Participants	_
99-2	15887-15895	included	_
99-3	15896-15898	in	_
99-4	15899-15902	the	_
99-5	15903-15911	analysis	_
99-6	15912-15915	for	_
99-7	15916-15920	each	_
99-8	15921-15928	imaging	_
99-9	15929-15937	modality	_
99-10	15938-15941	are	_
99-11	15942-15947	shown	_
99-12	15948-15950	in	_
99-13	15951-15956	Table	_
99-14	15957-15958	2	_
99-15	15958-15959	.	_

#Text=Cerebral metabolism
#Text=Decreased regional cerebral glucose metabolism in methamphetamine abusers (MAA and MAP group) compared to healthy controls.
100-1	15960-15968	Cerebral	_
100-2	15969-15979	metabolism	_
100-3	15980-15989	Decreased	_
100-4	15990-15998	regional	_
100-5	15999-16007	cerebral	_
100-6	16008-16015	glucose	_
100-7	16016-16026	metabolism	_
100-8	16027-16029	in	_
100-9	16030-16045	methamphetamine	_
100-10	16046-16053	abusers	_
100-11	16054-16055	(	_
100-12	16055-16058	MAA	_
100-13	16059-16062	and	_
100-14	16063-16066	MAP	_
100-15	16067-16072	group	_
100-16	16072-16073	)	_
100-17	16074-16082	compared	_
100-18	16083-16085	to	_
100-19	16086-16093	healthy	_
100-20	16094-16102	controls	_
100-21	16102-16103	.	_

#Text=Local maxima of the statistical non-parametric maps are given.
101-1	16104-16109	Local	_
101-2	16110-16116	maxima	_
101-3	16117-16119	of	_
101-4	16120-16123	the	_
101-5	16124-16135	statistical	_
101-6	16136-16150	non-parametric	_
101-7	16151-16155	maps	_
101-8	16156-16159	are	_
101-9	16160-16165	given	_
101-10	16165-16166	.	_

#Text=X,Y,Z refer to MNI coordinates.
102-1	16167-16168	X	_
102-2	16168-16169	,	_
102-3	16169-16170	Y	_
102-4	16170-16171	,	_
102-5	16171-16172	Z	_
102-6	16173-16178	refer	_
102-7	16179-16181	to	_
102-8	16182-16185	MNI	_
102-9	16186-16197	coordinates	_
102-10	16197-16198	.	_

#Text=Table 3\t \t
#Text=Cluster pFWE-corr\tCluster size (# voxels)\tPeak pFWE-corr\tT\tX Y Z\tAnatomical localization\t \t0.047\t652\t0.006\t6.25\t−44 6 2\tLeft insula\t \t0.100\t4.87\t−54 4 20\tLeft precentral gyrus\t \t0.016\t1164\t0.035\t5.38\t−4 40 12\tLeft anterior cingulate\t \t0.121\t4.76\t12 44 12\tRight anterior cingulate\t \t
#Text=Abbreviations: HC: healthy controls; MAA: methamphetamine abusers without psychotic symptoms; MAP: methamphetamine abusers with psychotic symptoms.
103-1	16199-16204	Table	_
103-2	16205-16206	3	_
103-3	16210-16217	Cluster	_
103-4	16218-16227	pFWE-corr	_
103-5	16228-16235	Cluster	_
103-6	16236-16240	size	_
103-7	16241-16242	(	_
103-8	16242-16243	#	_
103-9	16244-16250	voxels	_
103-10	16250-16251	)	_
103-11	16252-16256	Peak	_
103-12	16257-16266	pFWE-corr	_
103-13	16267-16268	T	_
103-14	16269-16270	X	_
103-15	16271-16272	Y	_
103-16	16273-16274	Z	_
103-17	16275-16285	Anatomical	_
103-18	16286-16298	localization	_
103-19	16301-16306	0.047	_
103-20	16307-16310	652	_
103-21	16311-16316	0.006	_
103-22	16317-16321	6.25	_
103-23	16322-16323	−	_
103-24	16323-16325	44	_
103-25	16326-16327	6	_
103-26	16328-16329	2	_
103-27	16330-16334	Left	_
103-28	16335-16341	insula	_
103-29	16344-16349	0.100	_
103-30	16350-16354	4.87	_
103-31	16355-16356	−	_
103-32	16356-16358	54	_
103-33	16359-16360	4	_
103-34	16361-16363	20	_
103-35	16364-16368	Left	_
103-36	16369-16379	precentral	_
103-37	16380-16385	gyrus	_
103-38	16388-16393	0.016	_
103-39	16394-16398	1164	_
103-40	16399-16404	0.035	_
103-41	16405-16409	5.38	_
103-42	16410-16411	−	_
103-43	16411-16412	4	_
103-44	16413-16415	40	_
103-45	16416-16418	12	_
103-46	16419-16423	Left	_
103-47	16424-16432	anterior	_
103-48	16433-16442	cingulate	_
103-49	16445-16450	0.121	_
103-50	16451-16455	4.76	_
103-51	16456-16458	12	_
103-52	16459-16461	44	_
103-53	16462-16464	12	_
103-54	16465-16470	Right	_
103-55	16471-16479	anterior	_
103-56	16480-16489	cingulate	_
103-57	16493-16506	Abbreviations	_
103-58	16506-16507	:	_
103-59	16508-16510	HC	_
103-60	16510-16511	:	_
103-61	16512-16519	healthy	_
103-62	16520-16528	controls	_
103-63	16528-16529	;	_
103-64	16530-16533	MAA	_
103-65	16533-16534	:	_
103-66	16535-16550	methamphetamine	_
103-67	16551-16558	abusers	_
103-68	16559-16566	without	_
103-69	16567-16576	psychotic	_
103-70	16577-16585	symptoms	_
103-71	16585-16586	;	_
103-72	16587-16590	MAP	_
103-73	16590-16591	:	_
103-74	16592-16607	methamphetamine	_
103-75	16608-16615	abusers	_
103-76	16616-16620	with	_
103-77	16621-16630	psychotic	_
103-78	16631-16639	symptoms	_
103-79	16639-16640	.	_

#Text=Significant decreased regional glucose metabolism in the MA dependence groups (MAA and MAP) compared to the healthy control group shown in red on three axial slices with the z-coordinate of the slice in MNI space on top.
104-1	16641-16652	Significant	_
104-2	16653-16662	decreased	_
104-3	16663-16671	regional	_
104-4	16672-16679	glucose	_
104-5	16680-16690	metabolism	_
104-6	16691-16693	in	_
104-7	16694-16697	the	_
104-8	16698-16700	MA	_
104-9	16701-16711	dependence	_
104-10	16712-16718	groups	_
104-11	16719-16720	(	_
104-12	16720-16723	MAA	_
104-13	16724-16727	and	_
104-14	16728-16731	MAP	_
104-15	16731-16732	)	_
104-16	16733-16741	compared	_
104-17	16742-16744	to	_
104-18	16745-16748	the	_
104-19	16749-16756	healthy	_
104-20	16757-16764	control	_
104-21	16765-16770	group	_
104-22	16771-16776	shown	_
104-23	16777-16779	in	_
104-24	16780-16783	red	_
104-25	16784-16786	on	_
104-26	16787-16792	three	_
104-27	16793-16798	axial	_
104-28	16799-16805	slices	_
104-29	16806-16810	with	_
104-30	16811-16814	the	_
104-31	16815-16827	z-coordinate	_
104-32	16828-16830	of	_
104-33	16831-16834	the	_
104-34	16835-16840	slice	_
104-35	16841-16843	in	_
104-36	16844-16847	MNI	_
104-37	16848-16853	space	_
104-38	16854-16856	on	_
104-39	16857-16860	top	_
104-40	16860-16861	.	_

#Text=The statistical map was thresholded using an uncorrected p < 0.001 at the voxel level combined with an FWE-corrected p < 0.05 at the cluster level.
105-1	16862-16865	The	_
105-2	16866-16877	statistical	_
105-3	16878-16881	map	_
105-4	16882-16885	was	_
105-5	16886-16897	thresholded	_
105-6	16898-16903	using	_
105-7	16904-16906	an	_
105-8	16907-16918	uncorrected	_
105-9	16919-16920	p	_
105-10	16920-16921	 	_
105-11	16921-16922	<	_
105-12	16922-16923	 	_
105-13	16923-16928	0.001	_
105-14	16929-16931	at	_
105-15	16932-16935	the	_
105-16	16936-16941	voxel	_
105-17	16942-16947	level	_
105-18	16948-16956	combined	_
105-19	16957-16961	with	_
105-20	16962-16964	an	_
105-21	16965-16978	FWE-corrected	_
105-22	16979-16980	p	_
105-23	16980-16981	 	_
105-24	16981-16982	<	_
105-25	16982-16983	 	_
105-26	16983-16987	0.05	_
105-27	16988-16990	at	_
105-28	16991-16994	the	_
105-29	16995-17002	cluster	_
105-30	17003-17008	level	_
105-31	17008-17009	.	_

#Text=Images are displayed in neurological convention.
106-1	17010-17016	Images	_
106-2	17017-17020	are	_
106-3	17021-17030	displayed	_
106-4	17031-17033	in	_
106-5	17034-17046	neurological	_
106-6	17047-17057	convention	_
106-7	17057-17058	.	_

#Text=Fig. 1
#Text=Analysis of PET data showed significantly decreased glucose metabolism in the methamphetamine abusers (MAA and MAP group) compared to healthy controls in the left insula, left precentral gyrus and the anterior cingulate cortex (ACC) (Table 3.
107-1	17059-17062	Fig	_
107-2	17062-17063	.	_
107-3	17064-17065	1	_
107-4	17066-17074	Analysis	_
107-5	17075-17077	of	_
107-6	17078-17081	PET	_
107-7	17082-17086	data	_
107-8	17087-17093	showed	_
107-9	17094-17107	significantly	_
107-10	17108-17117	decreased	_
107-11	17118-17125	glucose	_
107-12	17126-17136	metabolism	_
107-13	17137-17139	in	_
107-14	17140-17143	the	_
107-15	17144-17159	methamphetamine	_
107-16	17160-17167	abusers	_
107-17	17168-17169	(	_
107-18	17169-17172	MAA	_
107-19	17173-17176	and	_
107-20	17177-17180	MAP	_
107-21	17181-17186	group	_
107-22	17186-17187	)	_
107-23	17188-17196	compared	_
107-24	17197-17199	to	_
107-25	17200-17207	healthy	_
107-26	17208-17216	controls	_
107-27	17217-17219	in	_
107-28	17220-17223	the	_
107-29	17224-17228	left	_
107-30	17229-17235	insula	_
107-31	17235-17236	,	_
107-32	17237-17241	left	_
107-33	17242-17252	precentral	_
107-34	17253-17258	gyrus	_
107-35	17259-17262	and	_
107-36	17263-17266	the	_
107-37	17267-17275	anterior	_
107-38	17276-17285	cingulate	_
107-39	17286-17292	cortex	_
107-40	17293-17294	(	_
107-41	17294-17297	ACC	_
107-42	17297-17298	)	_
107-43	17299-17300	(	_
107-44	17300-17305	Table	_
107-45	17306-17307	3	_
107-46	17307-17308	.	_

#Text=Fig. 1).
108-1	17309-17312	Fig	_
108-2	17312-17313	.	_
108-3	17314-17315	1	_
108-4	17315-17316	)	_
108-5	17316-17317	.	_

#Text=HC vs methamphetamine abusers
#Text=Comparison of regional cerebral glucose metabolism in methamphetamine abusers with and without psychotic symptoms.
109-1	17318-17320	HC	_
109-2	17321-17323	vs	_
109-3	17324-17339	methamphetamine	_
109-4	17340-17347	abusers	_
109-5	17348-17358	Comparison	_
109-6	17359-17361	of	_
109-7	17362-17370	regional	_
109-8	17371-17379	cerebral	_
109-9	17380-17387	glucose	_
109-10	17388-17398	metabolism	_
109-11	17399-17401	in	_
109-12	17402-17417	methamphetamine	_
109-13	17418-17425	abusers	_
109-14	17426-17430	with	_
109-15	17431-17434	and	_
109-16	17435-17442	without	_
109-17	17443-17452	psychotic	_
109-18	17453-17461	symptoms	_
109-19	17461-17462	.	_

#Text=Local maxima of the statistical non-parametric maps are given.
110-1	17463-17468	Local	_
110-2	17469-17475	maxima	_
110-3	17476-17478	of	_
110-4	17479-17482	the	_
110-5	17483-17494	statistical	_
110-6	17495-17509	non-parametric	_
110-7	17510-17514	maps	_
110-8	17515-17518	are	_
110-9	17519-17524	given	_
110-10	17524-17525	.	_

#Text=X,Y,Z refer to MNI coordinates.
111-1	17526-17527	X	_
111-2	17527-17528	,	_
111-3	17528-17529	Y	_
111-4	17529-17530	,	_
111-5	17530-17531	Z	_
111-6	17532-17537	refer	_
111-7	17538-17540	to	_
111-8	17541-17544	MNI	_
111-9	17545-17556	coordinates	_
111-10	17556-17557	.	_

#Text=Table 4\t \t
#Text=Cluster pFWE-corr\tCluster size (# voxels)\tPeak pFWE-corr\tT\tX Y Z\tAnatomical localization\t \tMAA > MAP\t\t\t\t\t\t \t 0.028\t872\t0.034\t6.11\t−54 10 42\tLeft precentral gyrus\t \t 0.016\t1164\t0.082\t5.58\t−58 26 26\tLeft inferior frontal gyrus\t \t0.32\t4.62\t−50 38 28\tLeft inferior frontal gyrus\t \tMAA < MAP\t\t\t\t\t\t \t 0.022\t876\t0.030\t6.06\t−30 -12 0\tLeft putamen\t \t 0.039\t631\t0.040\t5.91\t30 -8 2\tRight putamen\t \t0.54\t4.08\t16 4 6\tRight pallidum\t \t
#Text=Abbreviations: MAA: methamphetamine abusers without psychotic symptoms; MAP: methamphetamine abusers with psychotic symptoms.
112-1	17558-17563	Table	_
112-2	17564-17565	4	_
112-3	17569-17576	Cluster	_
112-4	17577-17586	pFWE-corr	_
112-5	17587-17594	Cluster	_
112-6	17595-17599	size	_
112-7	17600-17601	(	_
112-8	17601-17602	#	_
112-9	17603-17609	voxels	_
112-10	17609-17610	)	_
112-11	17611-17615	Peak	_
112-12	17616-17625	pFWE-corr	_
112-13	17626-17627	T	_
112-14	17628-17629	X	_
112-15	17630-17631	Y	_
112-16	17632-17633	Z	_
112-17	17634-17644	Anatomical	_
112-18	17645-17657	localization	_
112-19	17660-17663	MAA	_
112-20	17663-17664	 	_
112-21	17664-17665	>	_
112-22	17665-17666	 	_
112-23	17666-17669	MAP	_
112-24	17677-17678	 	_
112-25	17678-17683	0.028	_
112-26	17684-17687	872	_
112-27	17688-17693	0.034	_
112-28	17694-17698	6.11	_
112-29	17699-17700	−	_
112-30	17700-17702	54	_
112-31	17703-17705	10	_
112-32	17706-17708	42	_
112-33	17709-17713	Left	_
112-34	17714-17724	precentral	_
112-35	17725-17730	gyrus	_
112-36	17733-17734	 	_
112-37	17734-17739	0.016	_
112-38	17740-17744	1164	_
112-39	17745-17750	0.082	_
112-40	17751-17755	5.58	_
112-41	17756-17757	−	_
112-42	17757-17759	58	_
112-43	17760-17762	26	_
112-44	17763-17765	26	_
112-45	17766-17770	Left	_
112-46	17771-17779	inferior	_
112-47	17780-17787	frontal	_
112-48	17788-17793	gyrus	_
112-49	17796-17800	0.32	_
112-50	17801-17805	4.62	_
112-51	17806-17807	−	_
112-52	17807-17809	50	_
112-53	17810-17812	38	_
112-54	17813-17815	28	_
112-55	17816-17820	Left	_
112-56	17821-17829	inferior	_
112-57	17830-17837	frontal	_
112-58	17838-17843	gyrus	_
112-59	17846-17849	MAA	_
112-60	17849-17850	 	_
112-61	17850-17851	<	_
112-62	17851-17852	 	_
112-63	17852-17855	MAP	_
112-64	17863-17864	 	_
112-65	17864-17869	0.022	_
112-66	17870-17873	876	_
112-67	17874-17879	0.030	_
112-68	17880-17884	6.06	_
112-69	17885-17886	−	_
112-70	17886-17888	30	_
112-71	17889-17890	-	_
112-72	17890-17892	12	_
112-73	17893-17894	0	_
112-74	17895-17899	Left	_
112-75	17900-17907	putamen	_
112-76	17910-17911	 	_
112-77	17911-17916	0.039	_
112-78	17917-17920	631	_
112-79	17921-17926	0.040	_
112-80	17927-17931	5.91	_
112-81	17932-17934	30	_
112-82	17935-17936	-	_
112-83	17936-17937	8	_
112-84	17938-17939	2	_
112-85	17940-17945	Right	_
112-86	17946-17953	putamen	_
112-87	17956-17960	0.54	_
112-88	17961-17965	4.08	_
112-89	17966-17968	16	_
112-90	17969-17970	4	_
112-91	17971-17972	6	_
112-92	17973-17978	Right	_
112-93	17979-17987	pallidum	_
112-94	17991-18004	Abbreviations	_
112-95	18004-18005	:	_
112-96	18006-18009	MAA	_
112-97	18009-18010	:	_
112-98	18011-18026	methamphetamine	_
112-99	18027-18034	abusers	_
112-100	18035-18042	without	_
112-101	18043-18052	psychotic	_
112-102	18053-18061	symptoms	_
112-103	18061-18062	;	_
112-104	18063-18066	MAP	_
112-105	18066-18067	:	_
112-106	18068-18083	methamphetamine	_
112-107	18084-18091	abusers	_
112-108	18092-18096	with	_
112-109	18097-18106	psychotic	_
112-110	18107-18115	symptoms	_
112-111	18115-18116	.	_

#Text=Comparison of the MA-dependence groups with and without psychotic symptoms.
113-1	18117-18127	Comparison	_
113-2	18128-18130	of	_
113-3	18131-18134	the	_
113-4	18135-18148	MA-dependence	_
113-5	18149-18155	groups	_
113-6	18156-18160	with	_
113-7	18161-18164	and	_
113-8	18165-18172	without	_
113-9	18173-18182	psychotic	_
113-10	18183-18191	symptoms	_
113-11	18191-18192	.	_

#Text=Group shown on a left sagittal slice at MNI coordinate x = −50 and an axial slice at MNI coordinate z = 2.
114-1	18193-18198	Group	_
114-2	18199-18204	shown	_
114-3	18205-18207	on	_
114-4	18208-18209	a	_
114-5	18210-18214	left	_
114-6	18215-18223	sagittal	_
114-7	18224-18229	slice	_
114-8	18230-18232	at	_
114-9	18233-18236	MNI	_
114-10	18237-18247	coordinate	_
114-11	18248-18249	x	_
114-12	18249-18250	 	_
114-13	18250-18251	=	_
114-14	18251-18252	 	_
114-15	18252-18253	−	_
114-16	18253-18255	50	_
114-17	18256-18259	and	_
114-18	18260-18262	an	_
114-19	18263-18268	axial	_
114-20	18269-18274	slice	_
114-21	18275-18277	at	_
114-22	18278-18281	MNI	_
114-23	18282-18292	coordinate	_
114-24	18293-18294	z	_
114-25	18294-18295	 	_
114-26	18295-18296	=	_
114-27	18296-18297	 	_
114-28	18297-18298	2	_
114-29	18298-18299	.	_

#Text=Decreases and increases in the MAP group compared to the MAA group are shown in red and blue, respectively.
115-1	18300-18309	Decreases	_
115-2	18310-18313	and	_
115-3	18314-18323	increases	_
115-4	18324-18326	in	_
115-5	18327-18330	the	_
115-6	18331-18334	MAP	_
115-7	18335-18340	group	_
115-8	18341-18349	compared	_
115-9	18350-18352	to	_
115-10	18353-18356	the	_
115-11	18357-18360	MAA	_
115-12	18361-18366	group	_
115-13	18367-18370	are	_
115-14	18371-18376	shown	_
115-15	18377-18379	in	_
115-16	18380-18383	red	_
115-17	18384-18387	and	_
115-18	18388-18392	blue	_
115-19	18392-18393	,	_
115-20	18394-18406	respectively	_
115-21	18406-18407	.	_

#Text=The statistical maps were thresholded using an uncorrected p < 0.001 at the voxel level combined with a FWE-corrected p < 0.05 at the cluster level.
116-1	18408-18411	The	_
116-2	18412-18423	statistical	_
116-3	18424-18428	maps	_
116-4	18429-18433	were	_
116-5	18434-18445	thresholded	_
116-6	18446-18451	using	_
116-7	18452-18454	an	_
116-8	18455-18466	uncorrected	_
116-9	18467-18468	p	_
116-10	18468-18469	 	_
116-11	18469-18470	<	_
116-12	18470-18471	 	_
116-13	18471-18476	0.001	_
116-14	18477-18479	at	_
116-15	18480-18483	the	_
116-16	18484-18489	voxel	_
116-17	18490-18495	level	_
116-18	18496-18504	combined	_
116-19	18505-18509	with	_
116-20	18510-18511	a	_
116-21	18512-18525	FWE-corrected	_
116-22	18526-18527	p	_
116-23	18527-18528	 	_
116-24	18528-18529	<	_
116-25	18529-18530	 	_
116-26	18530-18534	0.05	_
116-27	18535-18537	at	_
116-28	18538-18541	the	_
116-29	18542-18549	cluster	_
116-30	18550-18555	level	_
116-31	18555-18556	.	_

#Text=Images are displayed in neurological convention.
117-1	18557-18563	Images	_
117-2	18564-18567	are	_
117-3	18568-18577	displayed	_
117-4	18578-18580	in	_
117-5	18581-18593	neurological	_
117-6	18594-18604	convention	_
117-7	18604-18605	.	_

#Text=Fig. 2
#Text=When comparing the methamphetamine abusers with and without psychotic symptoms, we found increased cerebral metabolism in MAA compared to MAP in the left precentral gyrus and the left inferior frontal gyrus, and decreased metabolism in the putamen and the pallidum (Table 4, Fig. 2).
118-1	18606-18609	Fig	_
118-2	18609-18610	.	_
118-3	18611-18612	2	_
118-4	18613-18617	When	_
118-5	18618-18627	comparing	_
118-6	18628-18631	the	_
118-7	18632-18647	methamphetamine	_
118-8	18648-18655	abusers	_
118-9	18656-18660	with	_
118-10	18661-18664	and	_
118-11	18665-18672	without	_
118-12	18673-18682	psychotic	_
118-13	18683-18691	symptoms	_
118-14	18691-18692	,	_
118-15	18693-18695	we	_
118-16	18696-18701	found	_
118-17	18702-18711	increased	_
118-18	18712-18720	cerebral	_
118-19	18721-18731	metabolism	_
118-20	18732-18734	in	_
118-21	18735-18738	MAA	_
118-22	18739-18747	compared	_
118-23	18748-18750	to	_
118-24	18751-18754	MAP	_
118-25	18755-18757	in	_
118-26	18758-18761	the	_
118-27	18762-18766	left	_
118-28	18767-18777	precentral	_
118-29	18778-18783	gyrus	_
118-30	18784-18787	and	_
118-31	18788-18791	the	_
118-32	18792-18796	left	_
118-33	18797-18805	inferior	_
118-34	18806-18813	frontal	_
118-35	18814-18819	gyrus	_
118-36	18819-18820	,	_
118-37	18821-18824	and	_
118-38	18825-18834	decreased	_
118-39	18835-18845	metabolism	_
118-40	18846-18848	in	_
118-41	18849-18852	the	_
118-42	18853-18860	putamen	_
118-43	18861-18864	and	_
118-44	18865-18868	the	_
118-45	18869-18877	pallidum	_
118-46	18878-18879	(	_
118-47	18879-18884	Table	_
118-48	18885-18886	4	_
118-49	18886-18887	,	_
118-50	18888-18891	Fig	_
118-51	18891-18892	.	_
118-52	18893-18894	2	_
118-53	18894-18895	)	_
118-54	18895-18896	.	_

#Text=Cerebral perfusion
#Text=Decreased regional cerebral blood flow in methamphetamine abusers without psychotic symptoms compared to those with psychotic symptoms (MAA < MAP).
119-1	18897-18905	Cerebral	_
119-2	18906-18915	perfusion	_
119-3	18916-18925	Decreased	_
119-4	18926-18934	regional	_
119-5	18935-18943	cerebral	_
119-6	18944-18949	blood	_
119-7	18950-18954	flow	_
119-8	18955-18957	in	_
119-9	18958-18973	methamphetamine	_
119-10	18974-18981	abusers	_
119-11	18982-18989	without	_
119-12	18990-18999	psychotic	_
119-13	19000-19008	symptoms	_
119-14	19009-19017	compared	_
119-15	19018-19020	to	_
119-16	19021-19026	those	_
119-17	19027-19031	with	_
119-18	19032-19041	psychotic	_
119-19	19042-19050	symptoms	_
119-20	19051-19052	(	_
119-21	19052-19055	MAA	_
119-22	19055-19056	 	_
119-23	19056-19057	<	_
119-24	19057-19058	 	_
119-25	19058-19061	MAP	_
119-26	19061-19062	)	_
119-27	19062-19063	.	_

#Text=Local maxima of the statistical non-parametric maps are given.
120-1	19064-19069	Local	_
120-2	19070-19076	maxima	_
120-3	19077-19079	of	_
120-4	19080-19083	the	_
120-5	19084-19095	statistical	_
120-6	19096-19110	non-parametric	_
120-7	19111-19115	maps	_
120-8	19116-19119	are	_
120-9	19120-19125	given	_
120-10	19125-19126	.	_

#Text=X,Y,Z refer to MNI coordinates.
121-1	19127-19128	X	_
121-2	19128-19129	,	_
121-3	19129-19130	Y	_
121-4	19130-19131	,	_
121-5	19131-19132	Z	_
121-6	19133-19138	refer	_
121-7	19139-19141	to	_
121-8	19142-19145	MNI	_
121-9	19146-19157	coordinates	_
121-10	19157-19158	.	_

#Text=Table 5\t \t
#Text=Cluster pFWE-corr\tCluster size (# voxels)\tPeak pFWE-corr\tT\tX Y Z\tAnatomical localization\t \t0.031\t532\t0.38\t4.47\t28 -10 12\tRight putamen\t \t0.57\t4.09\t20 -2 2\tRight pallidum\t \t
#Text=Abbreviations: MAA: methamphetamine abusers without psychotic symptoms; MAP: methamphetamine abusers with psychotic symptoms.
122-1	19159-19164	Table	_
122-2	19165-19166	5	_
122-3	19170-19177	Cluster	_
122-4	19178-19187	pFWE-corr	_
122-5	19188-19195	Cluster	_
122-6	19196-19200	size	_
122-7	19201-19202	(	_
122-8	19202-19203	#	_
122-9	19204-19210	voxels	_
122-10	19210-19211	)	_
122-11	19212-19216	Peak	_
122-12	19217-19226	pFWE-corr	_
122-13	19227-19228	T	_
122-14	19229-19230	X	_
122-15	19231-19232	Y	_
122-16	19233-19234	Z	_
122-17	19235-19245	Anatomical	_
122-18	19246-19258	localization	_
122-19	19261-19266	0.031	_
122-20	19267-19270	532	_
122-21	19271-19275	0.38	_
122-22	19276-19280	4.47	_
122-23	19281-19283	28	_
122-24	19284-19285	-	_
122-25	19285-19287	10	_
122-26	19288-19290	12	_
122-27	19291-19296	Right	_
122-28	19297-19304	putamen	_
122-29	19307-19311	0.57	_
122-30	19312-19316	4.09	_
122-31	19317-19319	20	_
122-32	19320-19321	-	_
122-33	19321-19322	2	_
122-34	19323-19324	2	_
122-35	19325-19330	Right	_
122-36	19331-19339	pallidum	_
122-37	19343-19356	Abbreviations	_
122-38	19356-19357	:	_
122-39	19358-19361	MAA	_
122-40	19361-19362	:	_
122-41	19363-19378	methamphetamine	_
122-42	19379-19386	abusers	_
122-43	19387-19394	without	_
122-44	19395-19404	psychotic	_
122-45	19405-19413	symptoms	_
122-46	19413-19414	;	_
122-47	19415-19418	MAP	_
122-48	19418-19419	:	_
122-49	19420-19435	methamphetamine	_
122-50	19436-19443	abusers	_
122-51	19444-19448	with	_
122-52	19449-19458	psychotic	_
122-53	19459-19467	symptoms	_
122-54	19467-19468	.	_

#Text=Regions of significantly decreased regional cerebral perfusion in participants with methamphetamine dependence without psychotic symptoms compared to methamphetamine abusers with psychotic symptoms shown in blue on axial slices at MNI coordinates z = 4 and 12.
123-1	19469-19476	Regions	_
123-2	19477-19479	of	_
123-3	19480-19493	significantly	_
123-4	19494-19503	decreased	_
123-5	19504-19512	regional	_
123-6	19513-19521	cerebral	_
123-7	19522-19531	perfusion	_
123-8	19532-19534	in	_
123-9	19535-19547	participants	_
123-10	19548-19552	with	_
123-11	19553-19568	methamphetamine	_
123-12	19569-19579	dependence	_
123-13	19580-19587	without	_
123-14	19588-19597	psychotic	_
123-15	19598-19606	symptoms	_
123-16	19607-19615	compared	_
123-17	19616-19618	to	_
123-18	19619-19634	methamphetamine	_
123-19	19635-19642	abusers	_
123-20	19643-19647	with	_
123-21	19648-19657	psychotic	_
123-22	19658-19666	symptoms	_
123-23	19667-19672	shown	_
123-24	19673-19675	in	_
123-25	19676-19680	blue	_
123-26	19681-19683	on	_
123-27	19684-19689	axial	_
123-28	19690-19696	slices	_
123-29	19697-19699	at	_
123-30	19700-19703	MNI	_
123-31	19704-19715	coordinates	_
123-32	19716-19717	z	_
123-33	19717-19718	 	_
123-34	19718-19719	=	_
123-35	19719-19720	 	_
123-36	19720-19721	4	_
123-37	19722-19725	and	_
123-38	19726-19728	12	_
123-39	19728-19729	.	_

#Text=The statistical maps were thresholded using an uncorrected p < 0.001 at the voxel level combined with an FWE-corrected p < 0.05 at the cluster level.
124-1	19730-19733	The	_
124-2	19734-19745	statistical	_
124-3	19746-19750	maps	_
124-4	19751-19755	were	_
124-5	19756-19767	thresholded	_
124-6	19768-19773	using	_
124-7	19774-19776	an	_
124-8	19777-19788	uncorrected	_
124-9	19789-19790	p	_
124-10	19790-19791	 	_
124-11	19791-19792	<	_
124-12	19792-19793	 	_
124-13	19793-19798	0.001	_
124-14	19799-19801	at	_
124-15	19802-19805	the	_
124-16	19806-19811	voxel	_
124-17	19812-19817	level	_
124-18	19818-19826	combined	_
124-19	19827-19831	with	_
124-20	19832-19834	an	_
124-21	19835-19848	FWE-corrected	_
124-22	19849-19850	p	_
124-23	19850-19851	 	_
124-24	19851-19852	<	_
124-25	19852-19853	 	_
124-26	19853-19857	0.05	_
124-27	19858-19860	at	_
124-28	19861-19864	the	_
124-29	19865-19872	cluster	_
124-30	19873-19878	level	_
124-31	19878-19879	.	_

#Text=Images are displayed in neurological convention.
125-1	19880-19886	Images	_
125-2	19887-19890	are	_
125-3	19891-19900	displayed	_
125-4	19901-19903	in	_
125-5	19904-19916	neurological	_
125-6	19917-19927	convention	_
125-7	19927-19928	.	_

#Text=Fig. 3
#Text=Analysis of ASL data showed no significant difference between the healthy controls and the methamphetamine abusers (MAA and MAP group).
126-1	19929-19932	Fig	_
126-2	19932-19933	.	_
126-3	19934-19935	3	_
126-4	19936-19944	Analysis	_
126-5	19945-19947	of	_
126-6	19948-19951	ASL	_
126-7	19952-19956	data	_
126-8	19957-19963	showed	_
126-9	19964-19966	no	_
126-10	19967-19978	significant	_
126-11	19979-19989	difference	_
126-12	19990-19997	between	_
126-13	19998-20001	the	_
126-14	20002-20009	healthy	_
126-15	20010-20018	controls	_
126-16	20019-20022	and	_
126-17	20023-20026	the	_
126-18	20027-20042	methamphetamine	_
126-19	20043-20050	abusers	_
126-20	20051-20052	(	_
126-21	20052-20055	MAA	_
126-22	20056-20059	and	_
126-23	20060-20063	MAP	_
126-24	20064-20069	group	_
126-25	20069-20070	)	_
126-26	20070-20071	.	_

#Text=However, when comparing the methamphetamine abusers with (MAP group) and without (MAA group) psychotic symptoms, we found a decreased cerebral perfusion in the MAA group compared to the MAP group in the right putamen and right pallidum (Table 5, Fig. 3).
127-1	20072-20079	However	_
127-2	20079-20080	,	_
127-3	20081-20085	when	_
127-4	20086-20095	comparing	_
127-5	20096-20099	the	_
127-6	20100-20115	methamphetamine	_
127-7	20116-20123	abusers	_
127-8	20124-20128	with	_
127-9	20129-20130	(	_
127-10	20130-20133	MAP	_
127-11	20134-20139	group	_
127-12	20139-20140	)	_
127-13	20141-20144	and	_
127-14	20145-20152	without	_
127-15	20153-20154	(	_
127-16	20154-20157	MAA	_
127-17	20158-20163	group	_
127-18	20163-20164	)	_
127-19	20165-20174	psychotic	_
127-20	20175-20183	symptoms	_
127-21	20183-20184	,	_
127-22	20185-20187	we	_
127-23	20188-20193	found	_
127-24	20194-20195	a	_
127-25	20196-20205	decreased	_
127-26	20206-20214	cerebral	_
127-27	20215-20224	perfusion	_
127-28	20225-20227	in	_
127-29	20228-20231	the	_
127-30	20232-20235	MAA	_
127-31	20236-20241	group	_
127-32	20242-20250	compared	_
127-33	20251-20253	to	_
127-34	20254-20257	the	_
127-35	20258-20261	MAP	_
127-36	20262-20267	group	_
127-37	20268-20270	in	_
127-38	20271-20274	the	_
127-39	20275-20280	right	_
127-40	20281-20288	putamen	_
127-41	20289-20292	and	_
127-42	20293-20298	right	_
127-43	20299-20307	pallidum	_
127-44	20308-20309	(	_
127-45	20309-20314	Table	_
127-46	20315-20316	5	_
127-47	20316-20317	,	_
127-48	20318-20321	Fig	_
127-49	20321-20322	.	_
127-50	20323-20324	3	_
127-51	20324-20325	)	_
127-52	20325-20326	.	_

#Text=Discussion
#Text=The main findings of this study were 1) Methamphetamine abusers (MAA and MAP group) had decreased glucose metabolism compared to healthy controls in the left insula, left precentral gyrus, and the anterior cingulate cortex. 2) MAP participants had 2a) decreased glucose metabolism in the left precentral gyrus and the left inferior frontal gyrus and 2b) increased glucose metabolism in the putamen and pallidum compared to MAA participants, and 3) Compared to MAA, MAP had increased cerebral perfusion in the right putamen and right pallidum.
128-1	20327-20337	Discussion	_
128-2	20338-20341	The	_
128-3	20342-20346	main	_
128-4	20347-20355	findings	_
128-5	20356-20358	of	_
128-6	20359-20363	this	_
128-7	20364-20369	study	_
128-8	20370-20374	were	_
128-9	20375-20376	1	_
128-10	20376-20377	)	_
128-11	20378-20393	Methamphetamine	_
128-12	20394-20401	abusers	_
128-13	20402-20403	(	_
128-14	20403-20406	MAA	_
128-15	20407-20410	and	_
128-16	20411-20414	MAP	_
128-17	20415-20420	group	_
128-18	20420-20421	)	_
128-19	20422-20425	had	_
128-20	20426-20435	decreased	_
128-21	20436-20443	glucose	_
128-22	20444-20454	metabolism	_
128-23	20455-20463	compared	_
128-24	20464-20466	to	_
128-25	20467-20474	healthy	_
128-26	20475-20483	controls	_
128-27	20484-20486	in	_
128-28	20487-20490	the	_
128-29	20491-20495	left	_
128-30	20496-20502	insula	_
128-31	20502-20503	,	_
128-32	20504-20508	left	_
128-33	20509-20519	precentral	_
128-34	20520-20525	gyrus	_
128-35	20525-20526	,	_
128-36	20527-20530	and	_
128-37	20531-20534	the	_
128-38	20535-20543	anterior	_
128-39	20544-20553	cingulate	_
128-40	20554-20560	cortex	_
128-41	20560-20561	.	_
128-42	20562-20563	2	_
128-43	20563-20564	)	_
128-44	20565-20568	MAP	_
128-45	20569-20581	participants	_
128-46	20582-20585	had	_
128-47	20586-20588	2a	_
128-48	20588-20589	)	_
128-49	20590-20599	decreased	_
128-50	20600-20607	glucose	_
128-51	20608-20618	metabolism	_
128-52	20619-20621	in	_
128-53	20622-20625	the	_
128-54	20626-20630	left	_
128-55	20631-20641	precentral	_
128-56	20642-20647	gyrus	_
128-57	20648-20651	and	_
128-58	20652-20655	the	_
128-59	20656-20660	left	_
128-60	20661-20669	inferior	_
128-61	20670-20677	frontal	_
128-62	20678-20683	gyrus	_
128-63	20684-20687	and	_
128-64	20688-20690	2b	_
128-65	20690-20691	)	_
128-66	20692-20701	increased	_
128-67	20702-20709	glucose	_
128-68	20710-20720	metabolism	_
128-69	20721-20723	in	_
128-70	20724-20727	the	_
128-71	20728-20735	putamen	_
128-72	20736-20739	and	_
128-73	20740-20748	pallidum	_
128-74	20749-20757	compared	_
128-75	20758-20760	to	_
128-76	20761-20764	MAA	_
128-77	20765-20777	participants	_
128-78	20777-20778	,	_
128-79	20779-20782	and	_
128-80	20783-20784	3	_
128-81	20784-20785	)	_
128-82	20786-20794	Compared	_
128-83	20795-20797	to	_
128-84	20798-20801	MAA	_
128-85	20801-20802	,	_
128-86	20803-20806	MAP	_
128-87	20807-20810	had	_
128-88	20811-20820	increased	_
128-89	20821-20829	cerebral	_
128-90	20830-20839	perfusion	_
128-91	20840-20842	in	_
128-92	20843-20846	the	_
128-93	20847-20852	right	_
128-94	20853-20860	putamen	_
128-95	20861-20864	and	_
128-96	20865-20870	right	_
128-97	20871-20879	pallidum	_
128-98	20879-20880	.	_

#Text=Results from the PET analysis are in line with findings from London and colleagues who reported regions of decreased relative regional cerebral glucose metabolism in MA-dependent individuals in the ACC, which is involved in both cognitive and emotional processing, when compared to HC.
129-1	20881-20888	Results	_
129-2	20889-20893	from	_
129-3	20894-20897	the	_
129-4	20898-20901	PET	_
129-5	20902-20910	analysis	_
129-6	20911-20914	are	_
129-7	20915-20917	in	_
129-8	20918-20922	line	_
129-9	20923-20927	with	_
129-10	20928-20936	findings	_
129-11	20937-20941	from	_
129-12	20942-20948	London	_
129-13	20949-20952	and	_
129-14	20953-20963	colleagues	_
129-15	20964-20967	who	_
129-16	20968-20976	reported	_
129-17	20977-20984	regions	_
129-18	20985-20987	of	_
129-19	20988-20997	decreased	_
129-20	20998-21006	relative	_
129-21	21007-21015	regional	_
129-22	21016-21024	cerebral	_
129-23	21025-21032	glucose	_
129-24	21033-21043	metabolism	_
129-25	21044-21046	in	_
129-26	21047-21059	MA-dependent	_
129-27	21060-21071	individuals	_
129-28	21072-21074	in	_
129-29	21075-21078	the	_
129-30	21079-21082	ACC	_
129-31	21082-21083	,	_
129-32	21084-21089	which	_
129-33	21090-21092	is	_
129-34	21093-21101	involved	_
129-35	21102-21104	in	_
129-36	21105-21109	both	_
129-37	21110-21119	cognitive	_
129-38	21120-21123	and	_
129-39	21124-21133	emotional	_
129-40	21134-21144	processing	_
129-41	21144-21145	,	_
129-42	21146-21150	when	_
129-43	21151-21159	compared	_
129-44	21160-21162	to	_
129-45	21163-21165	HC	_
129-46	21165-21166	.	_

#Text=The current study also found decreased relative regional cerebral glucose metabolism in the ACC in the MA abusers' group when compared to HC.
130-1	21167-21170	The	_
130-2	21171-21178	current	_
130-3	21179-21184	study	_
130-4	21185-21189	also	_
130-5	21190-21195	found	_
130-6	21196-21205	decreased	_
130-7	21206-21214	relative	_
130-8	21215-21223	regional	_
130-9	21224-21232	cerebral	_
130-10	21233-21240	glucose	_
130-11	21241-21251	metabolism	_
130-12	21252-21254	in	_
130-13	21255-21258	the	_
130-14	21259-21262	ACC	_
130-15	21263-21265	in	_
130-16	21266-21269	the	_
130-17	21270-21272	MA	_
130-18	21273-21280	abusers	_
130-19	21280-21281	'	_
130-20	21282-21287	group	_
130-21	21288-21292	when	_
130-22	21293-21301	compared	_
130-23	21302-21304	to	_
130-24	21305-21307	HC	_
130-25	21307-21308	.	_

#Text=Decreased glucose metabolism was also shown in the left insula and precentral gyrus.
131-1	21309-21318	Decreased	_
131-2	21319-21326	glucose	_
131-3	21327-21337	metabolism	_
131-4	21338-21341	was	_
131-5	21342-21346	also	_
131-6	21347-21352	shown	_
131-7	21353-21355	in	_
131-8	21356-21359	the	_
131-9	21360-21364	left	_
131-10	21365-21371	insula	_
131-11	21372-21375	and	_
131-12	21376-21386	precentral	_
131-13	21387-21392	gyrus	_
131-14	21392-21393	.	_

#Text=Deficits in brain structure in cortical regions – the frontal cortex in particular – have been widely reported in MA users, with associated signs of cognitive and behavioral dysfunction.
132-1	21394-21402	Deficits	_
132-2	21403-21405	in	_
132-3	21406-21411	brain	_
132-4	21412-21421	structure	_
132-5	21422-21424	in	_
132-6	21425-21433	cortical	_
132-7	21434-21441	regions	_
132-8	21442-21443	–	_
132-9	21444-21447	the	_
132-10	21448-21455	frontal	_
132-11	21456-21462	cortex	_
132-12	21463-21465	in	_
132-13	21466-21476	particular	_
132-14	21477-21478	–	_
132-15	21479-21483	have	_
132-16	21484-21488	been	_
132-17	21489-21495	widely	_
132-18	21496-21504	reported	_
132-19	21505-21507	in	_
132-20	21508-21510	MA	_
132-21	21511-21516	users	_
132-22	21516-21517	,	_
132-23	21518-21522	with	_
132-24	21523-21533	associated	_
132-25	21534-21539	signs	_
132-26	21540-21542	of	_
132-27	21543-21552	cognitive	_
132-28	21553-21556	and	_
132-29	21557-21567	behavioral	_
132-30	21568-21579	dysfunction	_
132-31	21579-21580	.	_

#Text=These data further emphasize the effects that MA-use may have in this region.
133-1	21581-21586	These	_
133-2	21587-21591	data	_
133-3	21592-21599	further	_
133-4	21600-21609	emphasize	_
133-5	21610-21613	the	_
133-6	21614-21621	effects	_
133-7	21622-21626	that	_
133-8	21627-21633	MA-use	_
133-9	21634-21637	may	_
133-10	21638-21642	have	_
133-11	21643-21645	in	_
133-12	21646-21650	this	_
133-13	21651-21657	region	_
133-14	21657-21658	.	_

#Text=Decreased relative regional cerebral glucose metabolism in the left precentral gyrus and left inferior frontal gyrus was shown in the MAP group when compared to the MAA group.
134-1	21659-21668	Decreased	_
134-2	21669-21677	relative	_
134-3	21678-21686	regional	_
134-4	21687-21695	cerebral	_
134-5	21696-21703	glucose	_
134-6	21704-21714	metabolism	_
134-7	21715-21717	in	_
134-8	21718-21721	the	_
134-9	21722-21726	left	_
134-10	21727-21737	precentral	_
134-11	21738-21743	gyrus	_
134-12	21744-21747	and	_
134-13	21748-21752	left	_
134-14	21753-21761	inferior	_
134-15	21762-21769	frontal	_
134-16	21770-21775	gyrus	_
134-17	21776-21779	was	_
134-18	21780-21785	shown	_
134-19	21786-21788	in	_
134-20	21789-21792	the	_
134-21	21793-21796	MAP	_
134-22	21797-21802	group	_
134-23	21803-21807	when	_
134-24	21808-21816	compared	_
134-25	21817-21819	to	_
134-26	21820-21823	the	_
134-27	21824-21827	MAA	_
134-28	21828-21833	group	_
134-29	21833-21834	.	_

#Text=Although no studies have looked specifically at MA psychosis within these cortical regions, they have extensive connections.
135-1	21835-21843	Although	_
135-2	21844-21846	no	_
135-3	21847-21854	studies	_
135-4	21855-21859	have	_
135-5	21860-21866	looked	_
135-6	21867-21879	specifically	_
135-7	21880-21882	at	_
135-8	21883-21885	MA	_
135-9	21886-21895	psychosis	_
135-10	21896-21902	within	_
135-11	21903-21908	these	_
135-12	21909-21917	cortical	_
135-13	21918-21925	regions	_
135-14	21925-21926	,	_
135-15	21927-21931	they	_
135-16	21932-21936	have	_
135-17	21937-21946	extensive	_
135-18	21947-21958	connections	_
135-19	21958-21959	.	_

#Text=Evidence suggests that the frontal regions are largely implicated in the pathogenesis of psychotic disorders such as schizophrenia.
136-1	21960-21968	Evidence	_
136-2	21969-21977	suggests	_
136-3	21978-21982	that	_
136-4	21983-21986	the	_
136-5	21987-21994	frontal	_
136-6	21995-22002	regions	_
136-7	22003-22006	are	_
136-8	22007-22014	largely	_
136-9	22015-22025	implicated	_
136-10	22026-22028	in	_
136-11	22029-22032	the	_
136-12	22033-22045	pathogenesis	_
136-13	22046-22048	of	_
136-14	22049-22058	psychotic	_
136-15	22059-22068	disorders	_
136-16	22069-22073	such	_
136-17	22074-22076	as	_
136-18	22077-22090	schizophrenia	_
136-19	22090-22091	.	_

#Text=An increase in relative regional glucose metabolism in the putamen and pallidum in the MAP group when compared to the MAA group was shown in this study, and is in line with work by, who showed increased glucose metabolism in the basal ganglia in individuals with active psychosis in schizophrenia.
137-1	22092-22094	An	_
137-2	22095-22103	increase	_
137-3	22104-22106	in	_
137-4	22107-22115	relative	_
137-5	22116-22124	regional	_
137-6	22125-22132	glucose	_
137-7	22133-22143	metabolism	_
137-8	22144-22146	in	_
137-9	22147-22150	the	_
137-10	22151-22158	putamen	_
137-11	22159-22162	and	_
137-12	22163-22171	pallidum	_
137-13	22172-22174	in	_
137-14	22175-22178	the	_
137-15	22179-22182	MAP	_
137-16	22183-22188	group	_
137-17	22189-22193	when	_
137-18	22194-22202	compared	_
137-19	22203-22205	to	_
137-20	22206-22209	the	_
137-21	22210-22213	MAA	_
137-22	22214-22219	group	_
137-23	22220-22223	was	_
137-24	22224-22229	shown	_
137-25	22230-22232	in	_
137-26	22233-22237	this	_
137-27	22238-22243	study	_
137-28	22243-22244	,	_
137-29	22245-22248	and	_
137-30	22249-22251	is	_
137-31	22252-22254	in	_
137-32	22255-22259	line	_
137-33	22260-22264	with	_
137-34	22265-22269	work	_
137-35	22270-22272	by	_
137-36	22272-22273	,	_
137-37	22274-22277	who	_
137-38	22278-22284	showed	_
137-39	22285-22294	increased	_
137-40	22295-22302	glucose	_
137-41	22303-22313	metabolism	_
137-42	22314-22316	in	_
137-43	22317-22320	the	_
137-44	22321-22326	basal	_
137-45	22327-22334	ganglia	_
137-46	22335-22337	in	_
137-47	22338-22349	individuals	_
137-48	22350-22354	with	_
137-49	22355-22361	active	_
137-50	22362-22371	psychosis	_
137-51	22372-22374	in	_
137-52	22375-22388	schizophrenia	_
137-53	22388-22389	.	_

#Text=These results therefore seem to be specific to the psychotic group and include regions that are increasingly present in recent work on schizophrenia.
138-1	22390-22395	These	_
138-2	22396-22403	results	_
138-3	22404-22413	therefore	_
138-4	22414-22418	seem	_
138-5	22419-22421	to	_
138-6	22422-22424	be	_
138-7	22425-22433	specific	_
138-8	22434-22436	to	_
138-9	22437-22440	the	_
138-10	22441-22450	psychotic	_
138-11	22451-22456	group	_
138-12	22457-22460	and	_
138-13	22461-22468	include	_
138-14	22469-22476	regions	_
138-15	22477-22481	that	_
138-16	22482-22485	are	_
138-17	22486-22498	increasingly	_
138-18	22499-22506	present	_
138-19	22507-22509	in	_
138-20	22510-22516	recent	_
138-21	22517-22521	work	_
138-22	22522-22524	on	_
138-23	22525-22538	schizophrenia	_
138-24	22538-22539	.	_

#Text=A multicenter large-scale meta-analysis of neuroimaging data of subcortical brain abnormalities in schizophrenia, reported a larger pallidum in schizophrenia.
139-1	22540-22541	A	_
139-2	22542-22553	multicenter	_
139-3	22554-22565	large-scale	_
139-4	22566-22579	meta-analysis	_
139-5	22580-22582	of	_
139-6	22583-22595	neuroimaging	_
139-7	22596-22600	data	_
139-8	22601-22603	of	_
139-9	22604-22615	subcortical	_
139-10	22616-22621	brain	_
139-11	22622-22635	abnormalities	_
139-12	22636-22638	in	_
139-13	22639-22652	schizophrenia	_
139-14	22652-22653	,	_
139-15	22654-22662	reported	_
139-16	22663-22664	a	_
139-17	22665-22671	larger	_
139-18	22672-22680	pallidum	_
139-19	22681-22683	in	_
139-20	22684-22697	schizophrenia	_
139-21	22697-22698	.	_

#Text=This finding was replicated by Okada and colleagues who also showed asymmetries in various subcortical brain volumes, including a leftward asymmetry in the pallidum in schizophrenia patients when compared to HC.
140-1	22699-22703	This	_
140-2	22704-22711	finding	_
140-3	22712-22715	was	_
140-4	22716-22726	replicated	_
140-5	22727-22729	by	_
140-6	22730-22735	Okada	_
140-7	22736-22739	and	_
140-8	22740-22750	colleagues	_
140-9	22751-22754	who	_
140-10	22755-22759	also	_
140-11	22760-22766	showed	_
140-12	22767-22778	asymmetries	_
140-13	22779-22781	in	_
140-14	22782-22789	various	_
140-15	22790-22801	subcortical	_
140-16	22802-22807	brain	_
140-17	22808-22815	volumes	_
140-18	22815-22816	,	_
140-19	22817-22826	including	_
140-20	22827-22828	a	_
140-21	22829-22837	leftward	_
140-22	22838-22847	asymmetry	_
140-23	22848-22850	in	_
140-24	22851-22854	the	_
140-25	22855-22863	pallidum	_
140-26	22864-22866	in	_
140-27	22867-22880	schizophrenia	_
140-28	22881-22889	patients	_
140-29	22890-22894	when	_
140-30	22895-22903	compared	_
140-31	22904-22906	to	_
140-32	22907-22909	HC	_
140-33	22909-22910	.	_

#Text=Given that differences in glucose metabolism were seen between the methamphetamine abuser groups in the current study, it suggests that deficits in the respective regions specifically may be due to the development of psychosis and not the use of MA.
141-1	22911-22916	Given	_
141-2	22917-22921	that	_
141-3	22922-22933	differences	_
141-4	22934-22936	in	_
141-5	22937-22944	glucose	_
141-6	22945-22955	metabolism	_
141-7	22956-22960	were	_
141-8	22961-22965	seen	_
141-9	22966-22973	between	_
141-10	22974-22977	the	_
141-11	22978-22993	methamphetamine	_
141-12	22994-23000	abuser	_
141-13	23001-23007	groups	_
141-14	23008-23010	in	_
141-15	23011-23014	the	_
141-16	23015-23022	current	_
141-17	23023-23028	study	_
141-18	23028-23029	,	_
141-19	23030-23032	it	_
141-20	23033-23041	suggests	_
141-21	23042-23046	that	_
141-22	23047-23055	deficits	_
141-23	23056-23058	in	_
141-24	23059-23062	the	_
141-25	23063-23073	respective	_
141-26	23074-23081	regions	_
141-27	23082-23094	specifically	_
141-28	23095-23098	may	_
141-29	23099-23101	be	_
141-30	23102-23105	due	_
141-31	23106-23108	to	_
141-32	23109-23112	the	_
141-33	23113-23124	development	_
141-34	23125-23127	of	_
141-35	23128-23137	psychosis	_
141-36	23138-23141	and	_
141-37	23142-23145	not	_
141-38	23146-23149	the	_
141-39	23150-23153	use	_
141-40	23154-23156	of	_
141-41	23157-23159	MA	_
141-42	23159-23160	.	_

#Text=The putamen and pallidum were also shown to have increased CBF in MAP compared to MAA.
142-1	23161-23164	The	_
142-2	23165-23172	putamen	_
142-3	23173-23176	and	_
142-4	23177-23185	pallidum	_
142-5	23186-23190	were	_
142-6	23191-23195	also	_
142-7	23196-23201	shown	_
142-8	23202-23204	to	_
142-9	23205-23209	have	_
142-10	23210-23219	increased	_
142-11	23220-23223	CBF	_
142-12	23224-23226	in	_
142-13	23227-23230	MAP	_
142-14	23231-23239	compared	_
142-15	23240-23242	to	_
142-16	23243-23246	MAA	_
142-17	23246-23247	.	_

#Text=Abnormalities such as enlarged volumes in these structures have been shown to exist in schizophrenia.
143-1	23248-23261	Abnormalities	_
143-2	23262-23266	such	_
143-3	23267-23269	as	_
143-4	23270-23278	enlarged	_
143-5	23279-23286	volumes	_
143-6	23287-23289	in	_
143-7	23290-23295	these	_
143-8	23296-23306	structures	_
143-9	23307-23311	have	_
143-10	23312-23316	been	_
143-11	23317-23322	shown	_
143-12	23323-23325	to	_
143-13	23326-23331	exist	_
143-14	23332-23334	in	_
143-15	23335-23348	schizophrenia	_
143-16	23348-23349	.	_

#Text=The current study showed increased regional cerebral perfusion in subcortical structures.
144-1	23350-23353	The	_
144-2	23354-23361	current	_
144-3	23362-23367	study	_
144-4	23368-23374	showed	_
144-5	23375-23384	increased	_
144-6	23385-23393	regional	_
144-7	23394-23402	cerebral	_
144-8	23403-23412	perfusion	_
144-9	23413-23415	in	_
144-10	23416-23427	subcortical	_
144-11	23428-23438	structures	_
144-12	23438-23439	.	_

#Text=In contrast, ASL studies of polysubstance abusers and cocaine abusers have shown decreased cortical and subcortical CBF deficits, and cortical CBF deficits, respectively.
145-1	23440-23442	In	_
145-2	23443-23451	contrast	_
145-3	23451-23452	,	_
145-4	23453-23456	ASL	_
145-5	23457-23464	studies	_
145-6	23465-23467	of	_
145-7	23468-23481	polysubstance	_
145-8	23482-23489	abusers	_
145-9	23490-23493	and	_
145-10	23494-23501	cocaine	_
145-11	23502-23509	abusers	_
145-12	23510-23514	have	_
145-13	23515-23520	shown	_
145-14	23521-23530	decreased	_
145-15	23531-23539	cortical	_
145-16	23540-23543	and	_
145-17	23544-23555	subcortical	_
145-18	23556-23559	CBF	_
145-19	23560-23568	deficits	_
145-20	23568-23569	,	_
145-21	23570-23573	and	_
145-22	23574-23582	cortical	_
145-23	23583-23586	CBF	_
145-24	23587-23595	deficits	_
145-25	23595-23596	,	_
145-26	23597-23609	respectively	_
145-27	23609-23610	.	_

#Text=Different substances of abuse have their own individual mechanisms of action at specific sites, which these results may reflect.
146-1	23611-23620	Different	_
146-2	23621-23631	substances	_
146-3	23632-23634	of	_
146-4	23635-23640	abuse	_
146-5	23641-23645	have	_
146-6	23646-23651	their	_
146-7	23652-23655	own	_
146-8	23656-23666	individual	_
146-9	23667-23677	mechanisms	_
146-10	23678-23680	of	_
146-11	23681-23687	action	_
146-12	23688-23690	at	_
146-13	23691-23699	specific	_
146-14	23700-23705	sites	_
146-15	23705-23706	,	_
146-16	23707-23712	which	_
146-17	23713-23718	these	_
146-18	23719-23726	results	_
146-19	23727-23730	may	_
146-20	23731-23738	reflect	_
146-21	23738-23739	.	_

#Text=As with an increased glucose metabolism in the basal ganglia possibly contributing to psychosis, the same may apply here with an increased CBF in the putamen and pallidum shown in the MAP participants.
147-1	23740-23742	As	_
147-2	23743-23747	with	_
147-3	23748-23750	an	_
147-4	23751-23760	increased	_
147-5	23761-23768	glucose	_
147-6	23769-23779	metabolism	_
147-7	23780-23782	in	_
147-8	23783-23786	the	_
147-9	23787-23792	basal	_
147-10	23793-23800	ganglia	_
147-11	23801-23809	possibly	_
147-12	23810-23822	contributing	_
147-13	23823-23825	to	_
147-14	23826-23835	psychosis	_
147-15	23835-23836	,	_
147-16	23837-23840	the	_
147-17	23841-23845	same	_
147-18	23846-23849	may	_
147-19	23850-23855	apply	_
147-20	23856-23860	here	_
147-21	23861-23865	with	_
147-22	23866-23868	an	_
147-23	23869-23878	increased	_
147-24	23879-23882	CBF	_
147-25	23883-23885	in	_
147-26	23886-23889	the	_
147-27	23890-23897	putamen	_
147-28	23898-23901	and	_
147-29	23902-23910	pallidum	_
147-30	23911-23916	shown	_
147-31	23917-23919	in	_
147-32	23920-23923	the	_
147-33	23924-23927	MAP	_
147-34	23928-23940	participants	_
147-35	23940-23941	.	_

#Text=Our results indicate partial but not complete overlap of PET and ASL findings.
148-1	23942-23945	Our	_
148-2	23946-23953	results	_
148-3	23954-23962	indicate	_
148-4	23963-23970	partial	_
148-5	23971-23974	but	_
148-6	23975-23978	not	_
148-7	23979-23987	complete	_
148-8	23988-23995	overlap	_
148-9	23996-23998	of	_
148-10	23999-24002	PET	_
148-11	24003-24006	and	_
148-12	24007-24010	ASL	_
148-13	24011-24019	findings	_
148-14	24019-24020	.	_

#Text=A study by examining the correspondence between ASL and FDG-PET showed that – although there was an overall good correlation between CBF, measured by ASL, and glucose metabolism, measured by FDG-PET – there was also regional variation.
149-1	24021-24022	A	_
149-2	24023-24028	study	_
149-3	24029-24031	by	_
149-4	24032-24041	examining	_
149-5	24042-24045	the	_
149-6	24046-24060	correspondence	_
149-7	24061-24068	between	_
149-8	24069-24072	ASL	_
149-9	24073-24076	and	_
149-10	24077-24084	FDG-PET	_
149-11	24085-24091	showed	_
149-12	24092-24096	that	_
149-13	24097-24098	–	_
149-14	24099-24107	although	_
149-15	24108-24113	there	_
149-16	24114-24117	was	_
149-17	24118-24120	an	_
149-18	24121-24128	overall	_
149-19	24129-24133	good	_
149-20	24134-24145	correlation	_
149-21	24146-24153	between	_
149-22	24154-24157	CBF	_
149-23	24157-24158	,	_
149-24	24159-24167	measured	_
149-25	24168-24170	by	_
149-26	24171-24174	ASL	_
149-27	24174-24175	,	_
149-28	24176-24179	and	_
149-29	24180-24187	glucose	_
149-30	24188-24198	metabolism	_
149-31	24198-24199	,	_
149-32	24200-24208	measured	_
149-33	24209-24211	by	_
149-34	24212-24219	FDG-PET	_
149-35	24220-24221	–	_
149-36	24222-24227	there	_
149-37	24228-24231	was	_
149-38	24232-24236	also	_
149-39	24237-24245	regional	_
149-40	24246-24255	variation	_
149-41	24255-24256	.	_

#Text=Interestingly, the highest correlation between perfusion and metabolism was shown in the striatum.
150-1	24257-24270	Interestingly	_
150-2	24270-24271	,	_
150-3	24272-24275	the	_
150-4	24276-24283	highest	_
150-5	24284-24295	correlation	_
150-6	24296-24303	between	_
150-7	24304-24313	perfusion	_
150-8	24314-24317	and	_
150-9	24318-24328	metabolism	_
150-10	24329-24332	was	_
150-11	24333-24338	shown	_
150-12	24339-24341	in	_
150-13	24342-24345	the	_
150-14	24346-24354	striatum	_
150-15	24354-24355	.	_

#Text=Based on the considerable evidence implicating the involvement of the putamen and pallidum in psychosis, and the finding that, in the current study, differences were seen between the MAA and MAP groups, the alterations in these regions may potentially be associated with MA-induced psychosis; as a cause of the psychosis, or as a consequence.
151-1	24356-24361	Based	_
151-2	24362-24364	on	_
151-3	24365-24368	the	_
151-4	24369-24381	considerable	_
151-5	24382-24390	evidence	_
151-6	24391-24402	implicating	_
151-7	24403-24406	the	_
151-8	24407-24418	involvement	_
151-9	24419-24421	of	_
151-10	24422-24425	the	_
151-11	24426-24433	putamen	_
151-12	24434-24437	and	_
151-13	24438-24446	pallidum	_
151-14	24447-24449	in	_
151-15	24450-24459	psychosis	_
151-16	24459-24460	,	_
151-17	24461-24464	and	_
151-18	24465-24468	the	_
151-19	24469-24476	finding	_
151-20	24477-24481	that	_
151-21	24481-24482	,	_
151-22	24483-24485	in	_
151-23	24486-24489	the	_
151-24	24490-24497	current	_
151-25	24498-24503	study	_
151-26	24503-24504	,	_
151-27	24505-24516	differences	_
151-28	24517-24521	were	_
151-29	24522-24526	seen	_
151-30	24527-24534	between	_
151-31	24535-24538	the	_
151-32	24539-24542	MAA	_
151-33	24543-24546	and	_
151-34	24547-24550	MAP	_
151-35	24551-24557	groups	_
151-36	24557-24558	,	_
151-37	24559-24562	the	_
151-38	24563-24574	alterations	_
151-39	24575-24577	in	_
151-40	24578-24583	these	_
151-41	24584-24591	regions	_
151-42	24592-24595	may	_
151-43	24596-24607	potentially	_
151-44	24608-24610	be	_
151-45	24611-24621	associated	_
151-46	24622-24626	with	_
151-47	24627-24637	MA-induced	_
151-48	24638-24647	psychosis	_
151-49	24647-24648	;	_
151-50	24649-24651	as	_
151-51	24652-24653	a	_
151-52	24654-24659	cause	_
151-53	24660-24662	of	_
151-54	24663-24666	the	_
151-55	24667-24676	psychosis	_
151-56	24676-24677	,	_
151-57	24678-24680	or	_
151-58	24681-24683	as	_
151-59	24684-24685	a	_
151-60	24686-24697	consequence	_
151-61	24697-24698	.	_

#Text=Or, even as a compensatory effect.
152-1	24699-24701	Or	_
152-2	24701-24702	,	_
152-3	24703-24707	even	_
152-4	24708-24710	as	_
152-5	24711-24712	a	_
152-6	24713-24725	compensatory	_
152-7	24726-24732	effect	_
152-8	24732-24733	.	_

#Text=Several limitations should be mentioned.
153-1	24734-24741	Several	_
153-2	24742-24753	limitations	_
153-3	24754-24760	should	_
153-4	24761-24763	be	_
153-5	24764-24773	mentioned	_
153-6	24773-24774	.	_

#Text=It was not possible to measure the quantity of MA used, as these data are unreliable due to the fact participants bought the drug in “bags”, “packets”, “straws” or “grams” and is thus a limitation of this study.
154-1	24775-24777	It	_
154-2	24778-24781	was	_
154-3	24782-24785	not	_
154-4	24786-24794	possible	_
154-5	24795-24797	to	_
154-6	24798-24805	measure	_
154-7	24806-24809	the	_
154-8	24810-24818	quantity	_
154-9	24819-24821	of	_
154-10	24822-24824	MA	_
154-11	24825-24829	used	_
154-12	24829-24830	,	_
154-13	24831-24833	as	_
154-14	24834-24839	these	_
154-15	24840-24844	data	_
154-16	24845-24848	are	_
154-17	24849-24859	unreliable	_
154-18	24860-24863	due	_
154-19	24864-24866	to	_
154-20	24867-24870	the	_
154-21	24871-24875	fact	_
154-22	24876-24888	participants	_
154-23	24889-24895	bought	_
154-24	24896-24899	the	_
154-25	24900-24904	drug	_
154-26	24905-24907	in	_
154-27	24908-24909	“	_
154-28	24909-24913	bags	_
154-29	24913-24914	”	_
154-30	24914-24915	,	_
154-31	24916-24917	“	_
154-32	24917-24924	packets	_
154-33	24924-24925	”	_
154-34	24925-24926	,	_
154-35	24927-24928	“	_
154-36	24928-24934	straws	_
154-37	24934-24935	”	_
154-38	24936-24938	or	_
154-39	24939-24940	“	_
154-40	24940-24945	grams	_
154-41	24945-24946	”	_
154-42	24947-24950	and	_
154-43	24951-24953	is	_
154-44	24954-24958	thus	_
154-45	24959-24960	a	_
154-46	24961-24971	limitation	_
154-47	24972-24974	of	_
154-48	24975-24979	this	_
154-49	24980-24985	study	_
154-50	24985-24986	.	_

#Text=The MAA patients may have used less than the hospitalized MAP patients on average, which would make this a confound.
155-1	24987-24990	The	_
155-2	24991-24994	MAA	_
155-3	24995-25003	patients	_
155-4	25004-25007	may	_
155-5	25008-25012	have	_
155-6	25013-25017	used	_
155-7	25018-25022	less	_
155-8	25023-25027	than	_
155-9	25028-25031	the	_
155-10	25032-25044	hospitalized	_
155-11	25045-25048	MAP	_
155-12	25049-25057	patients	_
155-13	25058-25060	on	_
155-14	25061-25068	average	_
155-15	25068-25069	,	_
155-16	25070-25075	which	_
155-17	25076-25081	would	_
155-18	25082-25086	make	_
155-19	25087-25091	this	_
155-20	25092-25093	a	_
155-21	25094-25102	confound	_
155-22	25102-25103	.	_

#Text=It was also not possible to measure and compare the use of different substances across the groups due to unreliable drug histories and difficulty in quantifying amounts used.
156-1	25104-25106	It	_
156-2	25107-25110	was	_
156-3	25111-25115	also	_
156-4	25116-25119	not	_
156-5	25120-25128	possible	_
156-6	25129-25131	to	_
156-7	25132-25139	measure	_
156-8	25140-25143	and	_
156-9	25144-25151	compare	_
156-10	25152-25155	the	_
156-11	25156-25159	use	_
156-12	25160-25162	of	_
156-13	25163-25172	different	_
156-14	25173-25183	substances	_
156-15	25184-25190	across	_
156-16	25191-25194	the	_
156-17	25195-25201	groups	_
156-18	25202-25205	due	_
156-19	25206-25208	to	_
156-20	25209-25219	unreliable	_
156-21	25220-25224	drug	_
156-22	25225-25234	histories	_
156-23	25235-25238	and	_
156-24	25239-25249	difficulty	_
156-25	25250-25252	in	_
156-26	25253-25264	quantifying	_
156-27	25265-25272	amounts	_
156-28	25273-25277	used	_
156-29	25277-25278	.	_

#Text=The use of marijuana is a possible confounding factor of this study, given that marijuana use has been associated with psychotic symptoms.
157-1	25279-25282	The	_
157-2	25283-25286	use	_
157-3	25287-25289	of	_
157-4	25290-25299	marijuana	_
157-5	25300-25302	is	_
157-6	25303-25304	a	_
157-7	25305-25313	possible	_
157-8	25314-25325	confounding	_
157-9	25326-25332	factor	_
157-10	25333-25335	of	_
157-11	25336-25340	this	_
157-12	25341-25346	study	_
157-13	25346-25347	,	_
157-14	25348-25353	given	_
157-15	25354-25358	that	_
157-16	25359-25368	marijuana	_
157-17	25369-25372	use	_
157-18	25373-25376	has	_
157-19	25377-25381	been	_
157-20	25382-25392	associated	_
157-21	25393-25397	with	_
157-22	25398-25407	psychotic	_
157-23	25408-25416	symptoms	_
157-24	25416-25417	.	_

#Text=It should, however, be noted that all participants who used marijuana were only included if they met criteria for “abuse”, and not “dependence”, according to the Structured Clinical Interview for DSM-IV (SCID).
158-1	25418-25420	It	_
158-2	25421-25427	should	_
158-3	25427-25428	,	_
158-4	25429-25436	however	_
158-5	25436-25437	,	_
158-6	25438-25440	be	_
158-7	25441-25446	noted	_
158-8	25447-25451	that	_
158-9	25452-25455	all	_
158-10	25456-25468	participants	_
158-11	25469-25472	who	_
158-12	25473-25477	used	_
158-13	25478-25487	marijuana	_
158-14	25488-25492	were	_
158-15	25493-25497	only	_
158-16	25498-25506	included	_
158-17	25507-25509	if	_
158-18	25510-25514	they	_
158-19	25515-25518	met	_
158-20	25519-25527	criteria	_
158-21	25528-25531	for	_
158-22	25532-25533	“	_
158-23	25533-25538	abuse	_
158-24	25538-25539	”	_
158-25	25539-25540	,	_
158-26	25541-25544	and	_
158-27	25545-25548	not	_
158-28	25549-25550	“	_
158-29	25550-25560	dependence	_
158-30	25560-25561	”	_
158-31	25561-25562	,	_
158-32	25563-25572	according	_
158-33	25573-25575	to	_
158-34	25576-25579	the	_
158-35	25580-25590	Structured	_
158-36	25591-25599	Clinical	_
158-37	25600-25609	Interview	_
158-38	25610-25613	for	_
158-39	25614-25620	DSM-IV	_
158-40	25621-25622	(	_
158-41	25622-25626	SCID	_
158-42	25626-25627	)	_
158-43	25627-25628	.	_

#Text=All participants in the MAP group were current inpatients at a psychiatric hospital, and were all receiving antipsychotic medication.
159-1	25629-25632	All	_
159-2	25633-25645	participants	_
159-3	25646-25648	in	_
159-4	25649-25652	the	_
159-5	25653-25656	MAP	_
159-6	25657-25662	group	_
159-7	25663-25667	were	_
159-8	25668-25675	current	_
159-9	25676-25686	inpatients	_
159-10	25687-25689	at	_
159-11	25690-25691	a	_
159-12	25692-25703	psychiatric	_
159-13	25704-25712	hospital	_
159-14	25712-25713	,	_
159-15	25714-25717	and	_
159-16	25718-25722	were	_
159-17	25723-25726	all	_
159-18	25727-25736	receiving	_
159-19	25737-25750	antipsychotic	_
159-20	25751-25761	medication	_
159-21	25761-25762	.	_

#Text=Participants in the MAA group were medication-free.
160-1	25763-25775	Participants	_
160-2	25776-25778	in	_
160-3	25779-25782	the	_
160-4	25783-25786	MAA	_
160-5	25787-25792	group	_
160-6	25793-25797	were	_
160-7	25798-25813	medication-free	_
160-8	25813-25814	.	_

#Text=While this is a potentially important confound, and it is possible that some antipsychotics can affect brain perfusion, there was no significant association between duration of medication and glucose metabolism and cerebral perfusion in the MAP group.
161-1	25815-25820	While	_
161-2	25821-25825	this	_
161-3	25826-25828	is	_
161-4	25829-25830	a	_
161-5	25831-25842	potentially	_
161-6	25843-25852	important	_
161-7	25853-25861	confound	_
161-8	25861-25862	,	_
161-9	25863-25866	and	_
161-10	25867-25869	it	_
161-11	25870-25872	is	_
161-12	25873-25881	possible	_
161-13	25882-25886	that	_
161-14	25887-25891	some	_
161-15	25892-25906	antipsychotics	_
161-16	25907-25910	can	_
161-17	25911-25917	affect	_
161-18	25918-25923	brain	_
161-19	25924-25933	perfusion	_
161-20	25933-25934	,	_
161-21	25935-25940	there	_
161-22	25941-25944	was	_
161-23	25945-25947	no	_
161-24	25948-25959	significant	_
161-25	25960-25971	association	_
161-26	25972-25979	between	_
161-27	25980-25988	duration	_
161-28	25989-25991	of	_
161-29	25992-26002	medication	_
161-30	26003-26006	and	_
161-31	26007-26014	glucose	_
161-32	26015-26025	metabolism	_
161-33	26026-26029	and	_
161-34	26030-26038	cerebral	_
161-35	26039-26048	perfusion	_
161-36	26049-26051	in	_
161-37	26052-26055	the	_
161-38	26056-26059	MAP	_
161-39	26060-26065	group	_
161-40	26065-26066	.	_

#Text=This, however, could also be due to lack of statistical power.
162-1	26067-26071	This	_
162-2	26071-26072	,	_
162-3	26073-26080	however	_
162-4	26080-26081	,	_
162-5	26082-26087	could	_
162-6	26088-26092	also	_
162-7	26093-26095	be	_
162-8	26096-26099	due	_
162-9	26100-26102	to	_
162-10	26103-26107	lack	_
162-11	26108-26110	of	_
162-12	26111-26122	statistical	_
162-13	26123-26128	power	_
162-14	26128-26129	.	_

#Text=This is the first study to intensively study changes in brain metabolism and blood flow in MAA and MAP compared to HC using PET and ASL respectively and helps shed some light on the neurobiological mechanisms underlying MA-use disorders.
163-1	26130-26134	This	_
163-2	26135-26137	is	_
163-3	26138-26141	the	_
163-4	26142-26147	first	_
163-5	26148-26153	study	_
163-6	26154-26156	to	_
163-7	26157-26168	intensively	_
163-8	26169-26174	study	_
163-9	26175-26182	changes	_
163-10	26183-26185	in	_
163-11	26186-26191	brain	_
163-12	26192-26202	metabolism	_
163-13	26203-26206	and	_
163-14	26207-26212	blood	_
163-15	26213-26217	flow	_
163-16	26218-26220	in	_
163-17	26221-26224	MAA	_
163-18	26225-26228	and	_
163-19	26229-26232	MAP	_
163-20	26233-26241	compared	_
163-21	26242-26244	to	_
163-22	26245-26247	HC	_
163-23	26248-26253	using	_
163-24	26254-26257	PET	_
163-25	26258-26261	and	_
163-26	26262-26265	ASL	_
163-27	26266-26278	respectively	_
163-28	26279-26282	and	_
163-29	26283-26288	helps	_
163-30	26289-26293	shed	_
163-31	26294-26298	some	_
163-32	26299-26304	light	_
163-33	26305-26307	on	_
163-34	26308-26311	the	_
163-35	26312-26327	neurobiological	_
163-36	26328-26338	mechanisms	_
163-37	26339-26349	underlying	_
163-38	26350-26356	MA-use	_
163-39	26357-26366	disorders	_
163-40	26366-26367	.	_

#Text=In particular, there is evidence to further support the involvement of the ACC, insula and precentral gyrus in MA abuse, and disruption of the structures within the basal ganglia in MA-dependent individuals with psychotic symptoms.
164-1	26368-26370	In	_
164-2	26371-26381	particular	_
164-3	26381-26382	,	_
164-4	26383-26388	there	_
164-5	26389-26391	is	_
164-6	26392-26400	evidence	_
164-7	26401-26403	to	_
164-8	26404-26411	further	_
164-9	26412-26419	support	_
164-10	26420-26423	the	_
164-11	26424-26435	involvement	_
164-12	26436-26438	of	_
164-13	26439-26442	the	_
164-14	26443-26446	ACC	_
164-15	26446-26447	,	_
164-16	26448-26454	insula	_
164-17	26455-26458	and	_
164-18	26459-26469	precentral	_
164-19	26470-26475	gyrus	_
164-20	26476-26478	in	_
164-21	26479-26481	MA	_
164-22	26482-26487	abuse	_
164-23	26487-26488	,	_
164-24	26489-26492	and	_
164-25	26493-26503	disruption	_
164-26	26504-26506	of	_
164-27	26507-26510	the	_
164-28	26511-26521	structures	_
164-29	26522-26528	within	_
164-30	26529-26532	the	_
164-31	26533-26538	basal	_
164-32	26539-26546	ganglia	_
164-33	26547-26549	in	_
164-34	26550-26562	MA-dependent	_
164-35	26563-26574	individuals	_
164-36	26575-26579	with	_
164-37	26580-26589	psychotic	_
164-38	26590-26598	symptoms	_
164-39	26598-26599	.	_

#Text=This is consistent with prior literature focusing on these regions in other psychotic disorders, and with the hypothesis that methamphetamine-induced psychosis serves as a model for schizophrenia.
165-1	26600-26604	This	_
165-2	26605-26607	is	_
165-3	26608-26618	consistent	_
165-4	26619-26623	with	_
165-5	26624-26629	prior	_
165-6	26630-26640	literature	_
165-7	26641-26649	focusing	_
165-8	26650-26652	on	_
165-9	26653-26658	these	_
165-10	26659-26666	regions	_
165-11	26667-26669	in	_
165-12	26670-26675	other	_
165-13	26676-26685	psychotic	_
165-14	26686-26695	disorders	_
165-15	26695-26696	,	_
165-16	26697-26700	and	_
165-17	26701-26705	with	_
165-18	26706-26709	the	_
165-19	26710-26720	hypothesis	_
165-20	26721-26725	that	_
165-21	26726-26749	methamphetamine-induced	_
165-22	26750-26759	psychosis	_
165-23	26760-26766	serves	_
165-24	26767-26769	as	_
165-25	26770-26771	a	_
165-26	26772-26777	model	_
165-27	26778-26781	for	_
165-28	26782-26795	schizophrenia	_
165-29	26795-26796	.	_

#Text=By using multi-modal imaging, we have been able to find more extensive changes than would have been detected with any single modality.
166-1	26797-26799	By	_
166-2	26800-26805	using	_
166-3	26806-26817	multi-modal	_
166-4	26818-26825	imaging	_
166-5	26825-26826	,	_
166-6	26827-26829	we	_
166-7	26830-26834	have	_
166-8	26835-26839	been	_
166-9	26840-26844	able	_
166-10	26845-26847	to	_
166-11	26848-26852	find	_
166-12	26853-26857	more	_
166-13	26858-26867	extensive	_
166-14	26868-26875	changes	_
166-15	26876-26880	than	_
166-16	26881-26886	would	_
166-17	26887-26891	have	_
166-18	26892-26896	been	_
166-19	26897-26905	detected	_
166-20	26906-26910	with	_
166-21	26911-26914	any	_
166-22	26915-26921	single	_
166-23	26922-26930	modality	_
166-24	26930-26931	.	_

#Text=Further work, with specific radioligands to examine the molecular neuroanatomy of MA-induced psychosis, and using larger sample sizes, is needed to elucidate more fully the nature of these changes.
167-1	26932-26939	Further	_
167-2	26940-26944	work	_
167-3	26944-26945	,	_
167-4	26946-26950	with	_
167-5	26951-26959	specific	_
167-6	26960-26972	radioligands	_
167-7	26973-26975	to	_
167-8	26976-26983	examine	_
167-9	26984-26987	the	_
167-10	26988-26997	molecular	_
167-11	26998-27010	neuroanatomy	_
167-12	27011-27013	of	_
167-13	27014-27024	MA-induced	_
167-14	27025-27034	psychosis	_
167-15	27034-27035	,	_
167-16	27036-27039	and	_
167-17	27040-27045	using	_
167-18	27046-27052	larger	_
167-19	27053-27059	sample	_
167-20	27060-27065	sizes	_
167-21	27065-27066	,	_
167-22	27067-27069	is	_
167-23	27070-27076	needed	_
167-24	27077-27079	to	_
167-25	27080-27089	elucidate	_
167-26	27090-27094	more	_
167-27	27095-27100	fully	_
167-28	27101-27104	the	_
167-29	27105-27111	nature	_
167-30	27112-27114	of	_
167-31	27115-27120	these	_
167-32	27121-27128	changes	_
167-33	27128-27129	.	_

#Text=This may in turn ultimately facilitate correct diagnoses and optimize therapeutic interventions.
168-1	27130-27134	This	_
168-2	27135-27138	may	_
168-3	27139-27141	in	_
168-4	27142-27146	turn	_
168-5	27147-27157	ultimately	_
168-6	27158-27168	facilitate	_
168-7	27169-27176	correct	_
168-8	27177-27186	diagnoses	_
168-9	27187-27190	and	_
168-10	27191-27199	optimize	_
168-11	27200-27211	therapeutic	_
168-12	27212-27225	interventions	_
168-13	27225-27226	.	_

#Text=Funding
#Text=This work was supported by the Nuclear Technologies in Medicine and Biosciences Initiative (NTeMBI) which is funded by the  and hosted by the South African Nuclear Energy Corporation (Necsa).
169-1	27227-27234	Funding	_
169-2	27235-27239	This	_
169-3	27240-27244	work	_
169-4	27245-27248	was	_
169-5	27249-27258	supported	_
169-6	27259-27261	by	_
169-7	27262-27265	the	_
169-8	27266-27273	Nuclear	_
169-9	27274-27286	Technologies	_
169-10	27287-27289	in	_
169-11	27290-27298	Medicine	_
169-12	27299-27302	and	_
169-13	27303-27314	Biosciences	_
169-14	27315-27325	Initiative	_
169-15	27326-27327	(	_
169-16	27327-27333	NTeMBI	_
169-17	27333-27334	)	_
169-18	27335-27340	which	_
169-19	27341-27343	is	_
169-20	27344-27350	funded	_
169-21	27351-27353	by	_
169-22	27354-27357	the	_
169-23	27359-27362	and	_
169-24	27363-27369	hosted	_
169-25	27370-27372	by	_
169-26	27373-27376	the	_
169-27	27377-27382	South	_
169-28	27383-27390	African	_
169-29	27391-27398	Nuclear	_
169-30	27399-27405	Energy	_
169-31	27406-27417	Corporation	_
169-32	27418-27419	(	_
169-33	27419-27424	Necsa	_
169-34	27424-27425	)	_
169-35	27425-27426	.	_

#Text=Dan J.
170-1	27427-27430	Dan	_
170-2	27431-27432	J	_
170-3	27432-27433	.	_

#Text=Stein is supported by the .
171-1	27434-27439	Stein	_
171-2	27440-27442	is	_
171-3	27443-27452	supported	_
171-4	27453-27455	by	_
171-5	27456-27459	the	_
171-6	27460-27461	.	_

#Text=References
#Text=The phenomenology of experimentally induced amphetamine psychosis-preliminary observations
#Text=Causal association between cannabis and psychosis: Causal association between cannabis and psychosis: examination of the evidence examination of the evidence
#Text=Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder
#Text=The experimental reproduction of amphetamine psychosis
#Text=Cognitive and emotional influences in anterior cingulate cortex
#Text=Regional correlation between resting state FDG PET and pCASL perfusion MRI
#Text=Perfusion MRI and computerized cognitive test abnormalities in abstinent MA users
#Text=
#Text=Long-term follow-up of patients treated for psychotic symptoms that persist after stopping illicit drug use.
172-1	27462-27472	References	_
172-2	27473-27476	The	_
172-3	27477-27490	phenomenology	_
172-4	27491-27493	of	_
172-5	27494-27508	experimentally	_
172-6	27509-27516	induced	_
172-7	27517-27528	amphetamine	_
172-8	27529-27550	psychosis-preliminary	_
172-9	27551-27563	observations	_
172-10	27564-27570	Causal	_
172-11	27571-27582	association	_
172-12	27583-27590	between	_
172-13	27591-27599	cannabis	_
172-14	27600-27603	and	_
172-15	27604-27613	psychosis	_
172-16	27613-27614	:	_
172-17	27615-27621	Causal	_
172-18	27622-27633	association	_
172-19	27634-27641	between	_
172-20	27642-27650	cannabis	_
172-21	27651-27654	and	_
172-22	27655-27664	psychosis	_
172-23	27664-27665	:	_
172-24	27666-27677	examination	_
172-25	27678-27680	of	_
172-26	27681-27684	the	_
172-27	27685-27693	evidence	_
172-28	27694-27705	examination	_
172-29	27706-27708	of	_
172-30	27709-27712	the	_
172-31	27713-27721	evidence	_
172-32	27722-27732	Disruption	_
172-33	27733-27735	of	_
172-34	27736-27744	cortical	_
172-35	27745-27756	association	_
172-36	27757-27765	networks	_
172-37	27766-27768	in	_
172-38	27769-27782	schizophrenia	_
172-39	27783-27786	and	_
172-40	27787-27796	psychotic	_
172-41	27797-27804	bipolar	_
172-42	27805-27813	disorder	_
172-43	27814-27817	The	_
172-44	27818-27830	experimental	_
172-45	27831-27843	reproduction	_
172-46	27844-27846	of	_
172-47	27847-27858	amphetamine	_
172-48	27859-27868	psychosis	_
172-49	27869-27878	Cognitive	_
172-50	27879-27882	and	_
172-51	27883-27892	emotional	_
172-52	27893-27903	influences	_
172-53	27904-27906	in	_
172-54	27907-27915	anterior	_
172-55	27916-27925	cingulate	_
172-56	27926-27932	cortex	_
172-57	27933-27941	Regional	_
172-58	27942-27953	correlation	_
172-59	27954-27961	between	_
172-60	27962-27969	resting	_
172-61	27970-27975	state	_
172-62	27976-27979	FDG	_
172-63	27980-27983	PET	_
172-64	27984-27987	and	_
172-65	27988-27993	pCASL	_
172-66	27994-28003	perfusion	_
172-67	28004-28007	MRI	_
172-68	28008-28017	Perfusion	_
172-69	28018-28021	MRI	_
172-70	28022-28025	and	_
172-71	28026-28038	computerized	_
172-72	28039-28048	cognitive	_
172-73	28049-28053	test	_
172-74	28054-28067	abnormalities	_
172-75	28068-28070	in	_
172-76	28071-28080	abstinent	_
172-77	28081-28083	MA	_
172-78	28084-28089	users	_
172-79	28091-28100	Long-term	_
172-80	28101-28110	follow-up	_
172-81	28111-28113	of	_
172-82	28114-28122	patients	_
172-83	28123-28130	treated	_
172-84	28131-28134	for	_
172-85	28135-28144	psychotic	_
172-86	28145-28153	symptoms	_
172-87	28154-28158	that	_
172-88	28159-28166	persist	_
172-89	28167-28172	after	_
172-90	28173-28181	stopping	_
172-91	28182-28189	illicit	_
172-92	28190-28194	drug	_
172-93	28195-28198	use	_
172-94	28198-28199	.	_

#Text=Shanghai Arch
#Text=fMRI with BOLD and CBF (arterial spin labeling): Preliminary results in schizophrenia
#Text=Addiction and Imaging of the living human brain
#Text=Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex
#Text=Cocaine decreases cortical cerebral blood flow but does not obscure regional activation in functional magnetic resonance imaging in human subjects
#Text=Caudate, putamen, and globus pallidus volume in schizophrenia: a quantitative MRI study
#Text=The neurobiology of methamphetamine induced psychosis
#Text=Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan.
173-1	28200-28208	Shanghai	_
173-2	28209-28213	Arch	_
173-3	28214-28218	fMRI	_
173-4	28219-28223	with	_
173-5	28224-28228	BOLD	_
173-6	28229-28232	and	_
173-7	28233-28236	CBF	_
173-8	28237-28238	(	_
173-9	28238-28246	arterial	_
173-10	28247-28251	spin	_
173-11	28252-28260	labeling	_
173-12	28260-28261	)	_
173-13	28261-28262	:	_
173-14	28263-28274	Preliminary	_
173-15	28275-28282	results	_
173-16	28283-28285	in	_
173-17	28286-28299	schizophrenia	_
173-18	28300-28309	Addiction	_
173-19	28310-28313	and	_
173-20	28314-28321	Imaging	_
173-21	28322-28324	of	_
173-22	28325-28328	the	_
173-23	28329-28335	living	_
173-24	28336-28341	human	_
173-25	28342-28347	brain	_
173-26	28348-28352	Drug	_
173-27	28353-28362	addiction	_
173-28	28363-28366	and	_
173-29	28367-28370	its	_
173-30	28371-28381	underlying	_
173-31	28382-28397	neurobiological	_
173-32	28398-28403	basis	_
173-33	28403-28404	:	_
173-34	28405-28417	neuroimaging	_
173-35	28418-28426	evidence	_
173-36	28427-28430	for	_
173-37	28431-28434	the	_
173-38	28435-28446	involvement	_
173-39	28447-28449	of	_
173-40	28450-28453	the	_
173-41	28454-28461	frontal	_
173-42	28462-28468	cortex	_
173-43	28469-28476	Cocaine	_
173-44	28477-28486	decreases	_
173-45	28487-28495	cortical	_
173-46	28496-28504	cerebral	_
173-47	28505-28510	blood	_
173-48	28511-28515	flow	_
173-49	28516-28519	but	_
173-50	28520-28524	does	_
173-51	28525-28528	not	_
173-52	28529-28536	obscure	_
173-53	28537-28545	regional	_
173-54	28546-28556	activation	_
173-55	28557-28559	in	_
173-56	28560-28570	functional	_
173-57	28571-28579	magnetic	_
173-58	28580-28589	resonance	_
173-59	28590-28597	imaging	_
173-60	28598-28600	in	_
173-61	28601-28606	human	_
173-62	28607-28615	subjects	_
173-63	28616-28623	Caudate	_
173-64	28623-28624	,	_
173-65	28625-28632	putamen	_
173-66	28632-28633	,	_
173-67	28634-28637	and	_
173-68	28638-28644	globus	_
173-69	28645-28653	pallidus	_
173-70	28654-28660	volume	_
173-71	28661-28663	in	_
173-72	28664-28677	schizophrenia	_
173-73	28677-28678	:	_
173-74	28679-28680	a	_
173-75	28681-28693	quantitative	_
173-76	28694-28697	MRI	_
173-77	28698-28703	study	_
173-78	28704-28707	The	_
173-79	28708-28720	neurobiology	_
173-80	28721-28723	of	_
173-81	28724-28739	methamphetamine	_
173-82	28740-28747	induced	_
173-83	28748-28757	psychosis	_
173-84	28758-28766	Patients	_
173-85	28767-28771	with	_
173-86	28772-28787	methamphetamine	_
173-87	28788-28797	psychosis	_
173-88	28798-28806	admitted	_
173-89	28807-28809	to	_
173-90	28810-28811	a	_
173-91	28812-28823	psychiatric	_
173-92	28824-28832	hospital	_
173-93	28833-28835	in	_
173-94	28836-28841	Japan	_
173-95	28841-28842	.	_

#Text=A preliminary report
#Text=Effects of Methamphetamine Dependence and HIV Infection on Cerebral Morphology
#Text=Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers
#Text=Frontal glucose hypometabolism in abstinent methamphetamine users
#Text=Dose-dependent frontal hypometabolism on FDG-PET in methamphetamine abusers
#Text=Static and dynamic characteristics of cerebral blood flow during the resting state in schizophrenia
#Text=Psychosis in Alzheimer's disease is associated with frontal metabolic impairment and accelerated decline in working memory: findings from the Alzheimer's Disease Neuroimaging Initiative
#Text=Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers
#Text=Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers
#Text=Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging
#Text=Brain perfusion in polysubstance users: relationship to substance and tobacco use, cognition, and self-regulation
#Text=Abnormal asymmetries in subcortical brain volume in schizophrenia
#Text=A default mode of brain function
#Text=Flourine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination
#Text=Regional brain metabolism in schizophrenia: an FDG-PET study
#Text=Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms
#Text=Brain serotonin transporter density and aggression in abstinent methamphetamine abusers
#Text=Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects
#Text=Perfusion magnetic resonance imaging in psychiatry
#Text=Regional aerobic glycolysis in the human brain
#Text=Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium
#Text=Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence
#Text=Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex
#Text=Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers
#Text=Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence
#Text=Empirical optimization of ASL data analysis using an ASL data processing toolbox: ASLtbx
#Text=Precipitating factors in spontaneous recurrence of methamphetamine psychosis
#Text=Spontaneous recurrence of methamphetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change
#Text=Supplementary data
#Text=Supplementary data to this article can be found online at https://doi.org/10.1016/j.nicl.2018.10.023.
174-1	28843-28844	A	_
174-2	28845-28856	preliminary	_
174-3	28857-28863	report	_
174-4	28864-28871	Effects	_
174-5	28872-28874	of	_
174-6	28875-28890	Methamphetamine	_
174-7	28891-28901	Dependence	_
174-8	28902-28905	and	_
174-9	28906-28909	HIV	_
174-10	28910-28919	Infection	_
174-11	28920-28922	on	_
174-12	28923-28931	Cerebral	_
174-13	28932-28942	Morphology	_
174-14	28943-28952	Cognitive	_
174-15	28953-28961	function	_
174-16	28962-28965	and	_
174-17	28966-28979	nigrostriatal	_
174-18	28980-28987	markers	_
174-19	28988-28990	in	_
174-20	28991-29000	abstinent	_
174-21	29001-29016	methamphetamine	_
174-22	29017-29024	abusers	_
174-23	29025-29032	Frontal	_
174-24	29033-29040	glucose	_
174-25	29041-29055	hypometabolism	_
174-26	29056-29058	in	_
174-27	29059-29068	abstinent	_
174-28	29069-29084	methamphetamine	_
174-29	29085-29090	users	_
174-30	29091-29105	Dose-dependent	_
174-31	29106-29113	frontal	_
174-32	29114-29128	hypometabolism	_
174-33	29129-29131	on	_
174-34	29132-29139	FDG-PET	_
174-35	29140-29142	in	_
174-36	29143-29158	methamphetamine	_
174-37	29159-29166	abusers	_
174-38	29167-29173	Static	_
174-39	29174-29177	and	_
174-40	29178-29185	dynamic	_
174-41	29186-29201	characteristics	_
174-42	29202-29204	of	_
174-43	29205-29213	cerebral	_
174-44	29214-29219	blood	_
174-45	29220-29224	flow	_
174-46	29225-29231	during	_
174-47	29232-29235	the	_
174-48	29236-29243	resting	_
174-49	29244-29249	state	_
174-50	29250-29252	in	_
174-51	29253-29266	schizophrenia	_
174-52	29267-29276	Psychosis	_
174-53	29277-29279	in	_
174-54	29280-29291	Alzheimer's	_
174-55	29292-29299	disease	_
174-56	29300-29302	is	_
174-57	29303-29313	associated	_
174-58	29314-29318	with	_
174-59	29319-29326	frontal	_
174-60	29327-29336	metabolic	_
174-61	29337-29347	impairment	_
174-62	29348-29351	and	_
174-63	29352-29363	accelerated	_
174-64	29364-29371	decline	_
174-65	29372-29374	in	_
174-66	29375-29382	working	_
174-67	29383-29389	memory	_
174-68	29389-29390	:	_
174-69	29391-29399	findings	_
174-70	29400-29404	from	_
174-71	29405-29408	the	_
174-72	29409-29420	Alzheimer's	_
174-73	29421-29428	Disease	_
174-74	29429-29441	Neuroimaging	_
174-75	29442-29452	Initiative	_
174-76	29453-29457	Mood	_
174-77	29458-29470	disturbances	_
174-78	29471-29474	and	_
174-79	29475-29483	regional	_
174-80	29484-29492	cerebral	_
174-81	29493-29502	metabolic	_
174-82	29503-29516	abnormalities	_
174-83	29517-29519	in	_
174-84	29520-29528	recently	_
174-85	29529-29538	abstinent	_
174-86	29539-29554	methamphetamine	_
174-87	29555-29562	abusers	_
174-88	29563-29571	Cerebral	_
174-89	29572-29581	metabolic	_
174-90	29582-29593	dysfunction	_
174-91	29594-29597	and	_
174-92	29598-29606	impaired	_
174-93	29607-29616	vigilance	_
174-94	29617-29619	in	_
174-95	29620-29628	recently	_
174-96	29629-29638	abstinent	_
174-97	29639-29654	methamphetamine	_
174-98	29655-29662	abusers	_
174-99	29663-29670	Chronic	_
174-100	29671-29686	methamphetamine	_
174-101	29687-29692	abuse	_
174-102	29693-29696	and	_
174-103	29697-29712	corticostriatal	_
174-104	29713-29721	deficits	_
174-105	29722-29730	revealed	_
174-106	29731-29733	by	_
174-107	29734-29746	neuroimaging	_
174-108	29747-29752	Brain	_
174-109	29753-29762	perfusion	_
174-110	29763-29765	in	_
174-111	29766-29779	polysubstance	_
174-112	29780-29785	users	_
174-113	29785-29786	:	_
174-114	29787-29799	relationship	_
174-115	29800-29802	to	_
174-116	29803-29812	substance	_
174-117	29813-29816	and	_
174-118	29817-29824	tobacco	_
174-119	29825-29828	use	_
174-120	29828-29829	,	_
174-121	29830-29839	cognition	_
174-122	29839-29840	,	_
174-123	29841-29844	and	_
174-124	29845-29860	self-regulation	_
174-125	29861-29869	Abnormal	_
174-126	29870-29881	asymmetries	_
174-127	29882-29884	in	_
174-128	29885-29896	subcortical	_
174-129	29897-29902	brain	_
174-130	29903-29909	volume	_
174-131	29910-29912	in	_
174-132	29913-29926	schizophrenia	_
174-133	29927-29928	A	_
174-134	29929-29936	default	_
174-135	29937-29941	mode	_
174-136	29942-29944	of	_
174-137	29945-29950	brain	_
174-138	29951-29959	function	_
174-139	29960-29968	Flourine	_
174-140	29968-29969	-	_
174-141	29969-29971	18	_
174-142	29971-29972	-	_
174-143	29972-29990	fluorodeoxyglucose	_
174-144	29991-29994	PET	_
174-145	29995-29997	to	_
174-146	29998-30007	determine	_
174-147	30008-30016	regional	_
174-148	30017-30025	cerebral	_
174-149	30026-30033	glucose	_
174-150	30034-30045	utilization	_
174-151	30045-30046	:	_
174-152	30047-30048	a	_
174-153	30049-30063	re-examination	_
174-154	30064-30072	Regional	_
174-155	30073-30078	brain	_
174-156	30079-30089	metabolism	_
174-157	30090-30092	in	_
174-158	30093-30106	schizophrenia	_
174-159	30106-30107	:	_
174-160	30108-30110	an	_
174-161	30111-30118	FDG-PET	_
174-162	30119-30124	study	_
174-163	30125-30136	Association	_
174-164	30137-30139	of	_
174-165	30140-30148	dopamine	_
174-166	30149-30160	transporter	_
174-167	30161-30165	loss	_
174-168	30166-30168	in	_
174-169	30169-30172	the	_
174-170	30173-30186	orbitofrontal	_
174-171	30187-30190	and	_
174-172	30191-30203	dorsolateral	_
174-173	30204-30214	prefrontal	_
174-174	30215-30223	cortices	_
174-175	30224-30228	with	_
174-176	30229-30252	methamphetamine-related	_
174-177	30253-30264	psychiatric	_
174-178	30265-30273	symptoms	_
174-179	30274-30279	Brain	_
174-180	30280-30289	serotonin	_
174-181	30290-30301	transporter	_
174-182	30302-30309	density	_
174-183	30310-30313	and	_
174-184	30314-30324	aggression	_
174-185	30325-30327	in	_
174-186	30328-30337	abstinent	_
174-187	30338-30353	methamphetamine	_
174-188	30354-30361	abusers	_
174-189	30362-30372	Modulatory	_
174-190	30373-30380	effects	_
174-191	30381-30383	of	_
174-192	30384-30392	ketamine	_
174-193	30392-30393	,	_
174-194	30394-30405	risperidone	_
174-195	30406-30409	and	_
174-196	30410-30421	lamotrigine	_
174-197	30422-30424	on	_
174-198	30425-30432	resting	_
174-199	30433-30438	brain	_
174-200	30439-30448	perfusion	_
174-201	30449-30451	in	_
174-202	30452-30459	healthy	_
174-203	30460-30465	human	_
174-204	30466-30474	subjects	_
174-205	30475-30484	Perfusion	_
174-206	30485-30493	magnetic	_
174-207	30494-30503	resonance	_
174-208	30504-30511	imaging	_
174-209	30512-30514	in	_
174-210	30515-30525	psychiatry	_
174-211	30526-30534	Regional	_
174-212	30535-30542	aerobic	_
174-213	30543-30553	glycolysis	_
174-214	30554-30556	in	_
174-215	30557-30560	the	_
174-216	30561-30566	human	_
174-217	30567-30572	brain	_
174-218	30573-30584	Subcortical	_
174-219	30585-30590	brain	_
174-220	30591-30597	volume	_
174-221	30598-30611	abnormalities	_
174-222	30612-30614	in	_
174-223	30615-30619	2028	_
174-224	30620-30631	individuals	_
174-225	30632-30636	with	_
174-226	30637-30650	schizophrenia	_
174-227	30651-30654	and	_
174-228	30655-30659	2540	_
174-229	30660-30667	healthy	_
174-230	30668-30676	controls	_
174-231	30677-30680	via	_
174-232	30681-30684	the	_
174-233	30685-30691	ENIGMA	_
174-234	30692-30702	consortium	_
174-235	30703-30707	Loss	_
174-236	30708-30710	of	_
174-237	30711-30719	dopamine	_
174-238	30720-30732	transporters	_
174-239	30733-30735	in	_
174-240	30736-30751	methamphetamine	_
174-241	30752-30759	abusers	_
174-242	30760-30768	recovers	_
174-243	30769-30773	with	_
174-244	30774-30784	protracted	_
174-245	30785-30795	abstinence	_
174-246	30796-30799	Low	_
174-247	30800-30805	level	_
174-248	30806-30808	of	_
174-249	30809-30814	brain	_
174-250	30815-30823	dopamine	_
174-251	30824-30826	D2	_
174-252	30827-30836	receptors	_
174-253	30837-30839	in	_
174-254	30840-30855	methamphetamine	_
174-255	30856-30863	abusers	_
174-256	30863-30864	:	_
174-257	30865-30876	association	_
174-258	30877-30881	with	_
174-259	30882-30892	metabolism	_
174-260	30893-30895	in	_
174-261	30896-30899	the	_
174-262	30900-30913	orbitofrontal	_
174-263	30914-30920	cortex	_
174-264	30921-30932	Association	_
174-265	30933-30935	of	_
174-266	30936-30944	dopamine	_
174-267	30945-30956	transporter	_
174-268	30957-30966	reduction	_
174-269	30967-30971	with	_
174-270	30972-30983	psychomotor	_
174-271	30984-30994	impairment	_
174-272	30995-30997	in	_
174-273	30998-31013	methamphetamine	_
174-274	31014-31021	abusers	_
174-275	31022-31029	Partial	_
174-276	31030-31038	recovery	_
174-277	31039-31041	of	_
174-278	31042-31047	brain	_
174-279	31048-31058	metabolism	_
174-280	31059-31061	in	_
174-281	31062-31077	methamphetamine	_
174-282	31078-31085	abusers	_
174-283	31086-31091	after	_
174-284	31092-31102	protracted	_
174-285	31103-31113	abstinence	_
174-286	31114-31123	Empirical	_
174-287	31124-31136	optimization	_
174-288	31137-31139	of	_
174-289	31140-31143	ASL	_
174-290	31144-31148	data	_
174-291	31149-31157	analysis	_
174-292	31158-31163	using	_
174-293	31164-31166	an	_
174-294	31167-31170	ASL	_
174-295	31171-31175	data	_
174-296	31176-31186	processing	_
174-297	31187-31194	toolbox	_
174-298	31194-31195	:	_
174-299	31196-31202	ASLtbx	_
174-300	31203-31216	Precipitating	_
174-301	31217-31224	factors	_
174-302	31225-31227	in	_
174-303	31228-31239	spontaneous	_
174-304	31240-31250	recurrence	_
174-305	31251-31253	of	_
174-306	31254-31269	methamphetamine	_
174-307	31270-31279	psychosis	_
174-308	31280-31291	Spontaneous	_
174-309	31292-31302	recurrence	_
174-310	31303-31305	of	_
174-311	31306-31321	methamphetamine	_
174-312	31322-31331	psychosis	_
174-313	31331-31332	:	_
174-314	31333-31342	increased	_
174-315	31343-31354	sensitivity	_
174-316	31355-31357	to	_
174-317	31358-31364	stress	_
174-318	31365-31375	associated	_
174-319	31376-31380	with	_
174-320	31381-31394	noradrenergic	_
174-321	31395-31408	hyperactivity	_
174-322	31409-31412	and	_
174-323	31413-31425	dopaminergic	_
174-324	31426-31432	change	_
174-325	31433-31446	Supplementary	_
174-326	31447-31451	data	_
174-327	31452-31465	Supplementary	_
174-328	31466-31470	data	_
174-329	31471-31473	to	_
174-330	31474-31478	this	_
174-331	31479-31486	article	_
174-332	31487-31490	can	_
174-333	31491-31493	be	_
174-334	31494-31499	found	_
174-335	31500-31506	online	_
174-336	31507-31509	at	_
174-337	31510-31515	https	_
174-338	31515-31516	:	_
174-339	31516-31517	/	_
174-340	31517-31518	/	_
174-341	31518-31525	doi.org	_
174-342	31525-31526	/	_
174-343	31526-31533	10.1016	_
174-344	31533-31534	/	_
174-345	31534-31540	j.nicl	_
174-346	31540-31552	.2018.10.023	_
174-347	31552-31553	.	_
